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In the recent year, there have been a growing number of news stories highlighting the 
increased use of benzodiazepines, in particular Xanax, amongst children and young people in 
the UK. Despite the national governmental and societal concern, there have been very few 
efforts to research the use and misuse of these drugs. Through quantitative and qualitative social 
research methods, this mixed-methods, cross-disciplinary thesis presents the findings from a 
national survey (n=595) exploring the use and misuse of benzodiazepines predominantly amongst 
the UK student population, and gas chromatography-mass spectrometry (GC-MS) analysis of 29 
presumed Valium samples and 29 presumed Xanax samples.  
The various motivations included: self-medicating everyday sleep and/or anxiety issues; to sleep on 
long journeys; to feel more confident in social situations; to feel more confident in presentations 
and/or exams; to relax; to get high and heighten the effects of other drugs such as alcohol and/or 
cannabis; to counteract the effects of other drugs such as stimulants (MDMA, cocaine), psychedelics 
(acid, LSD) and/or study drugs (Modafinil/Ritalin); to avoid or dilute the negative emotional and 
physical side effects of hangovers and/or comedowns. To correct irregular sleep patterns, eradicate 
or ease physical pain. Ease of access, availability and low cost was acknowledged as a significant 
motive for some, especially when other substances were unavailable. Many highlighted the weak 
efficacy of NHS treatment services as a reason for self-medicating, and policy makers are urged to 
invest more into treatment services. However, negative side effects were also noted such as feeling  
overly sedated which impaired complex psychomotor tasks like driving; feeling hungover; the 
impairment of memory and black-outs; accidents and injuries; emotional blunting and depression; 
tolerance, dependency and withdrawal and; mortality. Benzodiazepines often made users feel 
‘invincible’ and that usage lead to irrational and erratic behaviour: Some reported shoplifting, 
breaking into places, purposefully breaking things, driving and crashing their car whilst intoxicated, 
getting into fights, and/or physically attacking people.  
GC-MS analysis revealed that the ‘Xanax’ samples (thought to contain 2 mg of Alprazolam) ranged 
from 0.70 – 2.21 mg and the ‘Valium’ samples (thought to contain 10 mg of Diazepam) ranged from 
12.97 – 26.79 mg. Six of the 29 ‘Xanax’ samples did not contain any active Alprazolam and of those, 







‘Anxiolytics’ – A drug used to relieve anxiety. 
‘Benzodiazepines’ – CNS depressant drugs used to assist in the management of anxiety and panic 
disorder and sleeping problems.  
‘CNS depressants’ – A family of drugs which slow down vital bodily functions in the CNS, like 
breathing and heartbeat.   
‘Counterfeit’ – A custom-pressed substance which is not of true content. Counterfeits often contain 
less active ingredient, more active ingredient or other adulterants and bulking agents.  
‘Drugs’ – Any substance, be it prescribed or non-prescribed, which alters the chemical levels in the 
brain and body. This can range from prescribed anti-anxiety medication like Diazepam to illicit drugs 
such as MDMA or Cocaine. This includes alcohol. 
‘Functional users’ – This category is similar to above, however there are some cases of ‘problematic’ 
drug users who are still able to function well within society. These individuals are also dependent on 
the substance they are taking. These can range from individuals taking the same prescribed 
psychotropic medication every day for numerous years to individuals self-medicating with illicitly 
bought Ketamine every day for years. 
‘Medicinal’ – Drugs which are used medicinally are used enhance an individual who is low in mood 
or who is physically ill. This can range from taking Diazepam (prescribed or non-prescribed) to 
eliminate feelings of anxiousness, to drinking a glass of wine in the evening to relax. This category 
and ‘problematic’ have a fine line in between the two, as it is easy to fall into problematic use. 
‘Misuse’ – Drugs which are used for a longer period than recommended or those that are taken in 
higher dosages than recommended. Drugs which are used in conjunction with other drugs, in order 
to potentiate the effects. 
‘Poly-drug use’ or ‘poly-substance use’ – When two or more drugs are taken together. This includes 
alcohol. 
‘Recreational’ –Drugs which are taken in order to have a good time. This can range from binge 
drinking alcohol when celebrating a friend’s birthday, to having a line of Cocaine when clubbing. 
‘Sedatives’ – Drugs that suppress anxiety and promote sleep. 
‘Stimulants’ – A class of drugs that stimulates the activity in the brain, increasing heart rate, blood 
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Chapter One: Introduction and thesis overview 
1.1 Introduction 
Patented in the 1960s, benzodiazepines are certainly not a new family of drugs. Users have ranged 
from anxious mothers to problematic heroin addicts over the decades (Susann, 1966; Stitzer et al., 
1981; Jones et al., 2012). However, in recent years, there has been a clear shift from the traditional 
‘problematic’ adult drug user to a more specific focus on a new user group. UK media headlines have 
been populated with reports of teen Xanax misuse, some stating children as young as 11 are taking 
the anti-anxiety medication (see BBC News, 2018a; BBC News, 2018d; Birmingham Mail, 2018; The 
Guardian, 2018c; VICE, 2018a).  
The popular young culture and lifestyle magazine VICE recently ran a series of articles, created a 
short film and launched a nationwide survey via social media in a bid to highlight the misuse of 
Xanax amongst teens (see VICE Channel: Xanxiety; VICE, 2018b; VICE, 2018c). Additional media 
headlines suggest young people are illicitly sourcing benzodiazepines in order to self-medicate for 
any underlying mental health issues (see BBC News, 2015; ITV News, 2018a; Metro, 2018; Mirror, 
2018; The Guardian, 2018b; The Guardian, 2018d; The Telegraph, 2018; VICE, 2018a). However, it 
must be noted that online journalist publications have the tendency to sensationalise and 
exaggerate stories (Kitzinger, 1999) and dominantly focus on negative accounts (Taylor, 2008). 
Indeed, there has been a long history of drug-related moral panics (see The New York Times, 1990 
on crack babies; The Independent, 1996 on Leah Betts). Thus, concerns are raised regarding the 
reliability and validity of the reports (Joo Chung et al., 2012). In summary, the current discourse on 
the use of benzodiazepines amongst young people in the UK is dominated by media reports and is 
lacking in more robust academic knowledge. The research that follows sets out to readdress this 
imbalance by providing an interdisciplinary study of benzodiazepine use and source and supply. In 
doing so, it provides a valuable and timely contribution to existing knowledge and understanding of 
an emerging drug trend. 
Leaving the potential for media exaggerations and moral panic aside, the most recent Home Office 
report revealed an approximate 63,000 person increase of non-prescribed tranquiliser use amongst 
adults in England and Wales within the last year (Home Office, 2018). Figures of usage within the last 
year have risen amongst 16 – 24 year olds since 1993, from 8.4% to 9.1% in males and from 19.2% to 
26% in females (ibid). However, CSEW data is usually collected from the head of the household, and 
fails to capture the student and young professional population, typically living away from the 
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parental home. Moreover, the term ‘tranquiliser’ is broad, and benzodiazepines such as Xanax and 
Valium may only account for a small fraction of the data.  
The popularity of Xanax is evident in many ways. When typing ‘Xanax’ into Etsy and EBay, 242 and 
656 items come up respectively (searched on 15th November 2018), ranging from engraved rings and 
necklaces to framed artistic prints (see appendix 1 and 2 for screenshots). Social media and celebrity 
culture has undoubtedly played an important role in what could be viewed as the ‘normalisation’ of 
benzodiazepine use (see Manning, 2007). Cultural accommodation and the popularity of 
benzodiazepines amongst celebrities and music artists will be discussed in section 2.4.2.  
Several international research papers have thoroughly scoped out the nature, prevalence and 
possible motivations for the non-medical use of prescription drugs (see Karam et al., 2000; McGabe, 
2005; Bardhi et al., 2007; Rigg and Ibañez, 2010; LeClair et al., 2015; Weaver, 2015; Beharry and 
Gibbons, 2016; Andersson and Kjellgren, 2017; Mateu-Gelabert et al., 2017) and one study even 
suggested that the UK had the highest amount of non-medical prescription drug users in Europe (see 
Novak et al., 2016). However, it is believed that there is currently only one published academic paper 
examining the nature and prevalence of the use and misuse of hypnotics and anxiolytics solely in the 
UK (see Kapil et al., 2014). However, as well as being severely outdated, the sample size is small: the 
total number of participants is stated to be 1500, however, only 392 reported having tried at least 
one benzodiazepine or Z-drug and merely 116 reported to have ‘misused’ them. Therefore, it cannot 
explain the recent spike in young people. In addition, the research paper incorporated the misuse of 
Z-drugs.  
Kapil et al.’s 2014 study also revealed that the majority of users obtained their benzodiazepines via 
legitimate or diverted prescription. Almost five years since the report was published, it can be 
assumed that the usual source of benzodiazepines has differed and that usage has escalated due to 
the growth of online drug markets. The online world has undoubtedly facilitated the growth and 
expansion of drug use due to dark- and clear-web markets, allowing small inconspicuous packages to 
be shipped globally at a relatively low cost (Barratt and Aldridge, 2016; Dittus et al., 2018) and it is 
assumed that the recent spike in Xanax use in the UK is an immediate reflection of this (elaborated 
in section 2.5). However, little is known about the source and supply and thus, this research project 
wishes to explore this further. 
Although the current research project wishes to explore the illicit use of benzodiazepines, even 
when following the recommendations of ‘proper’ use, it does not mitigate the development of 
problems. The adverse negative effects of the use and misuse of pharma-grade benzodiazepines 
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have been acknowledged for many years and present numerous life-threatening risks. Alongside 
their highly addictive potential (Hollister et al., 1961; Covi et al., 1973; de las Cuevas et al., 2003), 
benzodiazepines may also create paradoxical stimulation such as heightened anxiety, hyperactivity, 
and fury (Gardner and Cowdry, 1985; O’Sullivan et al., 1994; Paton, 2002) which sometimes results 
in erratic, violent behaviour (Ashton, 2002). For many years, they have been known to have 
powerful memory wiping effects (Bond et al., 1991; Griffin et al., 2013; Ford and Law, 2014) which 
may persist in the long-term (Curran, 1986; Curran et al., 1994). Their powerful sedative properties 
have proven to significantly impair everyday tasks (Kozená et al., 1995; Verster et al., 2002), and can 
lead to serious accidents (Friedman, 2006; Ravera et al., 2011). Deaths involving benzodiazepines 
have risen by 90% in the last decade (from 207 in 2007 to 391 in 2017), and Diazepam deaths have 
seen a 5-fold increase since 1993 (from 52 in 1993 to 226 in 2017) (Office for National Statistics 
(ONS), 2018). Their powerful CNS depressant properties increase the risk of mortality for those who 
exceed the recommended dosage and/or use them in conjunction with other depressant drugs like 
alcohol and ketamine (World Health Organisation (WHO), 2016). However, former studies 
highlighting the negative side effects are based upon the use and misuse of prescribed, legitimate 
benzodiazepines. Little is known about the desired and undesired side effects when they are used 
off-prescription, and the effects of street-bought benzodiazepines.  
In the past few years there have been numerous cases of hospitalisation after use: the BBC 
discovered that the North East Ambulance Service responded to 240 call-outs in 2017 alone, treating 
children aged 11 – 18 for Xanax misuse (BBC, 2018a). In June 2016, five teenagers were hospitalised 
in Sidmouth after taking Xanax alongside consuming alcohol (Sidmouth Herald, 2016); in early 2018, 
six young girls were rushed into A&E after taking too many Xanax bars during lunch time at school 
(Evening Standard, 2018); a further six needed treatment in Brighton and Hove (BBC News, 2018b) 
and; 20 teenagers were once collectively hospitalised in Salisbury after taking the drug (BBC News, 
2017a; ITV News, 2017). With the scaremongering media strongly focusing on cases of 
hospitalisation and in the absence of up to date academic research on use in the UK, we are left with 
little credible evidence and limited understanding of this apparent rising drug use trend.  
Almost double the amount of young people in England are accessing treatment services for 
benzodiazepine-related problems since last year (from 161 (2016 – 2017), to 315 (2017 – 2018)) 
(Public Health England, 2018). Specifically, those accessing treatment services who have issues with 
Xanax has increased 6-fold within the last year (from 8 (2016 – 2017) to 53 (2017 – 2018)) (ibid.). 
Another compelling concern with non-prescribed benzodiazepines users is the lack of structured 
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guidance and knowledge that would usually come from prescription packets and general 
practitioners. This may lead to more adverse negative reactions.  
An important and alarming consideration of the non-prescribed use of benzodiazepines, particularly 
in the UK context where Xanax is unobtainable via NHS prescription, is the likelihood that street 
Xanax is not of pharmaceutical standard. Recently, the UK media reported Xanax bought via social 
media was cut with Etizolam (BBC News, 2018), boric acid, rat poison, floor polish, and pesticides 
(Daily Mail, 2018). In Scotland, reports showed counterfeited street ‘Diazepam’ had been laced with 
benzodiazepine analogues Diclazepam, Etizolam and Flubromazepam, and synthetic opioid U-47700 
(Police Scotland, 2016). A major cause for concern is the presence of fentanyl-laced Xanax in the US 
(see CBS News, 2016; Fox News, 2018), and the possibility of it penetrating the UK scene. Consuming 
adulterated benzodiazepines can cause death by adverse drug interactions (Jackson et al., 2011) and 
health care professionals would not know how to treat any harrowing symptoms. There is a dearth 
of knowledge regarding any side effects from non-prescribed and potentially adulterated 
benzodiazepines, which will be explored throughout this thesis. Chapters Five and Six this research 
project will display the methodology and results from the analytical science in order to determine 
the true contents and purity levels of popular street samples such as ‘Valium’ and ‘Xanax’.  
To summarise, our current and existing academic knowledge about benzodiazepine usage and 
context is outdated, lacks generalisability and does not solely focus on the UK population. The 
somewhat unreliable media dominated discourse means there is little empirical evidence and it lacks 
in-depth analysis of the rising phenomenon. It is unknown as to where non-prescribed users source 
their benzodiazepines, and the content of what they are consuming. The following section will 








1.2 Research aims and objectives 
Without reliable, generalisable, up to date, in-depth data examining the context of and the 
motivations behind benzodiazepine use in the UK, it is impossible to understand the rising 
phenomenon and consequently prevent risks and dangers. Thus, a mixed methodology incorporating 
a web-based survey inclusive of open- and close-ended questions alongside semi-structured face-to-
face interviews were used to efficiently collect data from past and current benzodiazepine users in 
the UK, with the intent to explore: 
 Which benzodiazepines are popular? 
 Who is taking benzodiazepines? 
 What are the motivations for use? 
 What are the effects (both desired and undesired) of benzodiazepine usage? 
 Where do users source their non-prescribed benzodiazepines? 
 What factors influence benzodiazepine users’ decisions on what benzodiazepines they 
use and where they obtain them?   
The chemical analysis element of this project wishes to explore: 
 What are the true contents of illicitly sourced benzodiazepines? 
 Are street-bought ‘Valium’ tablets safer than ‘Xanax’ bars? 
The knowledge that this research project sets out to gather will be utilised to support an evidence 
based harm reduction approach to inform users, substance use practitioners and other relevant 
stakeholders of potential risks from misuse, including poly-substance use. 
1.3 Thesis structure  
The thesis is divided into seven chapters. Following on from this introduction chapter, the remaining 
chapters are as follows:  
Chapter Two will review the existing literature and draw upon national and international research 
papers alongside UK media coverage in an attempt to illustrate the current knowledge of non-
prescribed benzodiazepine use. It will begin by outlining the pharmacodynamics and 
pharmacokinetics of benzodiazepines, in particular: Diazepam (Valium) and Alprazolam (Xanax). 
Then, the history and evolution of benzodiazepines over the years and the respective user groups 
will be explored before examining the current media discourse in the UK. Ease of access, availability 
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and the cost of benzodiazepine drugs will be highlighted before examining the variety of possible 
motivations for usage. International research papers provide a broad variety of motivations for non-
prescribed benzodiazepine users, however, the UK just has one published research paper which 
consists of a small sample size and is outdated. Thus, UK user demographics and usage trends are 
based dominantly on media coverage. Chapter Two will end with a list of acknowledged adverse 
negative effects stemming from the use and misuse of benzodiazepines.  
Chapter Three will outline the social science research methods used for this project. It will begin by 
justifying the use of mixed methods in order to efficiently collect and analyse quantitative and 
qualitative data regarding individuals’ benzodiazepine use and misuse. It will then outline the 
quantitative and qualitative element respectively, specifically: a discussion of ethics; sampling and 
recruitment; survey distribution methods and; data analysis. The survey link was actively distributed 
and promoted between 1st March 2018 and 24th April 2018, and the survey was closed on the 8th 
June 2018. A wide range of online and offline distribution methods alongside inside knowledge of 
young people’s social media habits enabled rich data collection from 595 participants. Using 
Facebook to target the student population and Twitter to target academics proved to be a great way 
to access nationally dispersed participants. Chapter Three will end by reflecting on the methodology 
used and the limitations of the approach. 
Chapter Four will present the findings from the social science research element of this project. 
Following the layout of Chapter Two, it will begin with stating participants’ demographic information 
before highlighting the two dominant benzodiazepines used: Valium and Xanax. It will then go on to 
examine the ease of access, availability and the cost of both benzodiazepines, before presenting the 
wide range of user motivations, specifically: using them to aid sleep; self-medicating anxiety-related 
issues and/or to boost confidence; to get high, mostly in conjunction with other drugs; to counteract 
other drug effects and; to avoid hangovers and/or comedowns. Dosage and routes of administration 
were closely linked to user motivations which will be discussed throughout this chapter. It will then 
touch upon substance use replacement as an explanation for the recent spike in usage before 
presenting personal opinion of benzodiazepine preference, which often contradicted one another. 
Chapter Four will end by highlighting participants’ accounts of adverse negative effects on the brain 
and behaviour.  
Chapter Five will provide details of the methodology created and implemented in order to carry out 
the forensic testing of 29 presumed ‘Valium’ and 29 presumed ‘Xanax’ samples. It will begin by 
examining the scale of the illicit benzodiazepine market. It will then outline the issues with 
counterfeits, specifically: drugs laced with other, more harmful adulterants; those with a higher 
10 
 
concentration of the active ingredient and thus, increased purity and; those with less active 
ingredient. It will then examine the evolution of substance testing in the UK and its significance. The 
chapter will then outline the methodology created to perform chemical analysis to determine the 
content and purity of 29 seized ‘Valium’ samples and 29 seized ‘Xanax’ samples from Greater 
Manchester. The first half of the methodological chapter will outline the presumptive test used and 
the results, followed by methods of nuclear magnetic resonance (NMR) and the results. It will 
outline the gas chromatography-mass spectrometry (GC-MS) testing element, specifically: the GC-
MS settings used; the preparation of the eicosane stock solution; the preparation of the reference 
and calibration standards and; the unknown sample preparations. 
Chapter Six will present the findings from the quantitative and qualitative analysis of the 29 assumed 
‘Xanax’ bars and the 29 assumed ‘Valium’ tablets seized in Manchester. All samples ranged 
significantly in concentration. A small handful contained no active ingredient and some contained 
other adulterants. 
Chapter Seven, the final chapter, will provide a discussion regarding the contribution to knowledge 
and how this new data can be used to inform policy makers; mental health service providers; 
substance misuse organisations and charities and; current users. It will draw upon the key findings 
using existing and new knowledge in order to minimise harm and fatalities stemming from 












Chapter Two: Literature Review 
2.1 Introduction and chapter overview 
This chapter will begin by outlining the pharmacological profile of benzodiazepines, specifically: the 
mechanism of action (section 2.2.1); pharmacodynamics (section 2.2.2) and; the individual 
pharmacokinetics of Diazepam (Valium) (section 2.2.3.1) and Alprazolam (Xanax) (section 2.2.3.2). 
Section 2.3 will explore the evolution of benzodiazepine in a historical context, before section 2.4 
reviews the current knowledge in the UK as portrayed by popular media publications, specifically: 
the perceived demographics of users (section 2.4.1) and the drugs’ representation in celebrity and 
music culture (2.4.2). Section 2.5 will highlight the ease of access of benzodiazepines, specifically: 
using the clear-web and social media (section 2.5.1) and; the dark-web (section 2.5.2). Section 2.6 
will examine the possible motivations for benzodiazepine users by drawing upon international 
studies alongside the one UK-based study, specifically: perceived risk and social acceptance (section 
2.6.1); to treat sleep issues or insomnia (section 2.6.2) and/or; self-medicating anxiety issues (2.6.3). 
The following sub-section will explore recreational uses such as: relaxation (section 2.6.4.1); to get 
high (section 2.6.4.2) and/or; using them to come down from stimulant drugs (section 2.6.4.3). 
Section 2.7 will highlight the already acknowledged adverse negative effects: temporary sedation, 
complex psychomotor tasks, accidents and injuries (section 2.7.1); memory impairment and 
cognitive decline (section 2.7.2); paradoxical stimulation (section 2.7.3); emotional blunting and 
depression (section 2.7.4); poly-drug use dangers (section 2.7.5) and lastly; tolerance, dependency 
and withdrawal (section 2.7.6). 
2.2 Benzodiazepine pharmacology 
Before examining the evolution of benzodiazepines and how user demographics and motivations 
have significantly altered over the years, it is necessary to outline exactly what benzodiazepines are 
and how they pharmacologically compare in order to chart their popularity. The following sections 
will outline the general pharmacology of benzodiazepines: how the drugs act on the brain (section 
2.2.1) and behaviour (section 2.2.2). Section 2.2.3.1 will outline the correct use and appearance of 
Diazepam (Valium), and section 2.2.3.2 will explore Alprazolam (Xanax) and how their use is justified 
as an effective relief for those suffering with anxiety and/or insomnia, before the two popular 
benzodiazepines are compared (section 2.2.3.3). 
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2.2.1 Mechanism of action 
Anxiety and panic disorder are diverse and complex mental health issues (Gale and Oakley-Browne, 
2004), whereby a sufferer may experience an accelerated heartbeat, cold sweats and be 
disorientated (Dunn, 2016; Moran, 2017). To combat this, the natural inhibitory neurotransmitter 
gamma-aminobutyric acid (GABA) acts by reducing the excitability of neurons, thus creating a feeling 
of tranquillity in the brain (Kerr and Ong, 1995). By enhancing the activity of GABA at the GABAA 
receptor complex, benzodiazepines potentiate these senses, allowing the user to feel an influx of 
mental and physical relaxation (Carter et al., 2010). With the correct dosage and administration, 
benzodiazepines are able to cause positive calming affects to nearly every area of brain function 
(Lader, 2011). The psychotropics possess anxiolytic, sedative, hypnotic, muscle relaxant, 
anticonvulsant and amnesic properties, alongside being effective during alcohol withdrawal (Amato 
et al., 2010; Lader, 2012; Ford and Law 2014). 
2.2.2 Pharmacodynamics 
With the ability to cause effect on nearly every part of brain function, the spinal cord is just one of 
the sites of action of benzodiazepines, alongside the cerebellum, the brain stem, the cerebral cortex, 
and the limbic system (Rudolph et al., 1999; Lader, 2011; Ford and Law, 2014).  
The spinal cord and the cerebellum are responsible for the physical effects to the body. After 
administering the drug, the individual experiences relaxation in the muscles and posture, alongside a 
more rational and composed coordination of movement and a more stable balance (Ford and Law, 
2014). However, potential for misuse runs parallel to an increase of age, dosage, poly-drug use and 
in particular; the addition of alcohol (Maxwell et al., 2010). Users may feel mild physical sedation, 
unsteadiness and disorientation with effects lasting in the long-term (Block and Berchou, 1984; 
Baldwin et al., 2013; Griffin et al., 2013).  
The brain stem controls vital functions such as the regulation of the heartbeat, breathing and blood 
pressure (Nicholls and Paton, 2009). These are all significantly slowed down with the addition of a 
benzodiazepine (Bandelow et al., 2017), enabling a great sense of relief when combatting the first 
signs of panic and fret (Stahl, 2002). However, increased dosage and taking them in conjunction with 
other CNS depressant drugs like alcohol, ketamine, cannabis or opioids can be fatal (National 
Institute on Drug Abuse, 2011; Schmitz, 2016; WHO, 2016): an individual’s heartrate may be 
suppressed to such an extent that it stops completely. 
13 
 
The cerebral cortex is also affected: cognitive abilities are slightly fractured, levels of consciousness 
are altered and the user will become drowsy alongside losing the ability to maintain full 
concentration levels. Long-term benzodiazepine use has proven to have significant, detrimental 
effects on a users’ speed of processing, problem solving abilities, verbal memory skills and attention 
span (Block and Berchou, 1984; Barker et al., 2004; Michael et al., 2007).  
Lastly, benzodiazepines can cause direct effect to the limbic system (Rudolph et al., 1999), also 
known as the ‘emotional brain’, alongside effecting the mesolimbic dopamine system, whereby the 
drug has the power to dull down negative emotions such as fear and anxiety (Ford and Law, 2014). 
Even though these effects may abolish crippling anxiety, paradoxical effects may arise with 
prolonged use and increased dose, leading to feelings of emptiness, dysphoria or agitation and rage 
(Hollister et al., 1961; Ashton, 2002; Paton, 2002; Lader, 2012). 
Adverse negative effects will be elaborated further in section 2.7. 
2.2.3 Pharmacokinetics: individual clinical actions and their efficacy  
Pharmacokinetic properties show great diversity. Benzodiazepines can range from short- to 
extremely long-acting and subsequently their efficacy relies on the distribution, absorption, 
metabolism and excretion of the drug (Muscatello et al., 2012; Griffen et al., 2013). These shape the 
onset of action and the duration of effect, and must be considered with intricate detail before 
administration in order to reach the best potential of each drug and avoid any negative side effects. 
Typically, there are three different types of onset: short-acting (half-life = <5hrs); intermediate-
acting (5-24 hrs) and; long-acting (>24hrs). Short- and intermediate-acting benzodiazepines are 
favoured when treating insomnia, whereas long-acting benzodiazepines are preferably administered 
when seeking to diminish levels of anxiety or panic (Ford and Law, 2014; Dikeos et al., 2008). It must 
be noted that benzodiazepine analogues1 such as Etizolam, are particularly confusing for health care 
practitioners when attempting to treat unwanted side-effects and producing tapering plans.  
Generally speaking, benzodiazepines share relatively similar pharmacodynamic properties, however 
it must be noted that the levels of potency of each drug differs immensely (Griffin et al., 2013) and 
individual genetically determined activity of specific drug metabolising enzymes impacts users 
differently (Ashton, 2011). Using information from previous research papers and recommendations: 
Ashton (2002), Griffin et al. (2013), Ford and Law (2014) and the Ipswich and East Suffolk Clinical 
                                                          
1 Benzodiazepine analogues mimic the effects of benzodiazepines but differ in chemical structure 
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Commissioning Group (2016), the table below compares common benzodiazepines with regards to 
potency, speed of onset, peak of onset, duration of action, half-life and intended use.   
Table 1: Common benzodiazepines compared 
The following sub-sections will explore the two most common benzodiazepines more in-depth: 
Diazepam (Valium), and Alprazolam (Xanax) – the most commonly used by survey respondents (see 
Chapter Four: section 4.3). These were also considered to be the popular benzodiazepines based on 
prescription statistics and their mentions in medical literature, US rap culture on UK media headlines 
(see section 2.4). 
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5 mg Rapid 1 Long acting 20 – 100 
[36 – 200] 
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15 
 
2.2.3.1 Diazepam (Valium) 
Labelled as the ‘wonder drug’ when it was first patented (McGee, 2003), Diazepam, also known as 
Valium, was one of the first benzodiazepines which replaced the barbiturates as it was believed to 
be more effective and initially showed no addictive potential whatsoever (Lader, 2011; Wick, 2013). 
It has been sold in the UK since 1963 to treat symptoms of anxiety, insomnia and acute alcohol 
withdrawal. Usual dosages initially begin at 2 mg administered 3 times a day, which may be 
increased up to 15 – 30 mg (per day) if necessary. Those suffering with insomnia may be prescribed 
from 5 mg up to 15 mg daily, to be taken in the evening (National Institute for Health and Care 
Excellence (NICE), 2018).   
Diazepam enters the central nervous system quickly with a peak onset of 1 hour. It is also known to 
cause anticonvulsant and myorelaxant effects, and has a long half-life of 20 – 100 hours (see Table 1 
above). Diazepam carries a unique characteristic whereby its metabolism in the liver creates the 
active metabolites Temazepam, Oxazepam and Desmethyldiazepam (Griffin et al., 2013), which 
contribute to the drugs long elimination half-life of up to 4 days (Baldwin et al., 2013; Griffin et al., 
2013; Ford and Law, 2014). Thus, individuals may feel the sedative and muscle relaxant effects a few 
days after consumption (ibid), which increases the risk of accidents and injuries. However, Mak et al. 
(1993) discovered that although Diazepam carries sedative properties, users do not experience 
significant respiratory depression.  
Valium tablets are available in different dosage strengths: 2 mg (white, round), 5 mg (yellow or 
orange, round), and 10 mg (blue or green, round). The blue 10 mg tablets are most commonly used 
by non-prescribed users (see Drugs Map of Britain: Scotland’s Valium Crisis, 2016). See appendix 3 
for images.  
2.2.3.2 Alprazolam (Xanax) 
Released by the pharmaceutical company Upjohn (now known as Pfizer) in 1981, Alprazolam, also 
known as Xanax, is a potent, short-acting anxiolytic which was first recognised as sufficiently treating 
panic disorder (Chouinard et al., 1983; Ballenger et al., 1988). It is commonly prescribed in America 
for the short-term use in anxiety and acute alcohol withdrawal and in 2013, over 48 million 
prescriptions were dispensed making it the most commonly prescribed psychotropic across the 
nation (Grohol, 2018).  
Alprazolam has an intermediate speed of onset and peak effects are recognised after 1 – 2 hours. It 
is shorter-acting than Diazepam, with a half-life of 6 – 27 hours (see Table 1 above) and is therefore 
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preferred for individuals seeking fast relief of intermittent spells of anxiety and panic disorders 
(Alexander and Alexander, 1986; Jonas et al., 1993). However, its magnificent reinforcing effects 
increase the potential for over-use and due to its short elimination half-life, users must be aware 
that they may experience crippling rebound anxiety when halting the medication abruptly (Tesar, 
1990; Griffin et al., 2013).  
Although it is not available under NHS prescription in the UK, Xanax is readily available via private 
prescription and other, illicit sources (elaborated in section 2.5). Without correct harm reduction 
information, non-prescribed users are generally unaware of the drug’s pharmacological profile and 
the potential for misuse is much greater (Ashton, 2011). Moreover, illicitly sourced drugs are 
frequently adulterated with other and sometimes harmful substances (Liang, 2006; Cole et al., 
2010). The impact of encountering counterfeit pharmaceuticals will be explored further in Chapter 
Five: section 5.1.3. The commonly held perception that Xanax and other benzodiazepines in the UK  
are non-pharma produced has influenced the chemical analysis element of the research design. The 
forensic testing methodology and rationale will be presented in Chapter Five after which results will 
be presented in Chapter Six. 
The dominant dosage of Xanax populating current media headlines refers to the 2 mg Xanax bars 
(white, rectangular). Other dosages include 0.25 mg (white, oval or round), 0.5 mg (orange, oval), 0.5 
mg (peach, round), 1 mg (blue, oval), 1 mg (blue, round), 2 mg (white, round) and 2 mg (yellow, 
rectangular). All images can be found in appendix 4.  
2.2.3.3 Comparing the two 
Unlike Diazepam, Alprazolam has a short elimination half-life, and is much more potent. When 
comparing the chemical properties of the two, 5 mg of Diazepam equates to approximately 0.25 mg 
of Alprazolam (see Table 1 displayed above). The latter has a much quicker onset of action, a much 
more powerful effect and leaves the system quicker, resulting in the feeling of reinforcement being 
much greater. However, speed of onset has also been directly linked to levels of reinforcement 
(O’Brien, 2001, cited in Compton and Volkow, 2006). Compared to Alprazolam, Diazepam has a 




2.3 The evolution of benzodiazepines and shift in user demographics  
Post World War 2, chemists began to discover mind-altering drugs which could be administered 
during therapy (Tone, 2005). Replacing the formerly loved barbiturates (Lader, 1991), 
benzodiazepines were found to accelerate the production of GABA in the brain and subsequently 
create feelings of tranquillity and ease. These drugs initially showed little psychological or physical 
risk to users (Jonas et al., 1993; Lader, 2011; Wick, 2013; Ford and Law, 2014), and low addiction 
potential (Committee on the Review of Medicines (CRM), 1980). Benzodiazepines grew popular as 
their anxiolytic, anticonvulsant, hypnotic and muscle-relaxant properties were favoured to assist in 
the management of anxiety, panic disorder, insomnia and epilepsy (Chouinard et al., 1983; Ballenger 
et al., 1988; Wick, 2013). 
The expeditious growth of the benzodiazepine family had precise correlation with international 
prescription statistics: In 1978, the pharmaceutical company Hoffman La-Roche sold enough Valium 
pills to sedate half of the world’s population (Times Colonist, 2003, cited in Tone, 2005). Around the 
year 1991, it was believed that 15% of all NHS prescriptions were for hypnotics and anxiolytics 
(Lader, 1991). At first, it was perceived that users were middle-class, worried mothers and wives 
(The New York Times, 2012; Woods, 2016): 1 in 20 UK prescriptions were for Valium, predominantly 
for women (The Independent, 2003). In Jacqueline Susann’s 1966 novel Valley of the Dolls, she wrote 
about troubled, middle-class women who wished to relieve everyday stresses and then became 
dependent on prescription medication. In the same year, Mother’s Little Helper was a chart hit by 
The Rolling Stones, reiterating the belief that benzodiazepines were dominant amongst anxious 
mothers and wives post World War 2:  
(The Rolling Stones, 1966)3 
 
                                                          
3 Referring to the 5 mg yellow Diazepam tablets: see appendix 3 
‘Kids are different today’, I hear ey’ry mother say 
Mother needs something today to calm her down 
And though she’s not really ill 
There’s a little yellow pill 
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The use of small psychoactive tablets to help maintain a stable mind became fairly normalised (New 
Internationalist, 1984; The New York Times, 2012; National Institute on Drug Abuse (NIDA), 2011) 
however their addictive potential soon presented itself (de las Cuevas et al., 2003) alongside other 
harmful side effects such as: damaging memory functions; the impairment of psychomotor tasks 
leading to accidents and injuries; paradoxical stimulation and; emotional blunting (Block and 
Berchou, 1984; Curran, 1986; Kozená et al., 1995; Paton, 2002; Barker et al., 2004; Michael et al., 
2007; Maxwell et al., 2010; Billioti de Gage et al., 2012). By the 1970s, it became apparent that users 
could become dependent and show signs of withdrawal even after normal dosages (Hollister et al., 
1961; Covi et al., 1973). Thus, the Committee on the Safety of Medicines issued a report in 1988 
recommending that usage should not exceed 2-4 weeks (see Committee on the Safety of Medicines, 
1988). Addiction charities emerged such as the Bristol and District Tranquilliser Project (established 
in 1985) and Mind in Camden: REST Service (established in 1988) however campaigns to halt 
benzodiazepine production were seemingly ignored and many more of the psychotropic drugs were 
patented throughout the years (Lader, 1991), as displayed in the table below. 
Table 2: Examples of benzodiazepines and their year of introduction to the UK 
Generic Name Brand (Manufacturer) Sold since 
Chlordiazepoxide Librium et al. (Roche) 1960 
Diazepam Valium et al. (Roche) 1963 
Nitrazepam Mogadon et al. (Roche) 1965 
Oxazepam Serenid (Wyeth) 1966 
Lorazepam Ativan et al. (Wyeth) 1972 
Clorazepate Tranxene (Boehringer) 1973 
Flurazepam Dalmane (Roche) 1974 
Temazepam Euhpnos (FCE), Normison 
(Wyeth) 
1977 
Triazolam Halcion (Upjohn) 1979 
Bromazepam Lexotan (Roohoo) 1982 
              Alprazolam Xanax (Upjohn) 1983 
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Despite Alprazolam being around since 1983, it was not the benzodiazepine of choice in the UK until 
recently. The growth of online clear- and dark-web markets and the ease of access may be a 
potential explanation for this development which will be discussed further in section 2.5. 
Slowly, user demographics shifted from middle-class individuals seeking harmless relief in order to 
cope with everyday stress, to opioid users seeking to enhance levels of toxicity (see Stitzer et al., 
1981; Jones et al., 2012; Schmitz, 2016). Counterfeit pharmaceuticals and benzodiazepine-type NPS’ 
began to emerge (United Nations Office on Drugs and Crime (UNODC), 2017), smothering the dark 
market and enabling users to obtain various benzodiazepines quickly and cheaply (Barratt and 
Aldridge, 2016; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2016a; Dittus 
et al., 2018). The former ‘wonder drug’ Valium was accountable for 285 deaths in England and Wales 
in 2016 (ONS, 2018). 
The most recent years have seen growth in another group of users in the UK: children and young 
people. Despite almost 50 years since being discovered and levels of Diazepam prescriptions 
remaining fairly stable at around 4 – 5 million issued in England and Wales per annum 
(OpenPrescribing.net, 2018), there are still significant gaps in knowledge as to how they are used off-
prescription. The following section will examine media coverage and literature highlighting the 











2.4 Current media discourse in the UK 
As stated in Chapter One of this thesis, trade names Xanax (Alprazolam) and Valium (Diazepam) have 
been prominent buzz words in recent UK headlines, with reports of increased usage amongst 
children and young people (see BBC News, 2018a; BBC News, 2018d; Birmingham Mail, 2018; VICE, 
2018a). After an extensive search on LexisLibrary online from the past 2 years (14th September 2016 
– 14th September 2018), the term ‘Xanax’ featured 1,221 times in 125 UK newspapers and the word 
‘Valium’ alone had featured 2,429 times. Coupled with ‘young people’, 133 news articles were 
presented when associated with ‘Xanax’. See the table below for other combinations.  
Term Number of different sources Number of mentions 
‘Xanax’  126 1,221 
‘Valium’  215 2,429 
‘Benzos’ 43 188 
‘Xanax’ and ‘self-medicate’ 10 33 
‘Valium’ and ‘self-medicate’ 20 35 
‘Xanax’ and ‘young people’ 42 133 
‘Valium’ and ‘young people’ 36 104 
 
Table 3: LexisLibrary search from 14th September 2016 – 14th September 2018: UK Newspapers only 
The table above shows that Valium has been more prevalent in media headlines in the past two 
years than Xanax. Revisiting the UK study in 2014, the dominant benzodiazepine discussed was also 
Diazepam (n=62, 53.4%), followed by Lorazepam (n=26, 22.4%), Alprazolam (n=20, 17.2%), 
Oxazepam (n=14, 12.1%) and Nitrazepam (n=12, 10.3%).  
The media discourse as displayed in table 3 above suggests that Valium is still the most frequently 
discussed benzodiazepine and perhaps the most frequently used, however reliable, up to date, 
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academic evidence is lacking to confirm this continuation, thus, this research project wishes to fill 
that gap. This research project wishes to explore the truth behind media coverage, and discover 
which benzodiazepine has been used more frequently from a user perspective. 
Section 2.4.1 will explore the perceived demographics of benzodiazepine users based on 
investigative journalist pieces, government reports and the one academic study (Kapil et al., 2014). 
The popularity of Xanax and benzodiazepines amongst celebrities and music artists will be 
highlighted in section 2.4.2, in a bid to describe this rising phenomenon.   
2.4.1 User demographics 
In Kapil et al.’s 2014 UK-based online questionnaire inclusive of 1500 participants, the age of the 
sample population was predominantly 21 – 39 years (40.5%) and 50 – 59 years (29.3%) and only 
9.1% of the sample were aged 16 – 20. However, only 392 of the 1500 participants reported having 
tried at least one benzodiazepine or Z-drug, and only 116 had self-reported misusing4 them. A 
breakdown of the demographic information was unobtainable and therefore it is unknown whether 
these 391 participants were in the same age bracket of those portrayed across the media, and thus 
this data cannot be directly compared.  
Earlier this year, popular lifestyle and culture magazine VICE launched a nationwide survey using 
social media platform Snapchat, which asked questions regarding individuals’ knowledge of Xanax 
and their levels of use. Of the 85,000 respondents gathered which are assumed to be predominantly 
aged 13 – 24, 35% admitted to knowing at least one friend who takes Xanax (VICE, 2018b). This is the 
largest survey examining the prevalence of Xanax today, however, as noted in previous chapters, the 
level of legitimacy of news articles is almost always questionable and misleading (Sumner et al., 
2014) especially around the deviant topic of substance abuse (UK Drug Policy Commission (UKDPC), 
2012).  
With the scaremongering media strongly focusing on the negative side effects and in the absence of 
up to date academic research on use in the UK, we are left with little credible evidence and limited 
understanding of this apparent rising drug use trend.  
                                                          




2.4.2 Cultural accommodation 
The verbal exclamation of the efficacy of benzodiazepines is not a new phenomenon. As well as the 
Rolling Stones in 1966 highlighting the need for benzodiazepines as explored in section 2.3, in the 
late 1990s, famous rapper Ice-T exclaimed:  
(Body Count, 1997) 
Sad hip-hop and rap has become a popular music genre amongst young people in America and the 
UK in the last couple of years and may have influenced the normalisation of Xanax and other 
benzodiazepines in self-medicating terms. The discussion of the misuse of prescription drugs online 
and throughout music can act as negative behaviour reinforcement and create new social norms 
(Blake, 2007; Hanson et al., 2013). Using an online site with a colossal music database5, 
benzodiazepine terms and references were searched for and are displayed in the table below (all 
searches were made on the 15th November 2018): 





Table 4: Benzodiazepine terms within song lyrics 
The table above shows that the term ‘Valium’ had featured 310 times, 76 more times that the 
shorted Xanax term: ‘Xans’. It must be noted that the figures above may include unrelated mentions 
and/or fail to include every single relatable song lyric6.  
                                                          
5 www.lyrics.com : ‘The Web’s Largest Resource or Music, Songs & Lyrics’ 
6 The shortened terms ‘vallies’ and ‘vals’ were also searched for, but the results were not relatable to 
benzodiazepine drugs 
Need some Xanax, want some pills, ‘cause I don’t like 
the way I feel 
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2.5 Access, availability and cost 
It has been suggested that ease of access to certain drugs almost definitely increases rates of usage 
(Friedman, 2006; Fleary et al., 2013), and facilitates individuals indulging in drug experimentation 
(see LeClair et al., 2015). The source of benzodiazepines can vary. Evidence from Kapil et al.’s 2014 
UK study discovered that over half (n=64, 55.2%) of benzodiazepine using respondents had received 
the drugs via legitimate prescription, alongside two-fifths (n=46, 39.7%) obtaining them via friends 
and/or family members. A quarter (n=31, 26.7%) of individuals purchased them online; a fifth (n=23, 
19.8%) from street dealers and 13 (11.2%) sourced them from outside the UK. However, the study 
did not differentiate the types of benzodiazepines and Z-drugs.  
However, the expansion of clear- and dark-web markets since 2014 has been noted (see Monteith et 
al., 2016; Novak et al., 2016; Dittus et al., 2018) and current users are believed to obtain their 
benzodiazepines via other means, as opposed to via legitimate prescription as highlighted above. 
However, the source of benzodiazepines for current users remains relatively undiscovered. The vast 
development of technology and global interconnectivity undoubtedly facilitates easy access for users 
to obtain their drugs via other means: online-unregistered pharmaceutical companies; social media 
and; the dark-web. All points will be discussed respectively throughout the following sub-sections.  
2.5.1 Clear-web and social media 
Launched in the late 1990’s, the first online pharmaceutical sites had the intent to enable convenient 
access to prescription medication (United States General Accounting Office, 2000). However, 
unregistered, unlicensed pharmaceutical webpages began to mimic legitimate sites and have since 
penetrated the clear-web scene, and are frequently used when obtaining hypnotic and sedative 
drugs (Novak et al., 2016). Even though the MHRA has attempted to combat users buying from 
illegitimate sources by launching website with a list of all authorised online sellers of medicines (see 
MHRA, 2018b), several research papers have identified numerous illicit pharmaceutical sites for a 
variety of prescription drugs over the years (Wax, 2002; Bachhuber and Cunningham, 2013; 
Monteith et al., 2016), however there is limited published research examining the clear-web sales of 
benzodiazepine drugs.  
24 
 
A simple Google search of ‘Xanax tablets UK’ revealed a website selling numerous benzodiazepines 
such as Xanax for as little as £1.20 per pill. It stated:  
After a quick search on the MHRA register of authorised pharmacies (see MHRA, 2018b), it was soon 
discovered that www.sleeptab.com was an illegitimate website. See appendices 5 – 7 for 
screenshots.  
Although social media sites explicitly state that there should be no promotion of the use and sales of 
non-medical drugs (Facebook, 2018: see ‘community standards’), the ability to connect instantly and 
more frequently has been manipulated by illicit drug buyers and sellers and according to the think 
tank McAfee Institute7: ‘Finding drugs on Facebook is easier than buying a cup of coffee’ (McAffee 
Institute, 2018). Accommodating to cultural norms, former street dealers use apps to build online 
profiles where they may imply or state that they are selling substances using a range of key words 
(Katsuki et al., 2015). It is thought that buyer-seller conversations are then moved to encrypted 
messaging apps such as Wickr (Guardian, 2017; BBC News, 2018e). Similarly, drug-related forums 
such as Reddit and Bluelight are also useful in gaining information and advice about sourcing 
benzodiazepines, and members often encourage others to head to dark-web markets for discrete 
door to door delivery and cheap prices. See appendices 8 – 10 for screenshots of Twitter, Instagram 
and Reddit posts respectively8. 
However, WHO (2009) estimate that half of pharmaceuticals sold on unlicensed webpages are 
counterfeits (cited in Lavorgna, 2015) and thus, there is a desperate need for correct content 
analysis in order to minimise risk. Alarmingly, figures suggest that 1 in 4 higher education students, 
inclusive of those studying health care topics, are unaware of danger signs advertised by illegitimate 
internet pharmacies and are likely to be misled by professional-looking webpages, which closely 
imitate reputable sites (Ivanitskaya et al., 2010). Thus, researchers are urged to scope out the online 
sales of benzodiazepine drugs via unregistered pharmaceutical sites in order to limit sales.  
                                                          
7 ‘We offer professionals all around the world the ability to learn the topics they are most passionate about all 
online from their home, office, or anywhere else they want to learn.’ -  https://www.mcafeeinstitute.com/  
8 All searches were made on 26/10/2018 
You can buy Xanax pills online at cheap price from our 




In February 2011, the world became more vulnerable to technological deviancy with the emergence 
of the first successful cryptomarket – Silk Road (Soska and Christin 2015). Often referred to as the 
‘EBay for drugs’ (Barratt and Aldridge, 2016; EMCDDA, 2016a; Dittus et al., 2018), members could 
acquire digital goods or fireworks, but predominantly it was used to purchase drugs (Christin, 2012), 
by using a digital and non-identity-carrying payment method (Barratt and Aldridge, 2016). Silk Road 
has since been shut down, however law enforcement efforts of taking out vendors and closing whole 
cryptomarkets do not seem to prevent trading (Soska and Christin, 2015; Buskirk et al., 2017) and 
many more cryptomarkets swiftly emerged and continue to evolve. Evidence of the growth in this 
market highlight the limitations of previous, outdated research efforts (Kapil et al., 2014) and the 
need for more current research to scope out the source of benzodiazepines used in the UK. 
According to the most recent Global Drugs Survey publication (2018), respondents who purchase 






Figure 1: Percentage of benzodiazepine users purchasing via the dark-web 
Moreover, data from 2017 analysed by researchers at the Oxford Internet Institute discovered that 
22% of Xanax trades from the dark-web are accounted for by the UK. Out of the 1.5 million trades 
that were monitored, the group of researchers found that 50,000 of those were Xanax-related (cited 
in The Guardian, 2018a). Online dark-web markets namely Alpha Bay and Hansa were analysed, and 
transaction reports discovered that from 2015 to 2017 inclusive of 21 months, over 1.5 million fake 
Xanax bars were sold to Great Britain alone (BBC News, 2018c). It is thought that Xanax bars can be 
bought on dark-web markets for as little as 30p each (VICE, 2018a). However, this data is relatively 
broad and does not necessarily account for current, young users. Therefore, this research project 
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2.6 User motivations  
Based on the theory that motivations must be unpicked first in order to explain illicit drug use 
behaviours (see DiClemente, 1999), this section provides an overview of national and international 
studies exploring possible motivations for the non-prescribed use of benzodiazepines. After 
discussing the perception of risk and social acceptance in section 2.6.1, this section will be divided 
into separate user motivations based on Boyd et al.’s study (2006): those who use them to self-
medicate (section 2.6.2 for sleep issues and section 2.6.3 for anxiety issues) and those who use 
benzodiazepines for other, recreational purposes such as: to relax (section 2.6.4.1); to get high 
(section 2.6.4.2) and/or; to ‘come down’ from stimulant substances (section 2.6.4.3). 
2.6.1 Perceived risk and social acceptance  
A key motivator for purchasing and consuming benzodiazepines can be due to their low levels of 
perceived risk and deviance. Prescription drugs are thought to be a lot safer than street drugs 
(Friedman, 2006; Fleary et al., 2013; Kapil et al., 2014) and are therefore far more socially accepted 
(Bettinardi-Angres et al., 2012). Users often do not view their misuse and/or overuse of prescription 
drugs as problematic, as they are often able to sustain a conventional persona (Bardhi et al., 2007; 
Chandler et al., 2014) and it has been suggested that individuals who believe prescription drugs pose 
little harm are approximately 10 times more likely to partake in non-medical use (Arria et al., 2008). 
Consumer culture justifies the consumption of a small pill for fast pain relief (NIDA, 2011), and users 
trust that they are approved by health care advisors, regardless of their strong potency (Grahn, 
1983). However, it must be noted that non-prescribed, illicitly bought ‘pharmaceuticals’ are not 
always legitimate. In a UK context, Xanax is a special cause for concern as it is not available under 
NHS prescription, and is therefore likely to be custom pressed and illegitimate. The interdisciplinary 
nature of this research project includes chemical analyses of assumed ‘Xanax’ and ‘Valium’ street 
samples from Manchester, methods and results of which will be outlined in Chapter Five and Six 
respectively of this thesis.  
2.6.2 Sleep issues/insomnia 
As stated in section 2.2, the family of drugs possess powerful sedative properties and their efficacy 
has been noted. Although not all users visit the GP to obtain their benzodiazepines, international 
studies have shown that non-prescribed users commonly use benzodiazepines for their intended 
use: to get to sleep (see Boyd et al., 2006; Paredes et al., 2008; Andersson and Kjellgren, 2017), 
which runs parallel to UK users: two-thirds (n=77, 66.4%) of benzodiazepine users in Kapil et al.’s 
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study stated they did so to get to sleep. However, UK media coverage has solely focused on self-
medicating teens. For non-prescribed users who take benzodiazepines for their intended use, there 
is a vast lack of knowledge and thus, this research project wishes to bridge that gap.  
2.6.3 Self-medicating in the age of anxiety 
A consistent theme which has emerged throughout the recent media reports is that individuals are 
using Xanax, Valium and other benzodiazepines to self-medicate for any underlying mental health 
issues (see BBC News, 2015; ITV News 2018a; Metro, 2018; Mirror, 2018; The Guardian, 2018b; The 
Guardian, 2018d; The Telegraph, 2018; VICE, 2018a). In a short film by VICE, an 18-year-old female 
from London spoke about her Xanax use:  
(VICE, 2018c: 2min28secs)  
Although media reporting is often exaggerated and unreliable, many international academic 
research papers support this motive and have discovered that non-prescribed benzodiazepine users 
commonly do so to self-medicate for symptoms of anxiety, panic attacks, nervousness, social unease 
or big life stresses (see Pederson and Lavik, 1991; Rigg and Ibañez, 2010; Andersson and Kjellgren, 
2017). 43 respondents in the UK study also admitted to taking anxiolytics when they were stressed 
(Kapil et al., 2014). However, there is a huge lack of recent, UK-based academic evidence to back the 
copious amounts of media publications.   
Anxiety is the feeling of fear and excessive worry regarding everyday tasks and events (Gale and 
Oakley-Browne, 2004), whereby sufferers may experience an accelerated heart rate, 
hyperventilation, shortness of breath, cold sweats and disorientation (Dunn, 2016; Bandelow et al., 
2017). It is thought that anxiety levels peak during adolescence and early adulthood (Whiteford et 
al., 2013, cited in Vannucci et al., 2016; Hagell et al., 2015): three quarters of lifelong mental health 
issues arise before the age of 24 (Kessler et al., 2005). Data from Universities UK discovered a 
dramatic 5-fold increase of the number of undergraduate (UG) students disclosing a mental health 
condition in the last ten years (Universities UK, 2018): from 8,415 in 2007 – 08 to a colossal 49,265 in 
2017 – 18. The visual data presented in appendix 11 demonstrates the steep rise in reported mental 
health amongst UK students in the past decade. With teenage suicide rates having increased 67% 
“I was taking about 3-4 bars… They just numbed the 
horrible feelings of life and they just made you feel like 




since 2010 (ONS 2018, cited in The Independent, 2018), it is vital to maintain the well-being of young 
people and make sure there is adequate help and support for those suffering. This is a national 
health issue.  
Investigated by the National Union of Students (NUS) with the assistance of the drug charity Release, 
drug trends and user motivations were examined amongst 2,810 students. A third of respondents 
who take drugs did so to cope with stress (31%); just over a fifth claimed to use drugs to self-
medicate and alleviate any existing mental health issues (22%) and; 11% of respondents said they 
take drugs to cope with a difficult life event (NUS and Release, 2018). Although these figures do not 
specify the non-prescribed use of benzodiazepines, this data may be a useful indication of the rise of 
self-medicating young people. Self-medicating may be considered as the most private and 
sometimes the easiest way for short-term relief when other methods are unreliable.  
With soaring house prices and crippling university debt, it is widely acknowledged that young people 
of today have overwhelming concerns regarding their academic life and finances (Mind, 2008; 
Meltzer et al., 2013; Parmar et al., 2016; OECD, 2017; Young Women’s Trust, 2017; Gunnell et al., 
2018). Studies reveal that school pressure and money woes are the dominant causes of anxiety 
amongst young people (Varkey Foundation, 2017), and some teens even reported to self-medicate 
with Xanax when exam stress hits (see The Telegraph, 2018). Evidence suggests there is a strong 
association between financial strain and ill mental health (see Mind, 2008; Meltzer et al., 2013) and 
even suicide (see Parmar et al., 2016). The Institute of Fiscal Studies discovered that the average 
university graduate is left with a colossal debt of £50,800, and those from poorer backgrounds can 
be left with over £57,000 (cited in BBC News, 2017b).  
The online world is an exciting prospect of opportunity (Ofcom, 2016), however, internet and social 
media use has been directly associated with a decrease in personal well-being (see Kraut et al., 
1998) and excessive use has proven to spark symptoms of depression and anxiety (see Radabi et al., 
2017), decreased self-esteem and feelings of inferiority (Homewood Health, 2017). Maintaining a 
well-liked persona online and offline can be strenuous (Seo et al., 2014; EdCan, 2017; Homewood 
Health, 2017; Mental Health Foundation, 2018), and it has been reported that nearly half of 18 – 24 
year olds blame their high levels of stress due to comparing themselves to others online (Mental 
Health Foundation, 2018; EdCan, 2017).  
In addition, the online world exposes people to the dangers and horrors across the globe (Collier, 
2013; Livingstone and Smith, 2014), with scaremongering news articles highlighting concerns around 
famine, poverty, and terrorism (BBC News, 2018g; BBC News, 2018h; ITV News, 2018b respectively). 
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Seeing daily posts about incidents in neighbouring countries via the internet undoubtedly provokes 
feelings of discomfort, worry and fear and may evoke symptoms of anxiety and even PTSD (McHugh 
et al., 2018). Nearly one in five (19%) of internet users blame current affairs for their high levels of 
stress (Mental Health Foundation, 2018).   
In light of this growing body of evidence surrounding young people and anxiety, this research project 
specifically sets out to explore whether current generation Z9 users are using this group of drugs to 
self-medicate or whether their motivations for use are much broader.  
2.6.3.1 Lack of mental health services and failure of treatment 
UK citizens are fortunate in the fact that they have free access to mental health resources such as 
counselling and group therapy. However, figures show that only half of young people feel 
comfortable enough to discuss personal matters with their GP (Brooks et al., 2015), which may be a 
reason for anxiety issues often remaining undiagnosed (Kessler et al., 2002). Moreover, if they do 
approach help services, child and adolescent mental health service waiting lists are often long and 
some have been forced to wait up to 18 months (Care Quality Commission, 2017). Not only does 
mental health deteriorate whilst waiting for the appropriate support, the majority of those who wait 
are not directed to any other form of support or treatment in this time (Young Minds, 2018). This 
may be a key motive for anxious young people to source benzodiazepine drugs via other, illegitimate 
means and this research project wishes to explore this further. Moreover, it is not always certain 
that traditional treatment services are adequate. In the VICE film, a rap artist exclaimed:  
(VICE, 2018c: 7min20secs)  
Nonetheless, NHS England have acknowledged that it is fundamental to improve treatment services 
and have highlighted investment strategies to improve access to mental health services by 2020 (see 
Department of Health, 2014). However, produced five years ago, the strategies in the NHS report 
seem to be ineffective as young people are treating their symptoms in other ways.  
                                                          
9 Those born mid-1900s to early 2000s 
“I actually suffered from depression and anxiety... We 
[were] going to GPs, trying to get help but that made us 
worse… [They gave me] sertraline… Anti-depressants 
and anti-anxiety stuff. None of that shit worked. It 




2.6.4 Recreational use 
It is said we currently live in a society where using prescription drugs to ameliorate or positively 
intensify life experiences is exceedingly common (LeClair et al., 2015). Benzodiazepines’ euphoric 
effects are also enjoyed by international recreational users (Rigg and Ibañez, 2010; Vogel et al., 
2013; Kapil et al., 2014; Weaver, 2015; Andersson and Kjellgren, 2017; Mateu-Gelabert et al., 2017) 
and a handful even experience psychedelic effects (Beharry and Gibbons, 2016). The following 
section will draw upon predominantly international studies, which highlight the recreational use of 
benzodiazepines to: unwind and relax (section 2.6.4.1); actively get high (section 2.6.4.2) and; 
counteract the effects of stimulant drugs (section 2.6.4.3). Although the majority of the studies 
displayed in the following section are international, findings may provide an insight into user habits 
in the UK. 
2.6.4.1 Relaxation 
Using sedative drugs for anything other than their clinical uses is very much like alcohol intoxication 
(Weaver, 2015), and the recreational use of CNS prescription drugs has been noted to ‘intensify 
relaxation’ and ‘maximise down time’ (LeClair et al., 2015). Benzodiazepine drugs are commonly 
praised for their euphoric and relaxing effects, however, there is a deficit of up to date, academic 
evidence and it is not known whether current UK users use them for this reason. 
2.6.4.2 To get high 
Some recreational users claimed to use benzodiazepines in order to accentuate the high of the 
intoxication of other drugs, as explained by multiple participants in Rigg and Ibañez’s study (2010): 
‘[to] take it to another level’. It is also believed that alcohol drinkers consume benzodiazepines to 
augment the feeling of being drunk (Lader, 2011), and opioid users to increase the high (Vogel et al., 
2013). The majority of benzodiazepine users in an American study did so to ‘get high’ or ‘messed up’ 
(see Rigg and Ibañez, 2010). 
It was also noted that recreational users tend to ingest prescription drugs differently, in order to 
alter the high (Rigg and Ibañez, 2010; Andersson and Kjellgren, 2017). Non-oral methods include 
snorting, smoking and/or injecting. Benzodiazepine routes of administration amongst non-
prescribed users in the UK remains totally undiscovered, thus the sociological research element of 




2.6.4.3 To ‘come down’ from stimulants 
Benzodiazepines were also noted to be useful when wanting to eradicate the unwanted effects of 
other drugs (Schmitz, 2016) or to ‘come down’ from stimulants (Rigg and Ibañez, 2010; Kapil et al., 
2014; Beharry and Gibbons, 2016; Mateu-Gelabert et al., 2017) especially after excessive cocaine use 
(Bardhi et al., 2007; Motto-Ochoa et al., 2017). 
2.6.5 Section overview 
To summarise, motivations for the non-prescribed use of benzodiazepines vary greatly. The UK 
media has dominantly focused on self-medicating teens and despite only one academic report 
examining the non-medical use of benzodiazepines amongst UK users (see Kapil et al., 2014), 
international research studies and theories suggest CNS depressant drugs are frequently used to 
either heighten the feeling of intoxication (Andersson and Kjellgren, 2010; Rigg and Ibañez, 2010), 
and/or to counteract unwanted side effects of stimulant drugs (Bardhi et al., 2007; Rigg and Ibañez, 
2010; Kapil et al., 2014; Beharry and Gibbons, 2016; Schmitz, 2016; Mateu-Gelabert et al., 2017). 
However, the media dominated discourse raises questions of credibility, and the one reliable, UK 
academic paper is outdated and lacks in-depth analysis of user motivations. International studies 
begin to illustrate a picture of benzodiazepine use, however, these motivations may not be 
applicable to young UK users. Thus, this research project wishes to collect usage data from 











2.7 Adverse negative effects 
The following section will begin by recapping the effect of benzodiazepines on certain areas of the 
body and brain as explored at the start of this chapter. It will then outline the following dominant 
adverse negative effects: temporary sedation, complex psychomotor tasks, accidents and injuries 
(section 2.7.1); memory impairment and cognitive decline (section 2.7.2); paradoxical stimulation 
(section 2.7.3); emotional blunting and depression (section 2.7.4); poly-drug use dangers (section 
2.7.5) and lastly; tolerance, dependency and withdrawal effects (section 2.7.6). 
As outlined in section 2.2.2, benzodiazepines can cause effect to:  
1. The brain stem – This cares for vital bodily functions such as breathing, heartbeat and blood 
pressure. 
2. The spinal cord and cerebellum – Physical body such as muscle relaxation, motor 
coordination, balance and posture. 
3. The cerebral cortex – This affects the brain: consciousness, cognitive ability and 
concentration levels. 
4. The limbic system – This cares for emotions and memory. 
Despite a wide range of positive effects and functions as highlighted in section 2.2, the use of 
benzodiazepines, particularly for prolonged or sustained periods, can cause a range of potential 
harms and unintended side effects which have been noted for many decades (Hollister et al., 1961; 
Block and Berchou, 1984; Gardner and Cowdry, 1985; Thomas, 1988; Curran, 1986; Bond et al., 
1991; Bond and Silveira, 1993; Curran et al., 1994; O’Sullivan et al., 1994; Kozená et al., 1995; 
Ashton, 2002; Paton, 2002; Verster et al., 2002; Barker et al., 2004; Friedman, 2006; Michael et al., 
2007; Clegg and Young, 2010). The effects listed in the table below will be elaborated throughout 
















Table 5: Short- and long-term effects of BZD use 
2.7.1 Temporary sedation, complex psychomotor tasks, accidents and injuries 
The short-term feeling of sedation, unsteadiness and slight disorientation may be a bearable side 
effect of benzodiazepines, however prolonged sedation and psychological impairment is a common 
side effect of hypnotic and tranquiliser drugs, which can last up to a week after administration (Bond 
et al., 1991). Levels of consciousness are fractured leaving the individual drowsy and dull, and they 
may lose the ability to maintain full concentration levels (Lader, 2011), thus, increasing the risk of 
accidents and injuries (Friedman, 2006). Prolonged use means it may persist and negatively 
influence everyday psychomotor tasks (Block and Berchou, 1984).  
Whether prescribed or non-prescribed, benzodiazepine users must be aware that there is a direct 
link between usage and road traffic accidents (Ravera et al., 2011), corresponding with age and 
alcohol usage (Maxwell et al., 2010). Studies suggest that long half-life benzodiazepines (i.e. Valium) 
significantly distort individuals’ driving ability during the first few weeks of usage (see Smink et al., 
2010; Dassanayake et al., 2011) and risk of motor accidents among benzodiazepine users is 
approximately doubled (Thomas, 1988). Shorter-acting benzodiazepines have also caused alarming 
effects: a double-blind placebo study in Europe discovered that the administration of merely 0.5 mg 
of Alprazolam caused a significant deterioration in vigilance performance (Kozená et al., 1995). 
Supporting evidence comes from a double-blind crossover study collected by Verster, Volkerts and 
Verbaten (2002) who administered 1 mg of Alprazolam or a placebo to 20 healthy participants, who 
were then asked to complete a standardized 100 km Dutch driving test 1 hour after the drug was 
Short-term effects Long-term effects 
Temporary sedation and drowsiness  Impairment of memory processing functions 
Lack of concentration ability Emotional blunting  
Accidents and injuries Depression 
Memory loss and black-outs  Rebound anxiety  
Paradoxical rage and aggression  




taken orally. Alongside showing a diminish in alertness, decreased mental activation and a worsened 
quality of driving, 6 out of the 20 participants were unable to complete the driving test due to falling 
asleep at the wheel.  
2.7.2 Memory impairment and cognitive decline 
Many studies have proven that benzodiazepines significantly disturb vital attention and performance 
skills, alongside fracturing multiple processes such as visual perception and memory acquisition (see 
Block and Berchou, 1984; Barker et al., 2004; Michael et al., 2007) which increases with task 
difficulty (Curran, 1986). A French study examining the link between long-term benzodiazepine use 
and dementia discovered there was a 50% increased risk of developing the disorder (see Billioti de 
Gage et al., 2012), and prolonged use may permanently fracture memory and information storing 
(Curran, 1986; Curran et al., 1994). 
Although short-term memory impairment and amnesia may be useful when used as pre-medication 
for surgical procedures (Kanto, 1986), it is sometimes an unpleasant side effect for casual users. 
Episodic memory impairments may lead to complete ‘blackouts’ (Ford and Law, 2014) and may 
result in erratic and uncharacteristic behaviour (Ashton, 2002). These effects are amplified with the 
addition of alcohol (Bond et al., 1991) and other CNS depressants (Griffin et al., 2013). 
2.7.3 Paradoxical stimulation 
Controversially, disinhibitory reactions such as increased levels of anxiety, hyperactivity, agitation 
and rage present themselves in some benzodiazepine cases (see Gardner and Cowdry, 1985; 
O’Sullivan et al., 1994) which increases significantly with the addition of alcohol (Bond and Silveira, 
1993). It is believed that the powerful anxiolytic and amnesic effects waiver individuals’ capability of 
adhering to appropriate social behavioural norms (Paton, 2002). Intoxicated users may show levels 
of hostility and erratic behaviour (Griffin et al., 2013) and even indulge in criminal activity due to the 
drug making them feel ‘invincible’ (BBC Newsbeat, 2010; Ford and Law, 2014; Andersson and 
Kjellgren, 2017). As highlighted in the previous sub-section, it is often that users are totally unaware 
of any erratic behaviours whilst they are intoxicated, and have no recollection of the event (Lader, 
2011). Shorter-acting, more potent benzodiazepines (i.e. Xanax) are more likely to induce these 
paradoxical effects (Ait-Daoud et al., 2018).  
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2.7.4 Emotional blunting and depression 
Some researchers believe there is a link between benzodiazepine use and depression (Longo and 
Johnson, 2000) and some individuals may develop signs of delirium (Clegg and Young, 2010). On the 
other hand, Ashton (2002) claims that benzodiazepines may cause ‘emotional anaesthesia’, whereby 
a user is numb to pleasure or pain. However, this area remains fairly under researched and the lack 
of evidence means it is difficult to draw conclusions. Thus, this research project wishes to explore 
the negative psychological effects as well as physical effects that users may experience as a result of 
benzodiazepine use. 
2.7.5 Poly-drug use dangers 
Studies have shown that poly-drug use is common amongst those who misuse prescription drugs 
(see Busto et al., 1986; Rigg and Ibañez, 2010; Kurtz et al., 2011; Kelly et al., 2013; Andersson and 
Kjellgren, 2017; Mateu-Gelabert et al., 2017) and that benzodiazepines are not usually the first 
substance added to the poly-drug cocktail (Schmitz, 2016; Mateu-Gelabert et al., 2017). In addition, 
those misusing benzodiazepines alongside other substances are more likely to consume significantly 
higher dosages than those misusing benzodiazepines alone (Busto et al., 1986) which 
unquestionably increases the risk of overdose and fatalities.  
Altering vital bodily functions like the heart rate and breathing comes with added risk, and 
individuals who exceed the recommended dosages or take them in conjunction with other CNS 
depressants could be left in a coma or even face death (NIDA, 2011). Of the 3,756 registered poly-
drug poisoning deaths in England and Wales in 2017, 319 involved benzodiazepines (ONS, 2018). 
Benzodiazepine-only deaths have increased by 30% within the last year (from 17 to 22), and 
benzodiazepine poly-drug deaths involving selected substances have increased by 90% in the last 
decade (from 207 in 2007 to 391 in 2017). Deaths involving Diazepam have also risen significantly. 
Since data collection began back in 1993, the number of Diazepam-related deaths have seen a 5-fold 
increase (from 52 in 1993 to 226 in 2017) (ibid.). See appendix 12 for a visual representation of 
benzodiazepine-related fatalities in England and Wales. 
Issues also arise when users consume ‘uppers’ such as MDMA or cocaine, alongside ‘downers’ such 
as benzodiazepines in a short time frame. The individual effects of each drug on bodily functions are 
so juxtaposing that the body may become overwhelmed and suffer dramatic levels of stress. 
However, the exact chemical reactions in the body remain under researched and it is not known 
whether these effects are experienced by poly-drug users.  
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2.7.6 Tolerance, dependency and withdrawal 
Forming an addiction to prescribed pharmaceuticals is certainly not a new phenomenon: it has been 
known for many decades that misusing and/or overusing benzodiazepines can cause psychological 
dependency (Hollister et al., 1961; Covi et al., 1973; de las Cuevas et al., 2003). Thus, in 1988, the 
Committee on Safety of Medicines (CSM) strongly advised that benzodiazepine usage should not 
exceed 4 weeks (see Committee on the Safety of Medicines, 1988). The media have reported several 
cases of involuntary dependence over the years (BBC News, 2001; The Guardian, 2002; The 
Guardian, 2003; Hampshire, 2004), and Ray Nimmo was the first to legally sue his GPs in 2002 for 
involuntary addiction (The Independent, 2011).  
It must also be noted that because the speed of onset is also linked to routes of administration (Rigg 
and Ibañez, 2010; Andersson and Kjellgren, 2017), those who choose to snort their drugs feel 
reinforcing effects much faster and thus there is a higher potential of problematic use and addictive 
behaviour (Compton and Volkow, 2006). However, UK research has failed to capture user’s routes of 
administration and therefore it is unknown how current benzodiazepine users consume them.  
Those who disregard the recommendations are undoubtedly increasing their levels of tolerance, and 
are more liable to experience adverse negative effects explored in previous sections. Tolerance to 
benzodiazepine drugs becomes apparent just after a few weeks of continuous daily consumption 
(Hollister et al., 1961; de las Cuevas et al., 2003), which can result to an increased dosage and 
potentially increase the frequency of use. It is common that some individuals may still experience 
waves of negative symptoms like anxiety and unease whilst still taking benzodiazepines as they 
become tolerant to a certain volumes of dosage. This may lead to an increase in dose or the addition 
of another benzodiazepine (Ashton, 2002).  
Adverse negative effects, dangers and recommendations have been seemingly ignored and showed 
to have little effect on the length of prescriptions issued in the UK. Although there is a scarcity of 
legitimate statistics, researchers have previously estimated that around 500,000 to 1.5 million 
people are dependent on prescribed benzodiazepines in the UK alone (Heather et al., 2004; Ford and 
Law, 2014). However, this data does not account for those using benzodiazepines without 
prescription. Recent data from Public Health England revealed that figures for children and young 
people (under 18 years old) accessing benzodiazepine treatment has almost doubled in the last year: 
from 161 from 2016 – 2017, to 315 from 2017 – 2018 and those needing support for Xanax usage 
problems has increased 6-fold within the last year (see Public Health England, 2018). With the 
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majority of those aged 17 – 18, this data confirms that young people are sourcing these drugs for 
whatever reason and forming problematic habits.  
Benzodiazepine withdrawal is often characterized by aggressive rebound symptoms which are 
contradictory to the initial therapeutic effects, and long-term users may suffer with symptoms like 
rebound anxiety, depression, psychotic tendencies, agitation, loss of appetite, distorted perceptions 
of reality, abnormal body sensations and even seizures (see Hollister et al., 1961; Péterssun, 1994). 
After halting insomnia medication, the sleeping disorder can return with vengeance and may be 
more exaggerated: the time it takes to get to sleep is prolonged, sleep is often distorted and much 
shorter (Lader, 1991; 2012). 
Withdrawal symptoms may also form as new, unfamiliar emotions. Displayed in the table below, 
Ashton (2002) describes a handful of psychological and physical symptoms that users experienced 
whilst attending her benzodiazepine withdrawal clinic (n=50). Supervised tapering methods are 
advised when coming off CNS depressant drugs (NIDA, 2011). 
Psychological symptoms Physical symptoms 
Insomnia, bad dreams & other 
sleep disruptions 
Pain and stiff limbs 
Anxiety and panic attacks Weakness and fatigue 
Depression Muscle spasms 
Distortion of perception and 
reality  
Palpitations, increase in 
perspiration 
Aggressive behaviour and 
irritability  
Gastrointestinal issues  
Memory failure and poor 
concentration levels 
Numbness and altered 
sensations 
Table 6: Common benzodiazepine withdrawal symptoms  
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2.7.7 Section overview 
The adverse negative effects of benzodiazepine use have been noted for many decades, however 
studies and research papers displayed in the section above focused solely on pharmaceutical grade 
benzodiazepines and their side effects. What we do not know however, is the impact of non-
pharmaceutical grade substances and their proposed dangers. As the media suggests, current UK 
users are using benzodiazepines off-prescription which may incur many more unknown risks and 
hazards. Thus, this research project wishes to collect data regarding the effects (desired and 
undesired) experienced by non-prescribed users.  
In addition, non-prescribed benzodiazepine users are often unaware of the adverse negative effects 
of use and misuse (Ashton, 2011) and those who are illicitly sourcing substances may be exposed to 
counterfeit tablets, laced with other, sometimes harmful adulterants. Risks of fatalities are much 
higher, especially when taken in conjunction of other substances. The risk of counterfeit drugs will 
be explored in Chapter Five: section 5.1.3. 
2.8 Summary of chapter and conclusion   
To conclude, this chapter reviewed the existing literature regarding the use and misuse of 
benzodiazepines in the UK. It uncovered plentiful media coverage predominantly reporting on self-
medicating teens (see BBC News, 2015; ITV News 2018a; Metro, 2018; Mirror, 2018; The Guardian, 
2018b; The Guardian, 2018d; The Telegraph, 2018; VICE, 2018a, VICE, 2018c) and just one academic 
research paper (see Kapil et al., 2014). However, media publications are often unreliable and despite 
only being five years old, the reported steep rise of the use of Xanax is unlikely to have been 
captured in the study from 2014. Furthermore, the sample size is relatively small for a quantitative 
study (392 total benzodiazepine users, 116 reported to have ‘misused’ them) and thus cannot 
represent the wider population.  
A handful of international papers and just one UK-based study have suggested that non-prescribed 
benzodiazepine user motivations are: to help sleep and to alleviate symptoms of anxiety or stress 
(see Pederson and Lavik, 1991; Boyd et al., 2006; Paredes et al., 2008; Rigg and Ibañez, 2010; Kapil et 
al. 2014; Andersson and Kjellgren, 2017); to actively get high and/or to heighten other drug effects 
(see Andersson and Kjellgren, 2010; Rigg and Ibañez, 2010), or; to counteract the effects of stimulant 
drugs (Bardhi et al., 2007; Rigg and Ibañez, 2010; Kapil et al., 2014; Beharry and Gibbons, 2016; 
Schmitz, 2016; Mateu-Gelabert et al., 2017). Nonetheless, these are merely potential motivations for 
UK users. Without reliable, academic research exploring benzodiazepine user demographics, 
motivations, usage trends and the true contents of the illicitly sourced ‘medications’, it is impossible 
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to provide a confident overview of the phenomenon and advise users, policy makers and health care 
professionals in an attempt to reduce risks and fatalities.  
Recent statistics revealed that 22% of Xanax trades are accounted for by the UK (The Guardian, 
2018), highlighting the evolvement of technology and online clear- and dark-web markets as a direct 
reflection of the increase in usage. The ease of access to drugs is a key motive for some, and some 
have suggested Xanax is easier to obtain than alcohol which may account for the spike in young 
users. Thus, this review of existing literature has highlighted the need for further UK-based research 
into the use of benzodiazepines and in particular, Xanax and Valium.   
The end of the current chapter stated the short- and long-term adverse negative effects of 
benzodiazepine use which have been acknowledged for many decades (see: Hollister et al., 1961; 
Block and Berchou, 1984; Curran, 1986; Asthon, 2002; Paton, 2002; Verster et al., 2002). What we do 
not know however, is how the these drugs are used without prescription, and the side-effects from 
non-pharmaceutical grade benzodiazepines.  
The following chapter will outline the research methodology used for the social science element of 













Chapter Three: Sociological Methodology 
3.1 Introduction and chapter overview 
As highlighted in the previous chapter, there is a deficit of up to date, academic, reliable research 
examining the use and misuse of non-prescribed benzodiazepines in the UK. Thus, this mixed 
methods research project comprises of a web-based survey alongside face-to-face interviews which 
were used to efficiently collect quantitative and qualitative data from benzodiazepine users in the 
UK, with the intent to explore: 
 Which benzodiazepines are popular? 
 Who is taking benzodiazepines? 
 What are the motivations for use? 
 What are the effects (both desired and undesired) of benzodiazepine usage? 
 Where do users source their non-prescribed benzodiazepines? 
 What factors influence benzodiazepine users’ decisions on what benzodiazepines they 
use and where they obtain them?   
The previous chapter highlighted the development of technology and social media and the negative 
impact this may have on web users’ mental health (see section 2.6.3). However, it was also made 
clear that the online world has been embraced by the wider population (De Vaus, 2014), and 
geographical boundaries are waved due to the interconnectivity that social media enables (Ngai et 
al., 2015). By positively adapting to the cultural norm of social media and the online world, a web-
based survey was created using Qualtrics10, which was distributed on a handful of online networking 
pages mainly Facebook, Twitter and drug-related forums such as Reddit and Bluelight. Specifically, 
41 Facebook groups across the UK were joined. The 23-question survey (see appendix 13) consisted 
primarily of close-ended questions, however four open-ended questions were woven throughout 
enabling rich, textual data to be collected (Burnett, 2009). Almost all questions also allowed for 
‘other’ or ‘additional comments’, which enabled respondents to enclose personal experiences and 
opinions should they wish to.  
A handful of face-to-face interviews were also conducted for the elaboration and growth of key 
points (Rossman and Wilson, 1985). The desired number of interview participants was originally set 
at 10 – 15, however due to the higher than anticipated number of survey respondents, including a 
                                                          
10 Qualtrics: ‘It’s sophisticated, yet simple, giving you the power to create and distribute surveys for any 
audience via any channel’: https://www.qualtrics.com/uk/ 
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significant amount of free text comments (discussed further in section 3.5.2), this volume of 
interviews was deemed unnecessary. Subsequently, data was collected from a smaller number of 
five interviewees. The survey ran from the 1st March 2018 – 8th June 2018 and a total of 771 
responses were gathered prior to cleaning. Survey data was inclusive of 595 cleaned quantitative 
and qualitative responses. Interviews were carried out over the same period.  
The following chapter provides an overview of the methodology used for the social science research 
element. It will begin by outlining the rationale for adopting a mixed methods approach and a brief 
overview of the online survey and interviews in section 3.2. Section 3.3 will outline the research 
strategy for the online survey in-depth, specifically: a discussion of ethics (section 3.3.2); sampling 
recruitment methods (section 3.3.3) and; how and why the survey was distributed via social media 
and other means in order to target specific audiences (section 3.3.4). Section 3.4 will mimic the 
layout of the quantitative methodology yet will describe the research strategy for the qualitative 
element: the face-to-face interviews. The section will include: an ethical discussion (section 3.4.2) 
and; sampling and recruitment tactics (section 3.4.3). Data cleaning and analysis was a long and 
complex process and which will be outlined in section 3.5. Section 3.6 will reflect and highlight the 
issues of the social research method used. 
3.2 Mixed methods approach and rationale  
Ivankova et al. (2006) assert that using purely quantitative or qualitative research methods alone will 
not yield fully adequate results. New, intricate societal phenomena have created diverse and often 
complex issues for research personnel (Tashakkori and Teddlie, 2003; Creswell and Plano Clark, 
2011) and in order to determine complete and sufficient answers, sophisticated methodology and 
analysis inclusive of a variety of research methods is a popular approach used by many sociological 
researchers in recent decades (Lopez-Fernandez and Molina-Azorin, 2014). Considered as the ‘third 
methodological movement’ (Tashakkori and Teddlie, 2003; 2010), mixed methodology consists of 
the combination of quantitative and qualitative research tools in a single study exploring the same 
phenomenon (Denzin, 1978).  
Employing a mixed methods research design undoubtedly requires more effort and time (Adowitz 
and Toole, 2010) and some believe that that qualitative and quantitative tools belong in different 
paradigms (Tariq and Woodman, 2013). However, others believe that applying quantitative research 
tools enables the assessment of the extent and frequency of a certain social phenomenon, and 
extensive qualitative research methods are able to acquire deeper understanding and corroboration 
(Tashakkori and Teddlie, 2003; Johnson et al., 2007). Quantitative research methods seek to quantify 
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variation whereas qualitative methods of data collection and analyses use descriptive information to 
describe the variation (Bernard, 2011).  
In their 1989 paper, Greene et al. identified five key purposes and rationale for employing mixed 
methodology. Triangulation is defined by boosting levels of validity by presenting parallel findings 
through different research means; complementarity increases the interpretability and clarification of 
results; development is defined by adopting the results from one method in order to assist in the 
development of another; initiation is characterised by exposing paradoxical results through 
expanding the breadth and depth of the outcomes; and expansion seeks to use a variety of methods 
for distinct elements of inquiry. These have been displayed in various research studies in different 
disciplines over the years, see Campbell and Fiske (1959); Sieber (1973); Madey (1982); Rossman and 
Wilson (1985); and Creswell (2014). 
The utilisation of a mixed methods approach in the current study, as Blaikie (2009) stated, 
eliminated the possible limitations of each approach. The display of rich, textual qualitative data 
counteracted the ideology that quantitative data lacks elaborative detail (Rossman and Wilson, 
1985; Bryman, 2015) and as Sieber (1973) states: 
‘The integration of research techniques within a single project opens up enormous 
opportunities for mutual advantages in each of three major phases – design, data collection 
and analysis’ 
Using mixed methods has the potential to uncover unprecedented variance which may have been 
missed by single methods (Jick 1979), and is therefore an exceptionally useful tool when answering 
new, undetermined questions and filling gaps in research. Most importantly, multiple authors 
believe that triangulation magnifies the accuracy of conclusions (Denzin, 1978; Jick, 1979; Greene et 
al., 1989) and that utilizing multiple methods increases levels of validity (Rossman and Wilson, 1985), 
as it makes room for confirmatory questions (Hall, 2008).  
Where mixed methodologies that incorporate both qualitative and quantitative data collection 
techniques are increasingly advocated, this research project is unique in incorporating an 
interdisciplinary element: hard analytical science. Complex laboratory tasks using presumptive 
testing methods and GC-MS were used in order to determine the quantity and quality of seized 
street samples (assumed to be Xanax and Valium) from Greater Manchester Police (GMP). 




3.3 Quantitative methods – online survey  
As outlined above, the quantitative element of this research took form as a web-based survey 
constructed via the online software Qualtrics and had the intent to examine:  
 Which benzodiazepines are popular? 
 Who is taking benzodiazepines? 
 What are the motivations for use? 
 What are the effects (both desired and undesired) of benzodiazepine usage? 
 Where do users source their non-prescribed benzodiazepines? 
 What factors influence benzodiazepine users’ decisions on what benzodiazepines they 
use and where they obtain them?   
The following section will begin by outlining the survey research strategy and development (3.3.1) 
before discussing ethical issues, specifically: information sheet and consent (section 3.3.2.1); 
participant confidentiality (section 3.3.2.2) and; protection from harm (section 3.3.2.3). Section 3.3.3 
will discuss the sampling and recruitment tactics employed, in particular: how participants were 
addressed and targeted. Section 3.3.4 will outline distribution methods in-depth and state where 
and when the survey link was posted including screenshots of posts. Specifically: Facebook (section 
3.3.4.1); Twitter (section 3.3.4.2); The TAB Newspaper (section 3.3.4.3) and; physical QR code 
leaflets (section 3.3.4.4).  
3.3.1 Survey research strategy and development 
Surveys are the most popular method for collecting quantitative data (Burnett, 2009), and as a self-
funded post-graduate student, keeping research costs to a minimum was an important 
consideration. Surveys are usually low in cost (Buchanan and Hvizdak, 2009) and it is an efficient way 
of collecting data from a vast number of respondents (Suri and Patel, 2012). Therefore, the main 
element of research took form as an online survey which was widely distributed online and offline.  
It is highly important that research is reliable, valid, representable and generalisable (Sapsford, 2007; 
Burnett, 2009). Scholars have previously highlighted the importance of obtaining enough data 
(Burnett, 2009) and justifying rates of response (Baruch, 1999). However, as non-prescribed 
benzodiazepine use is an emerging trend in the UK, it was deemed necessary to obtain as many 
responses as possible.  
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It is important that pilot studies are run in order to gain feedback about the difficulty of task and 
engagement from participants (see Converse and Presser, 1986:54). Convenience sampling was used 
to recruit two participants before the survey link was officially distributed. A highlighted concern was 
that the length of survey would reflect negatively on rates of completion (Burchell and Marsh, 1992). 
With this to consider, questions were simplified and all questions except consent were optional. 
According to online information provided by Qualtrics, generally, up to 53% of respondents begin 
surveys via their mobile phone. Adjusting to this notion, the survey was mobile phone and tablet 
friendly in order to increase response and completion rates. Unfortunately, data examining how the 
respondent completed the survey could not be captured retroactively.  
It was noted that certain groups and populations are more inclined to be more active on social 
media than others (Ngai et al., 2015), and considerable differences may occur between platforms 
(Social Media Research Group (SMRG), 2016). Thus, Facebook was used to target a younger 
population, primarily students; Twitter was used to target academics; and Reddit and Bluelight were 
chosen as they are well known for publishing substance usage trends and may have appealed to 
other drug users. Specific Facebook groups were joined in order to access specific populations, which 
will be explored further in section 3.3.4.1. The researcher also distributed emails and private 
messages to those relevant. In addition, 250 single-sided leaflets containing the QR code of the 
survey (see section 3.3.4.4: image 8) were also distributed in Greater Manchester amongst 
restaurants, bars, clubs, popular coffee shops and bus stops in order to appeal to those who are 
inactive on social media. Physical distribution methods will be explored in-depth in section 3.3.4.4. 










The online survey was inclusive of four open- and nineteen close-ended questions, and was divided 
into six sections as follows:  
Section Questions Enquiry 
1: Demographics 1, 2, 3, 4, 5,6  Age, gender, sexual 
orientation, ethnicity, 
geographical location and 
occupation 
2: Which BZDs 7, 8, 9, 10 Which BZDs have been used 
ever and recently, BZD 
preference and why 
3: Why, how, when, where 11, 12, 13, 14, 15, 16 Motivations for use, 
administration, dosage and 
usage context  
4: Other substance use 17, 18 Other substance use/ in 
conjunction with BZDs 
5: Supply 19, 20, 21, 22 Route of supply, prices 
6: Substance replacement 23 Opinion regarding substance 
replacement 
Table 7: Survey content 
Relevant strengths were adopted from quantitative, statistical data collection methods. Close-ended 
questions allowed data to be collected more efficiently (Converse and Presser, 1986) and made it 
quick and easy for the participant with minimal effort required (Sue and Ritter, 2012) thus, 
increasing rates of completion (Burchell and Marsh, 1992). However, open-ended questions increase 
the likelihood of more valid responses (Sue and Ritter, 2012). Therefore, four optional, open-ended 
questions (see appendix 13: questions 10, 14, 16, 23) were sophisticatedly woven throughout the 
web-survey which enabled participants to enclose personal justifications for substance usage and 
give detailed accounts. These text answers enabled rich, emotional language which personified 
numerical data (Jick, 1979; Rossman and Wilson, 1985; Tashakkori and Teddlie, 2003). The majority 




3.3.2 Ethical discussion  
In order to legitimately validate research, ethical issues must be acknowledged and addressed (Suri 
and Patel, 2012). This study was potentially accessing a vulnerable population who were asked to 
enclose information about illicit substance use, purchasing drugs and ill mental health (Fox and 
Tracy, 1986; Nyamathi, 1998). Therefore, with adherence to ‘The Ethical Guidelines’ laid out by The 
Social Research Association in 2003, it was necessary to pursue objectivity when collecting and 
analysing data; refrain from undue intrusion; ensure full anonymity and confidentiality of 
participants and; minimise physical and psychological risk to field researchers and participants. See 
appendix 14 for granted ethical approval. 
3.3.2.1 Information sheet and consent 
It was crucial that participants were aware of the research aims and consequent purposes of the 
study to increase the quality of data (Buchanan and Hvizdak, 2009) and in order to give rationalised 
consent (Bryman, 2015). However, the difficulty of this increases when recruiting participants online 
as there is less of a chance for the participant to ask the researcher any questions, as there is no 
immediate physical interaction between the two (Moreno et al., 2013). However, participants were 
presented with a detailed information sheet (see appendix 15) before enclosing consent, where the 
researchers email was displayed encouraging individuals to email any questions regarding the study 
and their role. An issue with this, is that the participant may not choose to read the information 
properly (British Psychological Society, 2017). In order to encourage individuals to read the 
document, only crucial and relevant information was stated.  
For research involving human participants, informed consent is a legal and ethical requirement 
(Nijhawan et al., 2013). Thus, individuals were prohibited from participating in the survey if they did 
not give confirmed consent. See below for a screenshot of the consent question displayed before 









Image 1: Screenshot of compulsory consent question displayed on a mobile device 
3.3.2.2 Confidentiality and traceable IP addresses 
Despite using the advantages of the online world as will be discussed in the distribution methods in 
section 3.3.4, the use of online chat forums and social media sites to promote the survey brought 
additional ethical considerations, especially in relation to confidentiality. The online world is 
continuously growing and changing, leaving current laws and recommendations regarding data 
protection trailing behind (Suri and Patel, 2012) and maintaining privacy, anonymity and 
confidentiality is an overarching issue when using social media as means of participant recruitment 
and data collection (Hunter et al., 2018) due to traceable IP addresses (Suri and Patel, 2012). 
Although the privacy of a personal social media profile is controlled by the individual (SMRG, 2016), 
a click of a link or visit to another page is logged by that social media website and can potentially be 
traced back to that profile (British Psychological Society, 2017). Thus, participants in the current 
study were made aware that they could copy and paste the survey link in order to protect their 
identity. It must be noted that there is no static regulatory guidance regarding these ethical issues 
(Amon et al., 2014; Gelinas et al., 2017), and the full protection of participants’ online identity was 
out of the researchers control (Buchanan and Hvizdak, 2009). 
48 
 
3.3.2.3 Protection from harm 
Another dominant priority was to protect all participants from psychological harm. Due to the 
discussion of sensitive topics, it was thought that participants may feel signs of distress and guilt 
(British Society of Criminology, 2015). In order to eliminate these negative emotions, participants 
were made aware that their participation was voluntary and they had the right to withdraw at any 
point in a study (Social Research Association, 2003). However, online surveys may infringe this due 
to including mandatory responses (Suri and Patel, 2012). Thus, bar consent, no questions were 
compulsory and all participants are made aware that they have the right to withdraw at any time. 
Conducting research online may also mean participants fail to partake in the debriefing process 
(British Psychological Society, 2017). Instead, participants in the current study were urged to contact 
the researcher via email should they have any concerns or general questions. 
Psychological and physical risks toward the researcher must also be considered and kept at a 
minimum (Social Research Association, 2003). Stern (2003:249) highlights researchers’ exposure to 
‘encountering distressing disclosure’ when researching sensitive topics online. Individuals are more 
likely to express distressing information about harming themselves or others due to having ‘private 
authorship’ (see Stern, 2003:251). Conversely, possible physical risks of being a lone female were 
eliminated due to avoiding face-to-face interaction.  
The fine line between employing proper research conduct and ensuring ethical obligations to 
participants often causes tensions for online researchers (Suri and Patel, 2012). A route of bypassing 
arguably unethical research is to prioritise the importance of the findings (Ahmadulla, 2012), and 
ensure that the wider society will benefit (Social Research Association, 2003). For the current study, 
exploring an under researched, rising phenomenon, examining citizens’ benzodiazepine drug use 
habits has the ability to inform policy makers and health care professionals (LeClair et al., 2015; 
Järvinen -Tassopoulos, 2017), which has the capacity to directly protect users and the wider society 






3.3.3 Sampling and recruitment  
The growth of the internet and accessing hard-to-reach populations has prompted the use of 
purposive sampling techniques to access illicit drug users online (Barratt and Lenton, 2010, cited in 
Barratt et al., 2017). In the current study, the inclusion criteria stated that participants were required 
to have personal experience with benzodiazepines thus, it was hoped that participants could provide 
valuable information and insights on the topic in question (Denscombe, 2010). Participants were 
expected to have taken at least one benzodiazepine in their lifetime. This was made clear on the 
participant information sheet (see appendix 15), and written on the posts on social media sites and 
forums which will be discussed throughout the next section. As the screenshot below illustrates, it 
was made clear that although motivations for use may be different, anyone with past or present 
benzodiazepine use could take part: 
  
Image 2: Screenshot of Facebook post no.2 (on 14/03/2018) 
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Referring to the media coverage of benzodiazepine use and misuse in the UK, it became apparent 
that the dominant group of users were non-prescribed, young people, aged 11 – 25 (see Chapter 
Two: section 2.4.1). Therefore, certain language was adopted in order to make the survey relevant 
and understandable by the prospective participant group (Sue and Ritter, 2012). The researcher 
included the different street names, for example Diazepam (Valium) and Alprazolam (Xanax). The 
shortened terms ‘benzos’, ‘vals’ and ‘xans’ were also adopted after discovering the abbreviations in 
music lyrics (see Chapter Two: section 2.4.2). Facebook was used in order to reach the young adult 
population in the UK. The following section will explore the use of Facebook and other social media 
sites as a means of survey distribution. 
3.3.4 Survey distribution  
In order to obtain as many survey respondents as possible in the time given, the researcher was 
extremely proactive with methods of distribution. Using the internet and social media as a means of 
survey distribution was an efficient and cost effective way of accessing a geographically dispersed 
pool of respondents (Holmes, 2009; Suri and Patel, 2012; O’Connor et al., 2014; Wolfe et al., 2014; 
Whitaker et al., 2017), thus the dominant method of survey distribution in the current study was via 
Facebook and Twitter. Should they wish, Facebook users were able to share the post to their online 
network, Twitter users were able to re-tweet and private messages and emails were forwarded to 
relevant people. In research context this is named the snowball sampling technique (Olsen, 2012). 
The arguably go-to sites for distributing sociological and criminological research concerning drug use 
are the popular online blogs namely Reddit and Bluelight. These were initially chosen to access other 
benzodiazepine users, not just the student population. See appendices 16 and 17 for screenshots of 
both the Reddit and Bluelight posts. 
However, as the survey was still active, it became apparent that a significant amount of respondents 
resided overseas. It was assumed that the Reddit and Bluelight postings were responsible for this 
unintended survey response as the international blog forums can be accessed by anyone across the 
globe. Of the 771 respondents, 100 came from outside of England and were therefore discarded in 
the subsequent data cleaning and analysis. Thus, the survey was primarily distributed online using 
Facebook and Twitter. However, other methods were also utilised: sending out emails and private 
messages, handing out leaflets and putting up posters containing a QR code, and writing in an article 
in a student newspaper and attaching the survey link. 
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In total, 89 separate Facebook posts were made, alongside six individual tweets. Posts and tweets 
were often shared or re-tweeted, which significantly increased the number of those exposed to the 
survey link, which will be explored in the following section. A total of 250 leaflets were distributed 
across Greater Manchester including the survey QR code. The link was actively distributed and 
promoted between 1st March 2018 and 24th April 2018, and the survey was closed on the 8th June 
2018. A screenshot of the one of the first Facebook posts is displayed below.  
 
Image 3: Screenshot of Facebook post no.1 (01/03/2018) 
The following section outlines and reflects on each method in more depth, including dates and times 






3.3.4.1 Facebook  
Facebook is a well-known networking platform where members can post life updates, queries, seek 
advice or search for local events and activities. Statistics reveal there are approximately 1.47 billion 
daily active users (Facebook, June 2018), and it was seen as a useful tool to access a vast number of 
potential participants. In addition to drawing on methodological textbooks and previous studies, the 
unique research design was also informed by the researchers partial insider status of being a student 
in Manchester from the ages 18 – 22 and gaining inside knowledge about students’ social media 
habits. The researcher was able to join relevant Facebook groups to target the UK student 
population and was mindful of the best time to post. This meant relevant data could be collected 
quickly from competent participants, as some researchers have previously stated: 
‘Knowing about fieldwork means knowing what it like is to be in the field’ 
(Miller and Tewsbury, 2001:89) 
‘Really in-depth research requires informed informants, not just responsive respondents’ 
(Bernard, 2011:143) 
It was known that for those attending Manchester Metropolitan University (MMU), Manchester 
School of Art (MSoA), University of Manchester (UoM), Salford University, Royal Northern College of 
Music (RNCM) and BIMM Music College, there are designated Facebook pages. For example, for 
MMU there is a closed group page named ‘Manchester Metropolitan University Freshers 2017/18’, 
where new students can ask questions freely about the University process, enquire about or 
discover suitable accommodation and discover new social networking events happening within 
MMU or across the city. Another well-known Facebook group is ‘Fallowfield Students Group (FSG)’, 
which is inclusive of University students across Greater Manchester, and is managed by students. 










Image 4: Screenshot of Fallowfield Students Group Facebook bio 
Similar to the MMU freshers 17/18 page, this group is popular for finding accommodation, re-selling 
nightclub tickets, rehoming household items and general rants about local pub doormen. With 
almost 31,000 members (Fallowfield Students Group, Facebook, as at 31/07/2018), this page was 
seen as an important gateway for accessing a large number of the target population to complete the 
online survey.  
In order to reach out to the whole of the UK in order to provide generalisable data, the researcher 
referenced back to question five of the survey (see appendix 13) and produced a list of major cities 
in the UK. By adopting the cluster sampling technique (Sue and Ritter, 2012), specific geographical 
locations were targeted via Facebook. With adequate links to individuals attending separate 
universities across the country, the researcher contacted family, friends and acquaintances based in 
different cities to acquire knowledge and gain access to relevant Facebook groups. Similar to the 
unique Facebook pages for Manchester students, it was discovered that other cities had similar 
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Facebook pages and groups such as ‘Leeds Uni Tickets’ (Leeds), ‘Clifton and Stoke Bishop Tickets’ 
(Bristol) and ‘Official UAL Freshers’ 2017 – 18’ (London). The main group which was found in the 
majority of cities was ‘Overheard at XX’. This online community was not purely inclusive of students 
but also other Facebook users, which increased the likelihood of gaining participants of varied 
characteristics and therefore increasing generalisability beyond the university student population. 
Upon discovering the names of different Facebook pages, it became apparent that the majority were 
private, member-only groups. It was necessary to complete a small number of questions regarding 
the researchers’ intentions to gain exclusive membership. The researcher was able to gain access to 
groups in the following cities: Bath, Birmingham, Bournemouth, Bristol, Cardiff, Coventry, Durham, 
Edinburgh, Exeter, Hull, Lancaster, Liverpool, Leeds, Leicester, London, Manchester, Newcastle, 
Nottingham, Plymouth, Salford and Sheffield. A full list of the names and links of the Facebook pages 
and their geographical location is available in appendix 18. Access was rejected from 3 groups 
without a justified reason.  
The link to the survey was posted on six separate occasions from 1st March – 23rd April 2018, to a 
total of 41 different Facebook pages (not including the researchers personal Facebook page). See 




Image 5: Number of Facebook pages posted to by city 
Certain posts included images in order to capture individuals’ attention as they scrolled through. See 
appendices 19 – 24 for a full list of the Facebook pages, details of the time and date of each post and 
screenshots of the post. 
The following sub-section will review the success of the distribution methods used with regards to 
how many participants were gathered on each day.  
3.3.4.1.1 Lessons learnt 
After trial and error and reflection, it was discovered that the most popular time of day to post was 
in the evening (6 – 10pm), on a Sunday or a Monday. Students were unlikely to be scrolling through 
Facebook on a Friday and Saturday night as it was assumed they would be out socialising, or the 
Facebook pages would be inundated with members seeking to buy or sell a variety of nightclub 
tickets. Students were also unlikely to see the post on Facebook on Wednesdays due to sports 
fixtures taking place. 
It was noted that following a post on Monday the 26th March, there was a steep rise in survey 
respondents. Reasons for this may be that it was during the Easter break which meant students were 
most likely at home with their family and boredom equated to scrolling through Facebook. Another 












Alongside Facebook, Twitter is a popular social networking and news sharing site, where users 
convey thoughts and communicate in brief messages called tweets. It is popular for microblogging 
where people of all ages can express thoughts and life updates alongside academics sharing vast 
knowledge about their field of expertise (Fenner et al., 2012). Tweets can be liked or re-tweeted, 
which increases the number of individuals who are able to see it and reply (ibid). For the current 
study, Twitter was used to target the academic and professional community. The first tweet (see 
below for a screenshot) with the survey link was sent out on the 1st March 2018 at 11.49am: 
 
Image 6: Screenshot of Tweet no.1 (01/03/2018) 
In contrast to Facebook, it was deemed best to tweet during the day when academics were actively 
involved in discovering new research papers or articles and sharing them via Twitter. The original 
tweet received 10 re-tweets from criminologists and researchers across England. Their followers 
were then able to see the tweet, which increased interest (O’Connor et al., 2014). Table 8 below 
includes a handful of Twitter users who retweeted the original post, and the number of their 






Twitter user Number of followers 












Table 8: Those exposed to Tweet no.1 
According to table 8 above, at least 6,226 people were exposed to tweet no.1. However, this led to 
professionals in the field of drug use such as Henry Fisher – Drug Policy Think Tank Volteface – 
tweeting a separate post with the survey link which received 10 re-tweets, including Fiona Meesham 
– Professor of Criminology, ACMD member and founder of The Loop – who has 4,441 followers (as at 
10/09/2018). On the 7th March 2018, Harry Shapiro – director of DrugWise – sent out a call for 
research which the researcher saw and responded: 
 
Image 7: Screenshot of interaction with Harry Shapiro via Twitter 
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Max Daly, a VICE journalist, also tweeted the survey link at the end of March which was visible to his 
7,956 followers (as at 10/09/2018), which was re-tweeted by Hannah Rose Ewens, also a VICE 
journalist, who has over 18,000 followers (ibid). On the same day as the tweet by Max Daly 
(27/03/2018), 108 new responses were recorded. The number of responses along with the dates and 
times of postings will be elaborated further in section 3.3.4.5.   
These interactions were identified as extremely important, as the link was seen by a significant 
number of people, thus increasing the likelihood of gaining more participants. Print screens of all 
tweets can be found in appendices 25 – 30.    
3.3.4.3 The TAB Newspaper article 
In order to spread knowledge of the survey and gain more participants, the researcher decided to 
target the wider Manchester student population through publishing an online newspaper article. 
The TAB Newspaper is popular amongst students in the UK, where readers can discover lengthy 
reviews about local takeaways (The Tab, 2018a), discover life as a University fresher (The Tab, 
2018b) and the cheapest cocktail bars in Manchester (The Tab, 2018c).  
Including a handful of statistics, the self-composed article consisted of benzodiazepine 
pharmacological information and the dangers of poly-drug use and counterfeits. The academic 
literature was coupled with quotes from users who were well acquainted with the researcher. See 
appendix 31 for the short interviews. Full consent was given and the individuals were anonymised 
and given a pseudonym (adhering to ethical guidelines, see section 3.4.2.1). Pictures used in the 
article were taken by the researcher and did not expose any identities. The article was titled: ‘We 
asked Manchester students about their experiences with Xanax and Valium’ and can be found here 
(see The Tab, 2018d). 
See appendices 32 – 34 for a full copy of the published article alongside screenshots.  
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3.3.4.4 QR code leaflets 
In order to increase the number of survey respondents and to also appeal to those who are not 
necessarily active on social media, information about the research was also physically printed onto 
leaflets which were distributed around Manchester (see below). 
 
Image 8: Leaflet containing QR code 
The leaflet was made by the researcher with assistance from a Leeds based graphics student and an 
order was placed with solopress.com. Similar to the social media posts, the leaflet appealed to 
anyone who had taken at least one benzodiazepine in their lifetime, for whichever reason. Attached 
to it was a QR code which could be scanned using a smart phone camera.  
Due to the researcher residing in Manchester and lacking in time to travel elsewhere, the majority of 
the leaflets were distributed in popular bars and cafes around the Northern Quarter and Ancoats. A 
handful were pinned to notice boards and bus stops in highly student populated areas such as 
Withington, Fallowfield, Rusholme and near UOM, RNCM and MMU. They were also distributed to 
people in popular bars and pubs in Fallowfield and taped to bathroom doors.  
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3.3.4.5 Survey distribution overview and response rates 
Where and when the survey was distributed played a key factor in the number of responses. The 
days with the most response rates (over 10 responses on one day) are displayed in the table below. 
There was a continuous flow of responses even on days where the link was not posted onto any 
sites. This meant that original Facebook posts and tweets were still visible online and offline even 
















Table 9: Date and location of postings and number of survey completers 
Date Where the link was posted No. of responses 
01/03/2018 Facebook: 6 pages 
Twitter: Harriet Bloomfield (10 re-
tweets) 
20 
02/03/2018 Nothing posted – overflow from the 
previous day 
31 
13/03/2018 Twitter: Harriet Bloomfield replying to 
Hannah Ewens 
10 
26/03/2018 Facebook: 16 pages 86 
27/03/2018 Twitter: Max Daly (2 re-tweets) 108 
28/03/2018 Nothing posted – overflow from the 
previous days 
32 
29/03/2018 Nothing posted – overflow from the 
previous days 
17 
30/03/2018 Nothing posted – overflow from the 
previous days 
13 
01/04/2018 Nothing posted – overflow from the 
previous days 
19 
02/04/2018 Facebook: 9 pages 24 
03/04/2018 Facebook: 16 pages 21 
23/04/2018 Facebook: 37 pages 100 





See appendices 19 – 30 for screenshots of each post and where it was distributed. See appendix 30a 
for a full table of dates of postings and response rates11.  
3.4 Qualitative methods – face-to-face interviews 
Greene and McClintock (1985) highlight the importance of implementing mixed methods 
independently. This influenced the addition of semi-structured face-to-face interviews, which were 
inclusive of open-ended questions tailored to the interviewee. Similar to the quantitative methods, 
the interviews were conducted to discover:  
 Which benzodiazepines are popular? 
 Who is taking benzodiazepines? 
 What are the motivations for use? 
 What are the effects (both desired and undesired) of benzodiazepine usage? 
 Where do users source their non-prescribed benzodiazepines? 
 What factors influence benzodiazepine users’ decisions on what benzodiazepines they 
use and where they obtain them?   
Qualitative research methods enable the deeper exploration of a topic (Burnett, 2009) and thus in 
the current study, relevant quotes were extracted from interview transcripts in order to personify 
the copious amount of statistical data. One one-to-one interview (female, North West, age 31 – 40) 
was conducted alongside one focus group interview inclusive of 4 participants (all male, North West, 
aged 22 – 25). Initially, interviews were recorded on a voice recorder before being transcribed onto a 
Word document. The digital device offered high quality recordings and kept costs at a minimum 
(Kuckartz, 2014).  
The following section will outline the research strategy for the face-to-face interviews (section 
3.4.1), followed by an ethical discussion (section 3.4.2) specifically: participant confidentiality 
(section 3.4.2.1); protection from harm (section 3.4.2.2) and; participant information sheet and 
consent (section 3.4.2.3). Section 3.4.3 will discuss the sampling and recruitment tactics.    
3.4.1 Research strategy and development  
Qualitative research is known to generate rich, descriptive data (Burnett, 2009), and employing a 
semi-structured design meant a variety of perspectives could be collected regarding the same topic 
                                                          
11 It must be noted that these figures are before data cleaning and therefore n=720 
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of interest (Boyce and Neal, 2006). Interviewing individuals of different ages and backgrounds about 
their drug use habits and their perception of drug policies can pose as very useful and influential for 
the wider society and of course, policy makers (Järvinen-Tassopoulos, 2017). Qualitative research 
has been described as an ‘elaborate alibi to justify the exercise of power’ (Cohen, 1988:5 cited in 
Jupp et al., 2012). 
Initially, survey data was briefly analysed which created broad themes (analysis will be discussed in 
section 3.5). By adopting Greene et al.’s (1989) methods of development and expansion, specific 
themes extracted from the survey results were used to loosely shape the interview design. The 
addition of face-to-face interviews meant that this research was able to gain a more contextual 
illustration of drug use habits (Jick, 1979), providing elaboration (Rossman and Wilson, 1985). The lack 
of static structure encouraged spontaneity, and questions were modified with correspondence to the 
participant in question (Mack et al., 2005; Burnett, 2009). Visible social cues such as body language 
and intonation assisted with this (Opdenakker, 2006). For example, if the participant had stated former 
heavy usage of benzodiazepines, questions were tailored differently to those participants who were 
classed as current users. See appendix 35 for the interview guide.  
An advantage of conducting group interviews is that multiple opinions regarding the same topic can 
be collected quickly and efficiently (Tracy, 2012) and the conversation may lead to the discovery of 
new topics or ideas (Barbour, 2008). In the male focus group, the initial plan was to interview only 
one sole male (P1). However, the interview was conducted in a living room where multiple others 
were situated and it soon unravelled into a group interview inclusive of three more males in their 
20s (P2, P3 and P4). Murphy et al. (1992) believe that group interviews may lack validity as specific 
views may dominate the group and lead to conformity (cited in Barbour, 2008). In the current study 
however, P2, P3 and P4 chose to voice their opinions as they disagreed with P1, contradicting former 
beliefs of Murphy et al. (1992).   
3.4.2 Ethical discussion 
Similar to section 3.3.2, it was necessary to adhere to ethical guidelines to: ensure objectivity when 
collecting and analysing data; refrain from undue intrusion; ensure full anonymity and confidentiality 
of participants and; to minimise physical and psychological risk to field researchers and participants 
(Social Research Association, 2003).  
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3.4.2.1 Confidentiality  
Data security and protecting personal information is an overarching ethical challenge when 
researching and collecting data in a sociological and criminological field in the digital era (see 
Aldridge et al., 2010). The leakage of personal data and transcripts could mean that individuals’ illicit 
substance use could be exposed to the wider society and may incur legal repercussions 
(Liamputtong, 2007). Thus, participants in the current study were ensured that all data was secure 
and anonymised with compliance to the Data Protection Act 1998. The voice recordings were stored 
on a password-protected device, before immediately (within 2 hours) being transcribed to a 
document saved to a password-protected computer, which was only accessible by the researcher 
and supervisor (see Data Protection Act, 1988:50). Personal details such as name and exact age were 
removed and replaced with general references (Kuckartz, 2014), for example ‘P1: male, North West, 
aged 21 – 25’. 
3.4.2.2 Protection from harm 
It was acknowledged that the nature of the interviews may seem to be pose as exceedingly intrusive 
(Social Research Association, 2003) and participants may have felt like their social values and privacy 
were disregarded (Hunter et al., 2012). Complying with ethical regulations are especially important 
when researching sensitive topics (Bryman and Bell, 2011) such as illicit substance use (Fox and 
Tracy, 1986) and mental health (Nyamathi, 1998) in order to protect the participant from 
psychological harm (Social Research Association, 2003). Due to the nature of the interview it was 
deemed best to conduct them in a private space (National Drug Abuse Treatment Clinical Trials 
Network, accessed on 13th May 2019). The invitation for further research stated that participants 
were required to have ‘frequent and/or heavy’ past or present benzodiazepine usage (see below for 
a screenshot). The terms ‘frequent’ and ‘heavy’ were left undefined. This was because individuals’ 
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usage varies significantly and personal preferences and perception of ‘little’ or ‘a lot’ is too broad. 
Therefore, this decision was left to the participant. 
Image 9: Screenshot of the invitation for further research displayed at the end of the survey 
Therefore, it was expected that participants may be classed as ‘vulnerable’ (Silverman, 2013). Thus, 
the researcher employed sensitive terminology and proper research conduct in order to gain full 
trust and establish rapport (see Miller and Tewksbury, 2001) and to ensure the physical and 
psychological well-being of both the participant and the researcher (Liamputtong, 2007). The 
participant was debriefed after the interview and presented with organisations and helplines if they 
showed signs of concern (see ‘General Interview Guidelines’, National Drug Abuse Treatment Clinical 
Trials Network, accessed on 23rd October 2018).   
The researchers’ personal safety was also noted and they may have been at risk during the 
interviews as the participant may become violent as a consequence of feeling distressed (Lee, 1995). 
Psychoactive substance use is highly stigmatised (Room, 2005), and individuals may have felt 
distressed and shown levels of guilt, embarrassment and worthlessness (British Society of 
Criminology, 2015). Another added risk is that the researcher was a lone female (Social Research 
Association, 2003). Thus, the researcher made at least two people aware of the date, time and 
location of interviews for safety purposes (National Drug Abuse Treatment Clinical Trials Network, 
accessed on 13th May 2019). 
3.4.2.3 Information sheet and consent 
Participants were made aware of the nature of the interview and possible sensitive topics that 
would be discussed prior to the interview: they were required to read and acknowledge the 
information sheet (see appendix 36) after which they were required to sign and date the form of 
consent (see appendix 37). Participants were ensured that they had the right to withdraw at any 
time, meaning all their data would be destroyed. 
3.4.3 Sampling and recruitment 
Purposive sampling increases the likelihood to gain competent participants (Tongco, 2007), 
therefore, interviewees were gathered via an email address at the end of completing the online 
survey. See image 9 above for the invitation for further research. A total of 12 individuals expressed 
an interest in taking part in the interviews. However, due to time restrictions and the unexpected 
high number of survey responses coupled with the level and detail of free text comments gathered 
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in the online survey, and the additional time spent learning chemical analysis techniques and 






















3.5 Data analysis  
Using mixed methods in a single study did not only require intuitive data collection methods in order 
to keep it balanced (see Lopez-Fernandez and Molina-Azorin, 2014: 3 – 5), complex analytical skills 
were also needed to efficiently obtain useful, impactful data (Kuckartz, 2014). The following section 
will outline the analysis processes of both the quantitative and qualitative data.   
3.5.1 Quantitative data – survey  
Survey data was easily transferred to other statistical programmes which made it easy to correlate 
the findings (Rea and Parker, 2014). Initially, all responses (n=771) were transferred to Excel for 
cleaning. Unreliable and untrue answers such as extreme exaggeration and/or abusive or 
inappropriate comments were deleted (see screenshot below for examples). Unfinished surveys and 
responses from those who resided outside the UK were also discarded. Cleaned data (n=595) was 
then transferred to SPSS for coding. A detailed document of how each question was coded is 
available in appendix 38.  
 
Image 10: Screenshot of unreliable answers 
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3.5.2 Qualitative data – survey  
Alongside the four open-ended questions, participants were able to contribute text responses 
alongside close-ended questions throughout the survey, by leaving ‘other’ or ‘additional comments’. 
For example, when asking participants about benzodiazepine prices (see appendix 13: question 21), 
64 respondents left additional text answers. Text responses were exported back to Excel and coded 
accordingly due to the amount of data obtained. 
Altogether, the four free text questions received a total of 1,339 answers. The discussion of different 
benzodiazepines of different strengths and dosages, varied user motivations and multiple personal 
opinions were noted. All text was transferred to Excel to prepare for coding. It was evident that 
almost all responses were relating to Valium and/or Xanax, thus, others were discarded. Analysis 
methods were complex as opinions were broad and often contradicted one another. Methods of 
coding and themes will be outlined throughout this sub-section. 
3.5.2.1 Q10: Benzodiazepine preference – 413 answers  
Q9 asked ‘what is your preferred benzo?’ which was followed by a free text answer of ‘why is this 
your benzo of choice?’ (Q10). The latter received 413 answers. To begin with, Q9 was coded into 
numerical data on SPSS, after which answers specific to Valium from Q10 were extracted and 
transported to Excel. After reading the copious amounts of free text, common themes emerged. 
Headings were created and different quotes were assigned accordingly: ‘cost’, ‘accessibility/only one 
I have used/it is prescribed’, ‘enjoy the relaxing/anti-anxiety effects’, ‘it aids sleep’, ‘no/little/less 
side effects from Valium’, ‘Xanax effects= BAD: too strong/memory loss &black-outs’. Headings were 
different for those who chose Xanax as their preferred benzodiazepine: ‘easy to obtain/popular’, 
‘good mix with alcohol’, ‘stronger & better value for money’, ‘fast onset and shorter half-life’, ‘good 
for anxiety’, ‘good for sleep’, ‘good for comedowns’, Valium=BAD’. Screenshots of the coding in 
Excel can be found in appendix 39 and 40. This free text was used in the results section (see Chapter 
Four: section 4.7).  
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3.5.2.2 Q14: MG and dosage context – 385 answers 
Q14 was a very broad, thus it received copious amounts of variety and analysis was complex. See a 
screenshot of Q14 below.  
Image 11: Screenshot of question 14 from the online survey 
Data was initially split into two separate excel files: Valium and Xanax, before responses were coded 
further (see appendix 41 for a screenshot). With reference to user motivations explored in Chapter 
Two: section 2.6, pre-codes were used to initially categorise each quote. Valium responses (n=162) 
were split into three separate headings: ‘anxiety/insomnia’, ‘recreation – to get high’ and ‘recreation 
– to come down’ (see appendix 42 for a screenshot). The categories were then split further into 
common milligrams (2 mg, 5 mg, 10 mg, 15 mg, 20 mg or 30 mg) and dosages (1 – 10 tablets) and 
mentions were tallied separately. Xanax responses (n=159) were split differently. Four themes were 
inclusive of: ‘anxiety/insomnia’, ‘to get high/feel more intoxicated’, ‘after a night out/counteract 
stimulants/psychedelics’ and ‘to cure hangover/come down’. It was noted that milligrams ranged 
from 0.25 mg – 8 mg and dosages ranged from 1 – 5 bars corresponding to user motivations. 
Analysis for the Valium category was time consuming and tedious, thus, Xanax answers were not 
categorised as above. Some text answers were used throughout the results chapter to amplify or 
counteract other data.   
3.5.2.3 Q16: Memorable encounter – 422 answers 
It was decided to include a free text answer which enabled participants to describe a memorable 
encounter involving benzodiazepines to gain a deeper understanding of user habits (see appendix 
13: question 16). Common themes were already established due to mimicking the survey design, 
thus answers from Q16 were assigned to relevant sections throughout the results write-up.  
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3.5.2.4 Q23: Why benzos? – 119 answers  
Q23 influenced the exploration of substance use replacement. Alongside producing statistics, some 
respondents (n=119) left additional comments. As this number was significantly less, answers were 
not formally coded. Relevant and dominant quotes were used to enhance the statistical data from 
Q23.  
3.5.3 Qualitative data – interviews  
The interview script was sculpted after establishing common themes from survey answers, and 
interview data was analysed after the survey data. Thus, coding the qualitative interview data was 
simple, and relevant and useful quotes were used to clarify and/or elaborate survey data. 
3.6 Reflections and limitations  
The following section will highlight the limitations of the research methodology used. Upon cleaning, 
the researcher had to discard a total of 176 survey responses. Despite being mindful of the need to 
design a quick and easy survey (Sue and Ritter, 2007) that could be completed within 5 – 10 minutes, 
a handful of respondents exclaimed that the survey was too long and became boring. A total of 53 
surveys (6.8% of all data before cleaning) were started and not fully completed and therefore 
deleted. Moreover, as explored in previous chapters, social media platforms and online forums are 
available for anyone (Ngai et al., 2015), and online distribution methods meant information reached 
beyond the desired target sample, in this case, to non-UK residents. A total of 100 respondents came 
from overseas, therefore their answers were invalid. Furthermore, granting participants with a 
masked online identity may encourage false and unreliable responses (Lefever and Matthíasdóttir, 
2007). A total of 23 responses were deleted as the answers were deemed unreliable due to 
enclosing the use of excessive amounts and/or included abusive comments (see section 3.5.1: image 
10). The impact of this with regards to further research will be discussed in Chapter Seven. 
A major concern and limitation of using Qualtrics was that the identities of the survey participants 
were not totally anonymous. The GeoIP address was recorded for each respondent (see below for 
screenshots). This fault lies with the online survey software and is out of the researchers’ control. 
Nevertheless, it limited the level of confidentiality and anonymity that the researcher could offer to 
participants compared to other methods of survey administration such as face-to-face or postal 




Image 12: Screenshot of GeoIP address displayed at the end of the survey 
 
Image 13: Screenshot of GeoIP address displayed at the end of the survey 
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An additional limitation of the research methods employed was the lack of generalisability. Due to 
predominantly targeting the student population via specific Facebook groups, the sample consisted 
of primarily university students aged 18 – 25. The Manchester population was also dominantly 
targeted online and offline. Due to limited time and financial resources, the QR code leaflets were 
only distributable in Greater Manchester, and the code was only accessible with a smartphone. Due 
to being situated in Manchester and being conscious of time and costs, survey and interview 
participants were dominantly from the North West of England and therefore, this skewed the 
sample. It would be useful to replicate the study in other popular student areas and cities for 
example in Bristol, Leeds and Sheffield, following the same methodology displayed in this chapter.  
Moreover, four respondents did not wish to enclose their geographical information, however due to 
traceable GeoIP addresses displayed by Qualtrics, it was known that they resided in the UK. In 
hindsight, this question should have been made compulsory to ensure every participant was from 
the UK. Another minor limitation of this research was that the email address attached to the QR 
code leaflet was a personal email address. This should have been a University email address for 
professionalism. 
Not only is the researcher required to possess complex sampling and analytical skills in order to 
successfully process statistical and textual data for the same phenomenon (Bernard, 2011), analysing 
answers to open-ended questions can extremely time consuming (Burnett, 2009) and as stated 
towards the beginning of this chapter, employing a mixed methods research design requires higher 
levels of effort and time (Adowitz and Toole, 2010). This was negatively reflected in the small 
number of interview participants. Between the beginning of March and the middle of April, a total of 
12 individuals aged 20 – 44 individually approached the researcher via email and Facebook, 
expressing an interest in participating in further research. However, as stated in section 3.4.3 the 
unexpected high number of survey responses coupled with the level and detail of free text 
comments gathered in the online survey, alongside the additional time spent learning and applying 
chemical analysis techniques and carrying out the forensic testing led to the decision to restrict the 
number of in-depth interviews for this project. 
3.7 Summary of chapter 
To summarise, this chapter clearly justified the use of a mixed methods approach in order to 
efficiently collect and analyse quantitative and qualitative data regarding individuals’ benzodiazepine 
use and misuse. Inside knowledge of young people’s social media habits enabled rich data collection. 
Using Facebook and Twitter proved to be highly effective to access nationally dispersed participants, 
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and it is recommended that this method of participant recruitment is used in further research. 
Facebook can be useful when targeting the student population, however, due to their busy social 
lives, it was essential to post at a time when the networking pages were not swarmed with ticket 
selling posts and other queries. It was discovered that the best time to post was on Monday evening 
and outside of term time. Twitter proved to be useful to target the academic and professional 
population. Re-tweeting meant that more Twitter users were exposed to original tweets, thus 
gaining more survey participants with varied demographics.   
The traditional recommendation of conducting interviews in a public space when discussing drug use 
topics with potentially vulnerable participants was rejected in the current study. Interview 
participants did not want other citizens to possibly overhear sensitive information and the discussion 
of illicit activity which may have led to stigmatisation and/or legal repercussions. It was vital that 
other measures were put in place to ensure the full safety of both parties. This must be 
acknowledged by future researchers.  












Chapter Four: Sociological Results 
4.1 Introduction and chapter overview 
This chapter presents the quantitative and qualitative findings from the online survey (inclusive of 
595 respondents) and from the semi-structured interviews (five participants). Statistical data will be 
coupled with qualitative textual data to enhance the findings and help clarify each theme. All the 
percentages used throughout this chapter represent the findings from the survey data. It is 
important to note that other than demographic information, survey respondents were able to 
choose multiple answers. Thus, percentages do not always equate to 100. 
In order to stay concise, the following chapter will mimic the layout of Chapter Two. It will begin by 
stating participants’ demographic information (section 4.2), specifically: gender, ethnicity, age, 
occupation, and region in the UK. Section 4.3 will then outline the type of benzodiazepines being 
used and frequency of use. Section 4.4 will examine ease of access, availability and the cost of 
Valium (section 4.4.2) and Xanax (section 4.4.3). The diverse range of user motivations will be 
presented in section 4.5 which ranges from: needing them to sleep (section 4.5.1); self-medicating 
anxiety-related issues (section 4.5.2); to relax (section 4.5.3); to get high, mostly in conjunction with 
other drugs (section 4.5.4); to counteract other drug effects (section 4.5.5) and; to avoid hangovers 
and/or comedowns (section 4.5.6). Their sometimes overlapping and intertwining uses will be 
explored in section 4.5.7, before exploring substance use replacement as an explanation for the 
recent spike in usage (section 4.6). Dosage and routes of administration were closely linked to user 
motivations which will be discussed throughout this chapter. Section 4.7 will examine users’ 
preference of benzodiazepine, specifically: Valium (section 4.7.1) and Xanax (section 4.7.2) before 
highlighting some contradictory points (section 4.7.3). Section 4.8 will go on to explore participants’ 
accounts of adverse negative effects on the brain and behaviour, including: feeling overly-sedate 
which leads to the impairment of psychomotor skills (section 4.8.1); black-outs and memory loss 
(section 4.8.2); paradoxical stimulation and feeling ‘invincible’ (section 4.8.3); accidents and injuries 
(section 4.8.4); emotional blunting and depression (section 4.8.5); tolerance, dependency and 
withdrawal (section 4.8.6) and; mortality (section 4.8.7).  





4.2 Participant demographics 
The majority of respondents were male (n=326, 54.8%), 263 were female (44.2%) and one 
respondent was transgender. Over four-fifths of respondents were heterosexual (n=498, 83.7%), 68 
were bisexual (11.4%) and 18 were homosexual (3%). The majority of survey participants were white 
(n=529, 88.9%), 40 had a mixed ethnic background (6.7%), 14 were Asian (2.4%) and five were black 
(0.8%). Two participants were Chinese (0.3%), two were Arabic (0.3%) and one was Hispanic (0.2%). 
As expected due to survey distribution techniques (see Chapter Three: section 3.3.4), four-fifths of 
survey respondents were full- or part-time students (n=492: 82.7%). Others were employed (n=89, 
15%), unemployed (n=7, 1.2%) or ‘other’12 (n=3, 0.5%). Thus, the vast majority were of typical 
student age: over two-thirds of respondents were aged 18 – 21 (n=422, 70.9%), one-fifth were aged 
22 – 25 (n=127, 21.3%) and the rest were 26 and over (n=46, 7.7%). Due to predominantly targeting 
Greater Manchester online and offline (see section 3.3.4.1: image 5 and section 3.3.4.4), the 
majority of the respondents resided in the North West of England (n=170, 28.6%). 16.8% came from 
London (n=100), 14.3% from the South West (n=85) and 10.8% from Yorkshire and the Humber 
(n=64). Other survey participants came from the East Midlands (n=35, 5.9%), the South East (n=33, 
5.5%), the East of England (n=26, 4.4%), the West Midlands (n=26, 4.4%), Scotland (n=25, 4.2%), the 
North East of England (n=18, 3%), Ireland (n=5, 0.8%) and Wales (n=4, 0.7%). These figures are 
illustrated on image 14 below. Four participants (0.7%) preferred not to disclose their home region. 
However, due to traceable IP addresses (as discussed and displayed in Chapter Three: section 3.6), it 
was evident these respondents were from the UK (or were at the time of survey completion) 
therefore these 4 responses were not deleted. Their wish to not state their home region was 
respected and thus the figures displayed on the map below equate to 591.  
                                                          















Image 14: Map of the UK with number of respondents from specific regions  
4.3 Type of benzodiazepine and frequency of use 
In total, respondents spoke of 33 different types of benzodiazepines. However, two in particular 
dominated the research findings: the majority of respondents had tried either Valium (n=499, 
83.9%) and/or Xanax (n=481: 80.8%) at some point in their lifetime. Some respondents had also tried 
Klonopin (n=61, 10.3%), Ativan (n=47, 7.9%), Estazolam (n=36, 6.1%) and Etizolam (n=30, 5%). 5.1% 
of respondents had tried ‘other’13 benzodiazepines (n=31). For recent usage (in the past 2 months14), 
respondents had used Xanax more than Valium. Over half (n=313, 52.6%) had used Xanax in the last 
                                                          
13 ‘Other’ = Bromazepam, Brotizolam, Clobazam, Clonazolam, Deschloretizolam, Desetizolam, Diclazepam, 
Flubromazepam, Flubromazolam, Flunitrazepam, Flunitrazolam, Flurazepam, Flutazolam, Librium, 
Meclonazepam, Medazepam, Midazolam, Metizolam, Nifoxipam, Nitrazepam, Oxazepam, Prazepam, 
Pyrazolam, Temazepam, Tranxene, Triazolam (Halcion) and 'other research chemicals' 
14 The survey ran from the 1st March 2018 – 8th June 2018 therefore ‘recent usage’ accounts for 1st January 
2018 – 8th April 2018 
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2 months and 45.9% of respondents had used Valium (n=273). A third of respondents had not used 
them recently (n=181, 30.4%).   
Generally speaking, both Valium and Xanax were used for a number of motivations which will be 
explored in section 4.5. However, reported rates of usage varied heavily, and this was closely linked 
to motivations for use. 
‘It varies with how the weeks going, sometimes you just want the day to end, sometimes you 
wanna get fucked up, sometimes you wanna go on a nice walk’  
(Male, student, North West, aged 22 – 25) 
A third of survey respondents stated that they take benzodiazepines every few months (n=191, 
32.1%). 14.8% take them every month (n=88), 14.1% take them every 2 weeks (n=84) and 15.3% of 
people said they take them weekly (n=91). 26 respondents (4.4%) take them daily, and 17 (2.9%) 
take them whenever they feel the need to. 
‘When I need it or when I feel like I should (to take the edge off... When realistically there are 
other ways to relieve the tension... I'm in denial and I tell myself it's to relieve tension when 
lowkey it's like a little treat for myself rather’  
(Female, student, Yorkshire and the Humber, aged 18 – 21) 
‘It really depends. I smoke weed, so if I'm anywhere where I can't smoke weed for the night, I 
would take Diazepam to help me sleep. I also like it after a night out. However, my nights out 
are minimal, so my usage can vary. I can go months without using and then maybe use 3-4 
times in a fortnight’  
(Female, employed, West Midlands, aged 41+)  
49 respondents (8.2%) said they rarely take them or have only done so once or twice, and a further 
26 respondents (4.4%) had not taken them for a long time. Qualitative data was collected from 11 
respondents (1.8%) who ‘binge’: 
‘Every couple months I have a fat binge, normally for about a month. Then I stop again’  
(Male, student, North West, aged 18 – 21) 
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‘Sometimes benders come about where I end up going on a few days binge taking anywhere 
from 3 - 10 Valium a day. Then it can be months before I next take a benzo’  
(Male, student, East Midlands, aged 18 – 21) 
‘I will go weeks without having any, but when I have a supply I am more likely to use them. 
So it'll be bursts of 2 – 3 times a week (particularly during stressful periods), followed by 
maybe a month without any at all’  
(Male, employed, South East, aged 31 – 40) 
The amount of benzodiazepines consumed on each occasion varied, and it must be noted that there 
are different dosages available (as explored in Chapter Two: sections 2.2.3.1 and 2.2.3.2), which 
were not defined in the question. Just over a fifth (n=125, 21%) reported to taking 1 Valium, almost 
a third (n=180, 30.3%) take 2, and 11.6% (n=69) take 3 on each occasion. An alarming 15 
respondents (2.5%) consume over 10 Valium’s on one occasion. 14 Xanax users claimed to take ½ a 
bar on each occasion (2.4%), over a third take 1 bar on each occasion (n=220, 37%) and a quarter 
take 2 (n=147, 24.7%). Others take 3 (n=42, 7.1%), 4 (n=21, 3.5%) and 5 (n=11, 1.8%). This was also 
directly linked to user motivations. Generally speaking, there was a mild variation between 
motivations for use and the amount of benzodiazepines consumed. This will be discussed further 
throughout section 4.5.  
4.4 Access, availability and cost  
4.4.1 Source  
Survey respondents obtained their benzodiazepines from various sources. Over half acquired them 
through a dealer (n=340, 57.1%) and/or through a friend (n=316, 53.1%). Over a quarter claimed 
their purchases came from the dark-web (n=172, 28.9%), however there was no specific variation 
between Valium (n=153, 30.7%) and Xanax (n=163, n=33.9%). Other sources were through NHS 
prescription (n=75, 12.6%); diverted prescription (n=71, 11.9%); the clear-web (n=27, 4.5%); via a 
family member (n=22, 3.7%) and/or work or study colleague (n=22, 3.7%). A handful of participants 
said they obtained their benzodiazepines from overseas, primarily from Asia where they can often 




Of those who obtain their benzodiazepines through a dealer, a fifth (n=113, 19%) stated it was the 
same dealer who supplies another CNS depressant drug: ketamine. 90 respondents said it was the 
same dealer who supplied cannabis (15.1%), however a fifth said their dealer dealt them 
benzodiazepines only (n=108, 18.2%). This will be discussed further in Chapter Seven: section 7.5. 
Similar to Leclair et al. (2015), the current study has proven that the power of easy access and cheap 
prices can be a leading motivation for non-prescribed drug use, and it must not be underestimated. 
It may be accountable for substance use replacement: many said benzodiazepines are ‘cheaper than 
alcohol’. 
‘[Xanax is] cheaper than most drugs, therefore easier to buy more of and enjoy the relaxed 
feeling compared to other drugs available’  
(Female, student, East Midlands, aged 18 – 21) 
This will be examined further in section 4.7.  
The price of benzodiazepines varied greatly and was dependent on the source, as one individual 
said: 
‘Prices greatly depend on whether I buy from a street dealer (most expensive), from a friend 
who has usually ordered online (less expensive), or have ordered them myself (least 
expensive)’  
(Male, student, North West, aged 18 – 21) 
The general consensus in the current study was that buying in bulk meant that Valium pills and/or 
Xanax bars would be significantly less in price. A third of users buy 1 – 5 benzodiazepines at a time 
(n=182, 30.6%) and a fifth buy 6 – 10 at a time (n=118, 19.8%). 12.9% (n=77) buy 11 – 20, 12.8% 
(n=76) buy 21 – 50 and 9.2% (n=55) buy over 50.  
‘Valium can range from 13p (bulk price, 500+) to a pound each individually. And Xanax can 
range massively because the powdered pure form of [Alprazolam] can cost £15 for 100 mg 
where as a 2 mg tablet can cost up to £2’  




‘They're far too cheap and thus sold in large quantities, so, as stated, [I] end up taking too 
many’  
(Male, student, North West, aged 18 – 21) 
4.4.2 Valium (Diazepam) 
The majority of Valium users claimed to pay £1 per pill (n=142). However a vast number do not pay 
(n=135), and some pay 50p (n=87), £1.50 (n=35), £2 (n=48) and £3 (n=14). However, other prices 
such as 15p per pill, 20p per pill and 30p per pill were noted.  
4.4.3 Xanax (Alprazolam) 
‘Xanax prices vary depending on the strength/dealer. Dark web Xanax tend to be stronger 
but still cheap. Dealers usually charge more for stronger ones’ 
(Male, student, North West, aged 18 – 21) 
The majority of Xanax users pay £2 per bar (n=141).  
‘Xanax [is] more expensive because it's stronger’ 
(Male, student, East Midlands, aged 18 – 21) 
Others pay 50p (n=48), £1 (n=91), £1.50 (n=56), £3 (n=49) and £4 (n=13). A few individuals also 
stated they have once paid as little as 30p per bar, however one respondent stated once paying £5 
for one bar. 
‘Price generally depends as Xanax price varies on the dark web, there was a time when you 
could get 50 x 2 mg Xanax bars for £30’ 
(Male, employed, North West, aged 22 – 25) 
‘Depends on the dealer but normally around 7 Xanax for £10’ 
(Male, student, North West, aged 22 – 25) 
‘£20 for 6 bars of Xanax. Cannot buy less at once’ 
(Male, West Midlands, student, aged 18 – 21) 
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However, some say they have in fact lost their reliable source, which has halted or slowed down 
their usage: 
‘Now that certain vendors and markets are down or busted it's virtually impossible to get 
Xanax on the darknet and be confident of its quality so I stopped’ 
(Male, student, South East, aged 18 – 21) 
‘I used to be able to order them legally from chemicalwire.com, until they became illegal’ 
(Male, student, North West, aged 22 – 25) 
‘[My usage] used to be more regular when they were easy to get a hold of’ 
(Male, student, South East, aged 18 – 21) 
‘Xanax is … just that bit harder to source a good quality product and the fact it is never 
prescribed in England makes it that extra bit harder to get’ 
(Male, employed, South East, aged 18 – 21) 
135 respondents said they do not pay for Valium and 60 respondents said they do not pay for Xanax. 
‘My mate is always taking Vallies so he normally chucks [me] a couple if I'm worse for wear 
or if we [are] bored and chilling’ 
(Male, student, North West, aged 18 – 21) 
‘I have only ever been given them by friends not made to pay’ 
(Female, student, South West, aged 18 – 21) 
‘I got Xanax free with some other drugs I bought so I don't know the price’ 





4.5 User motivations 
The following section will present the multi-functional use of benzodiazepines. Generally speaking, 
user motivations in the current study were similar to those identified in previous studies (see 
Chapter Two: section 2.6) which identified individuals using benzodiazepines to either self-medicate: 
sleep issues, for anxiety, or stress; to use them for recreational purposes: to relax, to get high, to 
heighten the effects of other drugs, to ‘come down’ or to completely eradicate the effects of 
stimulants. Evidence from the current study also discovered that some individuals use 
benzodiazepines to: relieve anxiety about flying; boost confidence before a presentation, job 
interview or before socialising with peers; perform well in high pressure periods like deadlines and 
exams; sleep on long journeys; counteract the stimulant effects of study drugs such as Modafinil; 
counteract unwanted hallucinogenic effects of psychedelic drugs; eradicate any negative physical or 
emotional effects of hangovers and/or comedowns; ease or eradicate physical pain and; to correct 
irregular sleep patterns. 
‘[Benzodiazepines] can be used for multiple reasons. Help you sleep, chill you out, cheap 
alternative for a night out, straighten you out if [you’re] pranging due to other drugs (mainly 
psychedelics)’ 
(Male, student, Yorkshire and the Humber, aged 18 – 21) 
There was no significant difference between types of benzodiazepine used and user motivations. 
Both Xanax and Valium were used almost equally in a self-medicating and a recreational context. 
However, volume and dosages were clearly linked to user motivations, and dosage for those who 
used benzodiazepines in a recreational context generally doubled. Tolerance levels also varied 
significantly amongst participants thus every answer was different. Those using Valium took more 
than Xanax.  
‘I would [take] ½ [a Xanax] before public speaking. 1 to sleep or suppress stimulants (coke, 
MDMA) after a sesh. 1 or up to 2 depending on how I want to feel or how big the social event 
is (house party, going to a bar, a gig, dancing)’ 
(Female, student, Yorkshire and the Humber, aged 18 – 21) 
Routes of administration also revealed a direct link to user motivations and will be discussed 
throughout. Almost all (99.2%) of respondents usually swallow their benzodiazepines, however 96 
respondents (16.1%) said they snort them, 10 (1.7%) consume them sublingually, four dissolve it in 
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their drink, one person chews them and another one has injected them. The latter five routes of 
administration were notably linked to recreational users, particularly those who used them with 
other substances. As highlighted in previous studies (see Rigg and Ibañez, 2010; Andersson and 
Kjellgren, 2017), the speed of onset of benzodiazepines is significantly heightened when they are 
snorted. 
The layout of this section will mimic that of the literature review.  
4.5.1 To get to sleep 
Although the large majority of survey participants used benzodiazepines without prescription, their 
sedative properties were still praised and over half of respondents claimed to use benzodiazepines 
to ‘get to sleep’ (n=330, 55.5%): for long haul flights, overnight train journeys, long coach journeys 
and if their sleep pattern needed correcting.  
To assist in sleep, it was noted the majority of Valium users consumed around 5 - 10 mg. Although 
the dosage was not defined in the question, it was assumed users were referring to the blue 10 mg 
tablets. A third of those using Valium to get to sleep took 2 pills (n=108, 32.7%) and a quarter took 1 
(n=83, 25.2%). Others took 3 (n=39, 11.8%), 4 (n=18, 5.5%), 5 (n=16, 4.8%), 6-10 (n=10, 3%) or over 
10 (n=9, 2.7%).  
Those who used Xanax often used approximately 0.5 mg – 2 mg. Over a third claimed to take 1 
Xanax bar to get to sleep (n=125, 37.9%) and a quarter usually take 2 (n=78, 23.6%). Others take ½ 
(n=8, 2.4%), 3 (n=26, 7.9%), 4 (n=9, 2.7%) or 5 (n=5, 1.5%). 
‘0.25 to 1 mg of Xanax to get to sleep. Low dose if I'm at home, high dose if I'm on something 
like a noisy coach’ 
(Male, student, West Midlands, aged 18 – 21) 
As discovered in previous studies (see Rigg and Ibañez, 2010; Andersson and Kjellgren, 2017), some 
participants in the current study spoke of snorting their benzodiazepines which had an increased 
effect. 
‘Snorted some Valium on a coach and passed out in the foot well for the whole thing (the 
journey was about 20 hours long)’ 
(Male, self-employed, London, aged 22 – 25) 
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There were also reports of them being used in a poly-drug use context in order to get to sleep after 
heavy stimulant or psychedelic drug use; however, this will be explored in section 4.5.5.  
4.5.2 Self-medicate anxiety  
A third (n=195, 32.8%) of respondents claimed to take benzodiazepines for their anxiolytic 
properties and some did so to cope with ‘emotional distress’. Many praised the exhilarating anti-
anxiety effects, felt calm ‘and on top of the world’ (Female, student, North West, aged 22 – 25).  
For treating anxiety issues or stress, common doses for Valium users were 1 x 5 mg or 1 x 10 mg. 
Over a third of respondents took 2 Valium when self-medicating (n=69, 35.4%) and a fifth took 1 
(n=37, 19%). Others take 3 (n=24, 12.3%), 4 (n=12, 6.2%), 5 (n=10, 5.1%), 6-10 (n=7, 3.6%) or over 10 
(n=9, 4.6%). For Xanax users it ranged from 0.25 mg to 1 mg. A third of self-medicating respondents 
took 1 Xanax on each occasion (n=68, 34.9%) and a quarter took 2 (n=51, 26.2%). Others took ½ 
(n=3, 1.5%), 3 (n=16, 8.2%), 4 (n=8, 4.1%) or 5 (n=5, 2.6%). 
There was no significant difference in using benzodiazepines to self-medicate for anxiety and related 
issues in males (n=106, 32.5% of all males) and females (n=89, 33.8% of all females). However, there 
was a significant difference between self-medicating participants and age: it was less of a motivation 
amongst 18 – 21 year olds (n=128, 30.3% of all 18 – 21 year olds), but more amongst 22 – 25 year 
olds (n=47, 37% of all 22 – 25 year olds) and those aged 26 and over (n=20, 43.5% of all aged 26+).  
‘[Xanax is] very rapid acting and amazing for anxiety’  
(Male, unable to work, North East, aged 26 – 30) 
‘I had severe anxiety and could barely leave the house … when I was first prescribed [Valium] 
I went out on a bike ride and the freedom of being able to go outside was exhilarating’ 
(Male, student, North West, aged 26 – 30) 
‘[Valium] allows for conversation without unnecessary anxiety’ 
(Male, student, Yorkshire and the Humber, aged 18 – 21) 
‘[Valium] has a subtle calming effect without being overly sedative and can adequately 
reduce my anxiety or help me get to sleep if needed’ 
(Female, student, Ireland, aged 18 – 21) 
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‘[I] took a Xanax and all my problems disappeared’ 
(Male, student, South East, aged 18 – 21) 
‘[Valium] gives a nice noticeable yet subtle high, almost like feeling drunk and makes 
everything a little easier and enjoyable to get [through]’ 
(Male, student, North West, aged 18 – 21) 
A handful spoke about taking benzodiazepines to ease nervousness before flying, public speaking or 
‘performing in high pressure situations’ like job interviews and exams.  
‘If I have a speech or other presentation[s] I take a quarter bar of Xanax to help words flow 
more freely’ 
(Male, student, South East, aged 18 – 21) 
‘I take them constantly around assignment deadlines and exams. They take the edge off and 
help me focus’ 
(Male, student, North West, aged 26 – 30) 
‘I used to take 2 x 10 mg Pyrazolam or 1 x 10 mg Diazepam every single morning before work 
because I had to go out and approach people and talk to them. I felt I couldn't perform as 
well or sometimes go to work at all if I didn't take my benzos. I would call in sick if I didn't 
have access to benzos even though I wasn't ill, I just felt I couldn't go out and speak to 
people. I was aware of my addiction but I was performing great at work and delivering top 
results, whilst having fun and not worrying about anything. I felt care free, super confident 
and funny, chilled but motivated, very happy’ 







A few male participants said they preferred to self-medicate as opposed to disclosing their mental 
health issues to a doctor. Similar to information discovered in the investigative piece by VICE, (see 
Chapter Two: section 2.6.3.1), a handful of participants blamed the lack of mental health services 
and the weak efficacy of traditional treatment methods as a reason for self-medicating, and stated 
that benzodiazepines are the most efficient way to relieve symptoms of anxiety:  
‘I have tried the NHS route of bullshit antidepressants, tricyclics, tetracyclics, beta blockers 
and the list goes on. Whilst z-drugs like zopiclone are effective for insomnia, they do nothing 
for my anxiety so I decide to self-medicate with the top contender of sampled chemicals 
(trialled various alternatives for roughly 5 years now)’ 
(Male, self-employed, South West, aged 22 – 25) 
‘I… suffer from anxiety, and I find [Xanax] more beneficial than prescription medication I get 
prescribed’ 
(Female, employed, South West, aged 18 – 21) 
One participant, a former benzodiazepine addict, said the waiting list for psychotherapy treatment in 
her area is 14 months. 
A handful of participants said they were initially prescribed benzodiazepines which started their 
habit and often sparked addiction. The majority began with prescribed Diazepam before moving 
onto others obtained from the illicit market. 
‘I started with Diazepam as [it] was prescribed by a doctor at first but they would only give 
me small dose that didn't affect me. So I ordered a larger dose of Diazepam online, would 
take 10 mg a night to sleep. Then I switched to Xanax because I read online that it is faster 
acting on the body and also doesn't last as long as Diazepam, meaning I could wake up fresh 
and not feeling drowsy from the benzo still’  
(Female, student, Scotland, aged 22 – 25) 
‘I chose to get benzos from dealers after finding it extremely difficult to top up my 
prescriptions through the NHS despite having been prescribed them previously back home 
(abroad) since [aged] 15 to 18’ 
(Female, student, Yorkshire and the Humber, aged 18 – 21) 
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Although many participants spoke casually of relieving symptoms of anxiety, some individuals 
reported using them in more serious situations and at a significantly increased dosage. A handful 
spoke of suffering from severe anxiety, depression and attempted suicide.  
‘If I’m quite down or unhappy I just absolutely abuse drugs for a few weeks until my body 
can’t take anymore. Then I recover, and get a new job or something. I’ve recently got a job so 
I’m fine right now’ 
(Male, employed, North West, aged 22 – 25) 
‘I was very depressed and took 9 of my 2 mg Valium’s to make myself feel better’ 
(Female, employed, South West, aged 22 – 25) 
‘I was walking to [university] when I was at a very low point in my life illness wise and I began 
hitting myself in the head in public to help relieve the immense tension I felt from my PTSD. I 
got embarrassed that people were looking and watching me, and I didn't want to take my 
medication for a small episode as it was hard for me to get from the NHS, but the self-
harming got worse. I took a Valium and it blanked out the noise in my head, cooled me 
down, and accompanied with doodling I was able to recollect myself in uni. Even the ache 
from the self-harm was numbed a bit’ 
(Female, student, Yorkshire and the Humber, aged 18 – 21) 
‘[Suicidal] overdose 6 x 10 mg Diazepam’ 
(Female, student, North West, aged 22 – 25) 
‘Taken 90 tablets of Valium once to commit suicide. Passed out ended up in hospital’ 
(Female, student, Scotland, aged 22 – 25) 
‘One of my friends was self-medicating on Valium because he had cancer and was taking 
about 10 a day and is still taking them in hospital alongside his meds’ 




‘I once tried to commit suicide by taking about 20 Valium at Exeter train station, because my 
OCD had developed a theme where it was obsessively telling me I was causing terrible harm 
to others, and giving me compulsive urges to kill myself to 'prevent' this harm. I was 
delusional with very severe OCD and had no true desire to die’ 
(Female, student, South West, aged 26 – 30) 
4.5.3 To relax 
A theme which emerged from textual analysis was that participants often used benzodiazepines ‘to 
relax’ and ‘to get waved’. Many people seek relief and relaxation after a long day of work or studying 
by indulging in a glass of wine or pint of beer, as one interview participant described: 
‘…there is definitely some escapism by taking them. If I’ve been working flat out for a week, 
it’s the same as getting drunk really. You know when you’ve had a tough week and just want 
to get wankered?’ 
(Male, employed, North West, aged 22 – 25) 
However, the current study proved that individuals sometimes take benzodiazepines for similar 
effects: to feel good, happy, ‘light and floaty’.  
‘It's nice to take Xanax just to have a relaxed evening sometimes, not necessarily to get high’ 
(Unknown gender, student, South West, aged 18 – 21) 
‘Had a couple Xanies after a tough week at work and just needed to unwind and forget it for 
a while’ 
(Male, employed, North West, aged 22 – 25) 
‘Took 2 Valium in summer and went for a bike ride and picnic with my friends … It made the 
day so much more relaxing and enjoyable’ 
(Female, student, North East, aged 18 – 21) 
‘I took 1 Xanax, smoked a blunt on my own in my room and danced on my own to music in an 
extremely free and natural way’ 
(Male, student, Yorkshire and the Humber, aged 18 – 21) 
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One person said they sometimes take ½ of a 2 mg Xanax bar before work ‘to make it more fun’ 
(Male, student, South West, aged 22 – 25). 
4.5.4 To get high/poly-drug use 
Nearly two-thirds of respondents said they take benzodiazepines ‘to get high’ (n=368, 61.8%). A 
handful gave in-depth, detailed experiences of memorable encounters involving benzodiazepines 
some of which can be found in appendix 43, however the general motivation for this group of users 
was to ‘get messy’ and that they ‘like the buzz of it’. A small number of respondents stated feeling 
‘like a marshmallow’ whilst intoxicated.  
Dosage generally doubled when users were using them in a recreational context, however it ranged 
from 5 mg – 100 mg (Valium) and 0.5 mg – 20 mg (Xanax). A third of respondents took 1 Valium to 
get high (n=107, 29.1%). Others took 2 (n=47, 12.8%), 3 (n=48, 13%), 4 (n=23, 6.3%), 5 (n=22, 6%), 6-
10 (n=14, 3.8%) or over 10 (n=12, 3.3%). Two-fifths of Xanax users took 1 to get high (n=146, 39.7%) 
and a third took 2 (n=110, 29.9%). Others took ½ (n=15, 4.1%), 2 (n=34, 9.2%), 3 (n=34, 9.2%), 4 
(n=16, 4.3%), 5 (n=9, 2.4%), or over 10 (n=1, 0.3%). Males were more inclined to get high using 
benzodiazepines and other substances than females (m=224, 68.7% of all males; f=140, 53.2% of all 
females).  
‘[I take] 5 - 10 x 10 mg Valium on a night out with alcohol, and likely with ketamine, cocaine, 
MDMA, speed, or a mixture. Same with 3 - 5 x 2 mg white Xanax bars’ 
(Male, student, London, aged 18 – 21) 
‘I take at least around 7 [Valiums] in one occasion. It’s just so easy because you take 1, and 
then think ‘I can’t feel a fucking thing’ and then take 2 more and feel a little bit… But think 
‘fuck it I’ll take some more’ and take another 3 and then your heads gone just like that, and 
suddenly you wake up and there’s like 20 marks on your hand’ 
(Male, employed, North West, aged 22 – 25) 
‘5 x 5 mg Valium really helps me melt like a marshmallow’ 




The dominant mention of using benzodiazepines in conjunction with other drugs to heighten their 
effects was noted. Users spoke of poly-drug use, in particular, alcohol (n=395, 66.4%). A clear theme 
which emerged was that mixing the two heightened levels of intoxication quickly and cheaply. A 
third of users consumed ketamine alongside4 benzodiazepines (n=198, 33.3%) and a quarter of 
participants used cannabis (n=80, 13.4%). Some spoke of ‘fighting the sleep’ to get more high. 
‘When [Valium is] mixed with alcohol it gets you drunk faster and you just get a bit loose’ 
(Female, student, Yorkshire and the Humber, aged 18 – 21) 
‘Weed is the cake Xanax is the icing. + weed is not strong enough to forget about some 
things…’ 
(Male, student, North West, aged 22 – 25) 
‘Spent the night with friends in a flat, took MDMA, 2c-I, 2c-B and smoked hash. I remember a 
long, messy, weird, fun night. Gradually everybody peeled off and went to bed, and I took 
about 10 mg or 15 mg of Valium with whiskey to wind down, though I had no intention of 
sleeping. Intermingled with the MDMA: I felt just profoundly dreamy and relaxed, but also 
excited, the world seemed full of potential and I felt on the cusp of something exciting, the 
world seemed full of connections waiting to be discovered. Spent a few hours reading 
Wikipedia and listening to music, engrossed, got sleepy and went to bed’ 
(Male, student, North West, aged 22 – 25) 
For social situations, most dosages were reliant on what was available:  
‘It really depends on whatever someone has going’ 
(Male, student, North West, aged 22 – 25) 
‘Often people give them out like sweets after a long night’ 
(Male, student, North West, aged 18 – 21) 
‘After a night out depending on whether benzos have been ordered or how many are in the 
house massively depends on how many are consumed, it is very easy to get carried away and 
[sometimes] somewhat dangerous amounts are consumed’ 
(Male, student, North West, aged 18 – 21) 
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It was evident that a lot of users were unaware of the dosages they were consuming: 
‘1 –  3 Valium after a night out or at a festival to chill out (medium dose, not sure exactly 
maybe 12.5 milligram?)’ 
(Male, student, Yorkshire and the Humber, aged 18 – 21) 
‘Have no clue what mg they were bought off an unknown dealer at a festival, but I took 3 
bars of Xanax after using MDMA’ 
(Female, student, Yorkshire and the Humber, aged 18 – 21) 
A key theme which emerged from this group was that users choose to drink with them feel more 
confident. Some users claimed to consume a Valium pill or Xanax bar before going out to meet 
friends. 
‘They're a lot of fun to drink with. They relax me and make me very adventurous’ 
(Male, student, South West, aged 18 – 21) 
‘[Valium] makes me a bit more social on nights out’ 
(Male, student, North West, aged 18 – 21) 
‘1 x 10 mg Diazepam before I go and socialise to calm my nerves’ 
(Male, student, North West, aged 22 – 25) 
However, the negative side effects when mixing other substances with benzodiazepines were 
noticed by some:  
‘[I was] chilling at a mates house. [I] took a Xanax then after some time had some MDMA. 
[It] created a [very nice] high but in terms of physical wellbeing felt very alert and slow at the 
same time, as expected. [I] was scared for my heart the day after’ 





‘I took 2 Xanax and got very drunk and high (off weed). One of the weirdest experiences, I 
was constantly flipping between feeling to fucked and pretty much sober. I then proceeded to 
throw up all over the bottom floor of my mates house because benzos and alcohol are a very 
bad and dangerous mix’ 
(Male, student, South West, aged 18 – 21) 
A high number of respondents were aware that mixing benzodiazepines with alcohol often lead to 
memory loss and black-outs which will be explored further in section 4.8.2. The concurrent use of 
multiple depressant drugs is a concern as explored in previous chapters (see Chapter Two: section 
2.7.5). Harm reduction advice and recommendations will be discussed in Chapter Seven. 
4.5.5 To counteract other drug effects 
As discussed in previous chapters, benzodiazepines are sometimes needed to ‘come down’ off other 
drugs (Rigg and Ibañez, 2010; Kapil et al., 2014; Beharry and Gibbons, 2016; Mateu-Gelabert et al., 
2017) especially after excessive cocaine use (Bardhi et al., 2007; Motto-Ochoa et al., 2017). Rising 
purity levels may be at fault for will be explored in Chapter Five: section 5.1.3.2. The most dominant 
motivation, inclusive of three-fifths of survey participants, was ‘to counteract the effect of 
stimulants’ (n=369, 62%), after a rave, a house party, or at music festivals. A third of all respondents 
claimed they had used MDMA (n=208, 35%) and/or cocaine (n=189, 31.8%) alongside15 using 
benzodiazepines, other poly-drug users reported the use of amphetamines (n=59, 9.9%), Modafinil 
and/or Ritalin (n=27, 4.5%). Most users in this category used the drug to ‘end the night’. Males were 
more inclined to use benzodiazepines to counteract stimulants than females (m=222, 68.1% of all 
males; f=144, 54.8% of all females). 
Similar to those using benzodiazepines to get high, dosage generally doubled when users were using 
them to counteract other drug effects. Broadly, it ranged from 5 mg – 100 mg (Valium) and 0.5 mg – 
20 mg (Xanax).  
A third of Valium users claimed to take 2 when counteracting the effect of stimulant drugs (n=124, 
33.6%) and a fifth take 1 (n=78, 21.1%). Others take 3 (n=44, 11.9%), 4 (n=20, 5.4%), 5 (n=19, 5.1%), 
6-10 (n=13, 3.5%) or over 10 (n=9, 2.4%). Two-fifths of those using Xanax for the same reason take 1 
(n=157, 42.5%) and a quarter take 2 (n=93, 25.2%). Others take ½ (n=10, 2.7%), 3 (n=28, 7.6%), 4 
(n=15, 4.1%), 5 (n=5, 1.4%) or over 10 (n=1, 0.3%).  
                                                          
15 The question stated: ‘before/alongside/after taking benzos (within the hour)?’  
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‘[I] only use [them] after going out and taking harder drugs. After a night out it can help chill 
you out and helps you have a good, long, deep sleep’ 
(Male, student, Yorkshire and the Humber, aged 18 – 21) 
‘0.5 mg of Xanax or a 10 mg Valium after a night on MDMA, partly recreationally and partly 
to kill any residual stimulant effects’ 
(Male, student, West Midlands, aged 18 – 21) 
‘0.5 to 1 mg of Xanax to induce sleep at tail end of stimulant run’  
(Male, student, South West, aged 22 – 25) 
Over ten percent of respondents used benzodiazepines alongside3 hallucinogens (n=83, 13.9%). The 
majority of users in this category did so to completely get rid of any negative lingering hallucinogenic 
effects.  
‘10/20 mg Valium after a night out on stimulants/psychedelics. 1 or 2 mg Xanax for the same 
reason. As much as required, generally similar dose to kill an intense or uncomfortable trip 
on LSD or shrooms’ 
(Male, employed, South West, aged 18 – 21) 
‘I took 1 Valium during a bad acid trip, it completely calmed me down and turned a 
potentially traumatic experience into something very beautiful’ 
(Male, student, North West, aged 22 – 25) 
‘I took a [Xanax] after tripping at a festival when I couldn't sleep. I was seeing flashing 
images behind my eyelids; when the [Xanax] kicked in I felt tremendously relaxed. Possibly 
the best physical experience I have had in my life so far’ 






Some participants reported needing benzodiazepines after using common study drugs: Modafinil 
and Ritalin.  
‘I use [Xanax] for sleep because it is effective and doesn't have a come off / come down 
effect. A quarter bar Xanax (0.5 mg) can send me to sleep when finishing a stimulant session, 
Modafinil or other. It can also send me straight to sleep when having bad insomnia periods. 
When my sleeping pattern needs corrected, [I take] a Xanax at midnight and then set an 
alarm at 9am and a lot of coffee can correct the pattern’ 
(Male, student, Scotland, aged 18 – 21) 
It was suggested that Xanax was preferred when seeking to counteract the effect of other drugs due 
to its speed of onset, potency and shorter-acting properties. Similar to findings from Rigg and Ibanez 
(2010), a handful of recreational users in the current study snorted their benzodiazepines in order to 
experience the effects quicker.  
‘Crushing it up and sniffing it at the end of a night is useful to wind down, especially if you've 
been doing other drugs that night’ 
(Male, student, London, aged 22 – 25) 
‘I snorted a line of Xanax powder to get to sleep after doing coke all night and slept through 
the whole next day. I was asleep for 35 hours’ 
(Female, student, South West, aged 18 – 21)  
In most cases, participants claimed to use benzodiazepines after heavy stimulant or psychedelic 
substance use. However, some reported to use them in conjunction with other drugs:  
‘Most memorable experience involved taking one half of a bar of Xanax as a means to 
diminish any negative 'come-up' effects of three 100 – 125 mcg 1-P LSD tabs [the LSD 
analogue that was available on the greymarket for several years prior to the 'New 
Psychoactive Substances' bill] in conjunction with moderate amounts of cannabis. In this 
case, the benzos managed to allow for greater introspection than had previously been 
achieved in earlier psychedelic experiences’ 
(Male, student, West Midlands, aged 22 – 25) 
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One person stated they used benzodiazepines in the first few weeks of beginning Sertraline 
treatment, and another used benzodiazepines to counteract the effects of another class of drugs:  
‘To counteract the anxiety side-effect of cannabis smoke’  
(Male, student, Yorkshire and the Humber, aged 18 – 21) 
4.5.6 Avoid hangovers and comedowns 
Benzodiazepines were also reported to be useful to eradicate the unwanted, sometimes intense 
psychological and physical emotions associated with hangovers and comedowns. Those who used 
benzodiazepines for this purpose sometimes took them at the end of the night, however some took 
them the following day.  
‘I took it for the first time with my friend after we had been using MDMA and coke. That 
horrible come down feeling of no longer being high, but not being able to sleep totally went 
away when I took Diazepam. I just floated up to bed like a Marshmallow! Bliss’ 
(Female, employed, West Midlands, aged 41+) 
‘0.5 mg of Xanax to get rid of hangover shakes if I have something important I need to 
do/focus on’ 
(Male, student, West Midlands, aged 18 – 21) 
‘Sometimes I take 1 x 5 mg of Diazepam after drinking alcohol heavily to reduce the 
likelihood of anxiety the next day due to the effect alcohol can have on my mental health at 
times. I often have high anxiety and low mood for two days following a heavy night of 
drinking. I took one Diazepam before I went to bed because the alcohol made me emotional 
and I was crying uncontrollably about a situation that was going on in my life at the time. 
Found that the Diazepam actually prevented me from having the emotional hangover that I 
usually have, which was a nice surprise’ 




‘Love them on a hangover, totally chill you out and you don't feel anxious, usually take them 
in halves unless it's after a heavy night to help me sleep I'll have a full one then, only take 
them in the comfort of my own home normally don't want to be too spaced out in public’ 
(Male, student, North West, aged 18 – 21) 
Some used them to correct sleep patterns which were disrupted due to heavy substance use. 
‘Most likely 1 x 10 mg [of Valium] the following two days after [partying] to avoid sleep 
paralysis which I get from taking MDMA or large amounts of ketamine’ 
(Female, student, South West, aged 18 – 21) 
4.5.7 Multifunctional usage 
It was noted that motivations often merged together and/or overlapped. Some spoke of needing to 
take a benzodiazepine prior to a night-out of socialising in order to feel more confident and chatty 
which would then also heighten levels of intoxication.  
‘2 mg of Xanax if I’m feeling nervous before going out or if I want a cheap night out’ 
(Male, employed, West Midlands, aged 18 – 21) 
Benzodiazepine-intoxicated users’ spoke of enjoying their evening filled with other substances, 
before leaving the party and taking some more when relaxing with friends at home. At the end of 
the night, a few more are taken to induce a restful sleep. 
‘One 2 mg Xanax will do me good for any situation I need it in, like getting to sleep after a 
night out or just for jokes, would rarely go to 4 mg. With Valium I may take one 5 mg to take 
the edge off before going out then bang a few more towards the end of the night, maybe 
sniff a few at afters, I'll take however many I have on me cos they don't really knock you out 
like Xanax does which is a good thing’ 
(Male, student, South East, aged 18 – 21) 
Benzodiazepines are then also needed to correct irregular sleep patterns for the few days after the 




‘Depends, if it is a heavy week and I go multiple days in a row I will need to take Xans to put 
me to sleep after. Then I need Xans to get to bed for like two nights after that’ 
(Female, student, North West, aged 18 – 21) 
A timeline highlighting the multi-functional use of benzodiazepines in a recreational context can be 
found in appendix 57.  
4.6 Depressant substance replacement 
As explored in section 4.5.4 of this chapter, many participants stated that benzodiazepines were 
used in conjunction with alcohol to get drunk more quickly and cheaply. This implies users are 
mixing the two and need less alcohol to feel intoxicated effects and thus replacing half their usual 
alcohol intake with a benzodiazepine. After highlighting the ease of access and low cost of 
benzodiazepines in section 4.4, this may explain the recent spike in use amongst children and young 
people (aged under 18) (see Chapter Two: section 2.4.1) as Xanax may be the cheapest, most 
accessible substance made available to them. This will be discussed further in Chapter Seven. 
When respondents were asked why they prefer benzodiazepines to any other sedative substance 
like cannabis, four-fifths believe benzodiazepines have the best desired effect (n=350, 58.8%), over 
half say it is due to their cheap prices (n=317, 53.3%), two-fifths claim it is because they are easy to 
consume (n=261, 43.9%), and over a third say it’s because they are the most accessible (n=228, 
38.3%). Others said it is the only drug they had tried to get this effect (n=97, 16.3%) and that they 
are easy to hide (n=90, 15.1%). Some also said benzodiazepines seemed ‘safer’ than other drugs, and 
were ‘more socially accepted’. Some individuals simply ‘wanted to try it’. A few respondents claimed 
that they could go out in public high on benzodiazepines and it would go unnoticed, as opposed to 
any other drug. Many preferred them as there would be fewer legal repercussions if they were 
caught in possession.  
‘They are easier to carry round and it's more socially acceptable to take in certain situations 
than smoking weed’ 
(Female, employed, North East, aged 22 – 25) 
‘Repercussions of being caught with them is much less and [it is] easier to talk your way out 
of when compared to illegal drugs like weed’ 
(Male, student, Yorkshire and the Humber, aged 18 – 21) 
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 ‘[I] much prefer taking a pill rather than smoking a joint’ 
(Male, student, North West, aged 18 – 21) 
Some respondents said they much preferred benzodiazepines than smoking cannabis to relax or get 
high, as the latter caused anxiety, paranoia, hangovers and ‘pranging out’. 
‘Different weed strains have different effects, some make my anxiety worse. Xanax is a 
consistent feeling’ 
(Male, student, London, aged 18 – 21) 
‘It is the only available class of drugs that truly sedate your mind as well as body. Eliminates 
any anxiousness often felt during comedowns. Weed is relaxing but often can be quite 
introspective which isn't always wanted’ 
(Male, employed, North West, aged 18 – 21) 
However, some respondents do not see benzodiazepines as a direct replacement. If cannabis was 
not easily acquirable, benzodiazepines were simply viewed as ‘the next best option’.  
4.7 Benzodiazepine preference 
Preference of benzodiazepine was almost split equally between Valium (n=276, 46.4%) and Xanax 
(n=265, 44.5%). However, it was noted that out of all the respective gender group, significantly more 
females preferred Valium (f=50.6%, m=42.6%) and more males preferred the more potent 
benzodiazepine, Xanax (f=41.4%, m=47.2%). Key themes for both categories were: cost and value for 
money; availability and ease of access; strength; risk factor and; positive anxiolytic and tranquilising 
effects. When justifying their preferences, participants often compared the two and many 
contradicted each other. Having established Valium and Xanax as the dominant benzodiazepines 
used by this UK sample, the following section illustrates the key reasons why these two brand names 
are the most popular.  
A cross tabulation of participant age and benzodiazepine preference revealed that Xanax is the most 
popular amongst those aged 18 – 21 (n=202, 47.9% of all 18 – 21 year olds) compared to Valium 
(n=187, 44.2% of all 18 – 21 year olds). However, older participants preferred Valium. Over half of all 
22 – 25 year olds preferred Valium (n=67, 52.8%) compared to Xanax (n=47, 37%).  
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4.7.1 Valium (Diazepam) 
The predominant themes for those preferring Valium than any other benzodiazepine was the ease of 
access and low cost. 
‘[Valium is the] ideal strength for me personally and they tend to be cheap to acquire’ 
(Male, student, South West, aged 22 – 25) 
Valium was perceived to be a lot safer and had lower risk than other benzodiazepines as they are 
legitimately prescribed in the UK, and users believed the source would be via diverted prescription. 
Its legal status also swayed people to taking them as opposed to any other drug: repercussions of 
getting caught in possession would be much more relaxed, and individuals felt they could freely have 
Valium on their person in public and through airport customs.    
‘[Valium is] cheap and easy [to] go get real ones that are from a pharmacy and not pressed 
by someone else’ 
(Male, student, East Midlands, aged 22 – 25) 
‘[Valium] doesn't feel as 'drug-like' as the others’ 
(Male, student, North West, aged 22 – 25) 
Described as ‘the least sinister of the BZDs’ (male, North West, student, aged 18 – 21), Valium’s 
weaker potency meant users could easily and sensibly control the dosage, and take more if needed. 
There were also many accounts praising the efficacy of Valium, and the limited side effects (as 
opposed to other benzodiazepines). 
‘[Valium] doesn't taste funny or knock you out. It produces a warm pleasurable feeling’ 
(Male, student, North West, aged 22 – 25) 
‘[Valium] doesn't put you straight to sleep, it just makes you really chilled and care free’ 
(Male, student, North West, aged 22 – 25) 
‘[Valium is] long lasting and has a lower potential of abuse’ 
(Male, student, London, aged 18 – 21) 
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‘Not as high dosage so you still get the anxiety relief and slight euphoria while still being able 
to function and remember everything’ 
(Female, student, London, aged 18 – 21) 
‘Valium [is a] lower strength and [I] have found it has a shorter effect allowing you to do 
things more easily in the morning’ 
(Male, student, South West, aged 18 – 21) 
Those who have tried both Valium and Xanax were quick to compare the two. Xanax was frequently 
described as ‘intense’, ‘hectic’ and ‘too much’, thus, many preferred Valium. Participants spoke of 
the negative effects of Xanax such as headaches, grogginess, total memory loss and black-outs which 
were amplified with the addition of alcohol. Alongside being put off the possibility of counterfeits, a 
handful of individuals also disliked the feeling the day after taking Xanax. Hangover effects were 
described as feeling ‘like a zombie’ and ‘spaced out’ the next day. Adverse negative effects will be 
explored more in-depth in the section 4.8. 
‘Valium has better recreational ability. Xanax just knocks you out with little memory or 
enjoyment. Valium is more of a slow progression into hilarity which can be remembered 
more easily. Basically, Valium is more fun’ 
(Male, student, East of England, aged 22 – 25) 
‘Alprazolam is too strong and should not be taken recreationally... [I] always wake up with a 
cracking headache. Valium is the perfect blend in my opinion. I feel at ease and free to enjoy 
myself’ 







4.7.2 Xanax (Alprazolam)  
The predominant theme in the Xanax category was that it is ‘the most popular’ amongst peers and 
thus ‘easily available’. Many said they simply do not know of anyone selling any others and that they 
only know people with Xanax. Of the 184 qualitative answers, over a third (n=66, 35.9%) expressed 
comments such as: 
‘It's the one all of my friends take’ 
(Female, student, London, aged 18 – 21) 
‘[Xanax is] cheap and easy to get. [It’s a] guaranteed product from my supplier. [I] don't 
know of anyone selling the others. Xanax has definitely surpassed Valium use in student 
circles’ 
(Male, student, North West, aged 18 – 21) 
‘It's a popular drug with young students and easiest to get hold of from dealers’ 
(Female, student, Yorkshire and the Humber, aged 18 – 21) 
As explored in Chapter Two: section 2.4.2, it is believed celebrity culture and adopted norms may 
account for the recent spike in non-prescribed benzodiazepine use: 
‘[Xanax] acts faster on the body, getting me to sleep really quickly after a day on Ritalin. 
Much stronger and fairly cheap. Plus all the celebs crack on with it’ 
(Female, student, Scotland, aged 22 – 25) 
However, one participant thought otherwise: 
‘SoundCloud rappers have ruined Xanax’ 





On the contrary to those who disliked Xanax due to its high potency, a lot of respondents in the 
second category saw this as a positive and preferred Xanax as it is ‘better value for money’. A handful 
of respondents are impressed by Xanax’s fast onset of action and its short-acting properties. 
‘[Xanax] doesn't last as long and is stronger than Vallies’ 
(Male, student, North West, aged 18 – 21) 
‘I find [Xanax] faster-acting and better for inducing a restful state (compared to Diazepam). 
I've also found it has less of a knock-on effect the next day due to its much shorter half-life’ 
(Male, employed, South East, aged 31-40) 
One user simply liked ‘the shape of them’ (male, self-employed, North West, aged 41+) and some 
thought the bars were easy to split. Similar to Valium lovers who disliked Xanax, those who 
preferred Xanax also had negative perceptions of Valium.  
‘[Xanax is] best for getting rid of anxiety. Valium doesn't even touch the side’ 
(Female, student, North West, aged 18 – 21) 
‘[Xanax] is stronger than Valium. Valium doesn't always have strong enough effects for me 
to enjoy as much as I might a Xan’ 
(Male, student, South West, aged 22 – 25) 
‘[Xanax] makes me feel more wasted than Valium which is why I take them’ 
(Female, employed, South West, aged 18 – 21) 
4.7.3 Contradictory points  
It was noted that participants had many varied viewpoints, which often contradicted one another.  
Some spoke negatively of Xanax’s potent knockout effects, however many saw this as a positive as 
they were better value for money. Compared to Valium, the majority of respondents thought Xanax 
was more dangerous due to its high potency and the possibility of encountering counterfeits. 
However, some spoke of street dealers and online vendors who produced ‘reliable’ and ‘quality’ 
Xanax, and others thought it was the safest due to its shorter elimination half-life.  
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‘[Xanax] kicks in quick, doesn't have as much of a hangover as other benzodiazepines and 
most reliable to obtain in terms of quality’ 
(Male, student, London, aged 18 – 21) 
‘[Xanax has a] shorter half-life, less risk of dying because of dubious dosages’ 
(Male, employed, North West, aged 31-40) 
‘Xanax makes me feel very tired the next day and makes me want to fall asleep as soon as it 
hits, whereas Diazepam doesn't. Diazepam also lasts a lot longer and makes you less prone 
to blackouts than Xanax when taken in higher doses or mixed with alcohol’ 
(Male, student, North West, aged 18 – 21) 
A key stated preference was that Valium users felt less hungover or groggy the morning after use, 
however a handful of respondents spoke negatively of Valium’s long half-life which ‘ruined’ the 
following day due to tiredness. Some users on the other hand claimed to feel anti-anxiety ‘after-
glow’ effects up to two days after use and spoke of no negative effects. 
As previously stated, many claimed Xanax was ‘too much’, and the powerful knockout effects made 
it impossible to enjoy the drug without falling asleep soon after taking it. Other participants however 
thought Xanax was ‘more subtle’ and some believed Valium was too sedative. 
‘[Xanax] doesn't leave me feeling tired the next morning like Valium does’ 
(Female, student, Yorkshire and the Humber, aged 18 – 21) 
‘[Xanax is] shorter acting than Valium, and is less noticeable and more subtle’ 
(Male, student, West Midlands, aged 18 – 21) 
‘Valium knocks you out whilst Xanax gives you a buzz too’ 
(Female, student, South West, aged 18 – 21) 
‘Don't get sleepy like you do with Valium or the others and you get a better high [with 
Xanax]. With Valium you have to take more to reach a similar sort of high’ 
(Male, student, North West, aged 18 – 21) 
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4.8 Adverse negative effects 
Counter to participants justifying their motivations for the non-prescribed use of benzodiazepines, 
individuals also reported a wide range of negative effects. By loosely following the layout of Chapter 
Two: section 2.7, participants in the current study spoke of temporary sedation impairing 
psychomotor tasks and feeling hungover after use (section 4.8.1); black-outs and total memory loss 
(section 4.8.2); the feeling of invincibility and causing havoc (section 4.8.3); accidents and injuries 
(section 4.8.4); emotional blunting and depression (section 4.8.5); tolerance, dependency and 
withdrawal (section 4.8.6) and; mortality (section 4.8.7).  
4.8.1 Temporary sedation, complex psychomotor tasks, ‘hangover’ effects 
A few respondents spoke of unwanted side effects such as headaches and slurred speech, especially 
after consuming Xanax and many claimed to feel ‘spaced out’ or ‘sluggish’ the day after use. Many 
felt drowsy and struggled to walk the next day. Similar to previous studies which highlighted the link 
between benzodiazepine use and fractured cognitive abilities (see Chapter Two: section 2.7.2), many 
users felt they could not fully concentrate the day after use.  
‘Xanax leaves you feeling so spaced out the following day’ 
(Male, student, South West, aged 22 – 25) 
 ‘[My] brain felt like it was on fire two days after [use]’  
(Male, employed, unknown home region, aged 31 – 40) 
Similar to the Dutch driving study where six participants fell asleep at the wheel 1 hour after orally 
ingesting 1 mg of Xanax (Verster et al., 2002), one respondent from the current study felt the effects 
of the drug whilst driving even the day after: 
‘I took some Xanax in powder form after having a few lines of coke one night in order to get 
to bed around 12. My friend must have given me too much … I fell asleep in my driving lesson 
the next morning. Needless to say, my instructor never contacted me for another lesson’ 
(Male, student, South East, aged 22 – 25) 
‘Crashed my car after stupidly driving after taking around 5 x 10 mg Diazepam’ 
(Male, employed, North West, aged 22 – 25) 
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One respondent reported being spiked: 
‘Was in a Casino in [London] on my usual stimulant cocktail with a female friend; a gay guy in 
his 50's spiked our drinks and thankfully because of my tolerance when I realised I was 
coming down way too early and my friend was unsteady I quickly realised the case and 
handled the situation’ 
(Male, unable to work, East of England, aged 22 – 25) 
4.8.2 Black-outs and memory loss 
‘Memories are quite a blur with Xanax’ 
(Male, student, South West, aged 18 – 21) 
Although it has been acknowledged for many years that benzodiazepines are powerful hypnotics 
and are extremely useful for insomniacs (Kerr and Ong, 1995; Carter et al., 2010; Lader, 2011), their 
powerful knockout effects overwhelmed some. Individuals were often taken aback at how quickly 
they fell asleep, some within 5 minutes, and how nothing could awake them. Individuals claimed to 
have slept for extremely long periods of time (sometimes 2 or 3 whole days) and the effects lingered 
for up to a week after use. 
‘I took 1 at a uni house party and ended up falling asleep face first on the floor. The party 
carried on while I slept and woke up in the morning with a banging headache and no dignity 
left’ 
(Male, employed, North West, aged 22 – 25) 
‘I got really drunk and thought it would be funny to take a Xanax, fell asleep after 10 minutes 
of taking it and passed out for 2 days. After I arose from my very long sleep I felt anxious and 
wasn't properly recovered until another 3 days’ 
(Female, student, East Midlands, aged 18 – 21) 
‘One time I consumed 15 in one night and had a black out for 3 days being [lethargic] and 
low energy for about 5 days. This is [something] I regret and would never do again’ 
(Male, student, North West, aged 18 – 21) 
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A key theme and negative side effect of benzodiazepine use was that users would fail to remember 
the night on them, which deterred a lot of individuals from using them altogether. Memory-wiping 
effects mainly happened when Xanax was consumed with other substances, in particular alcohol. 
Some claimed that the memory wiping effects persisted for up to 3 days after consumption. 
‘Took a Xanax to counteract the effects of cocaine, thought I'd gone to sleep after but turns 
out I had a whole night out which I cannot remember at all. I was only aware due to the state 
of my bank balance and multiple people messaging me to ask if I was okay as they'd seen me 
out, and I obviously seemed very fucked’ 
(Female, student, Yorkshire and the Humber, aged 18 – 21) 
‘Took a 2 mg Xanax pill before going out to dinner. Can't remember what we ate. Can't 
remember how we got home. My boyfriend had to prop me up and support me for some of 
the journey home apparently. Apparently I had my head on my boyfriend's shoulder and 
looked like the girl from the ring with my hair all my face. According to my boyfriend, people 
around us looked concerned’ 
(Female, student, London, aged 18 – 21) 
‘I took 3 Xanax and drunk a couple of bottles of wine. Had no recollection of going out to a 
night club or anything afterwards. Yet photos and videos tell me I was partying for over 
24hrs. Complete memory loss’ 
(Male, student, South West, aged 18 – 21) 
‘I took a couple of Valium whilst drinking and was told the next day we visited a strip club. I 
was then told by my friend I got two lap dances for 50 pounds each or something. I don't 
even remember any of it. Feel really silly about that one’ 
(Male, student, South East, aged 18 – 21)  
‘Can't remember a whole month due to taking so much Xanax, had to re-do a year of uni … 
[I] try to avoid them now, and [I] will try to sleep without even if been taking uppers. Don't 
use them to get high anymore’ 
(Female, student, North West, aged 22 – 25) 
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Many reported losing things like excessive amounts of money, their house keys, passports and 
phones. 
‘Took 2 x 2 mg Xanax while out drinking and woke up with my bank account empty, a broken 
thumb and ripped jeans. No memory of events from about 30 minutes after taking first bar. 
Still had bank card in wallet so no idea what happened. Lied to bank and said it was stolen. 
Not used Xanax at all since this incident’ 
(Male, employed, North West, aged 31-40) 
‘Bought loads for a night at motion for cheap ended up taking loads forgot everything lost 
phone and passport and this random girl took me home as she was really worried about me’ 
(Male, student, East of England, aged 18 – 21) 
‘Took 6 Xanax went to the casino won £900 from £20 and gambled it all away within seconds 
and then got kicked out the casino for starting on the [manager]’ 
(Male, student, East Midlands, aged 18 – 21) 
Some accounts of total memory loss and black-outs were severely alarming regarding possible 
sexual exploitation and informed consent. Recommendations to reduce harm and dangers will be 
discussed in Chapter Seven. 
‘Took 1.5 bars of Xanax then [ketamine], both for the first time then woke up 15 hours later 
in someone else's bed in shorts I didn't have on the night before and minus £90 worth of 
good weed and 1g of MDMA. I never mixed Xanax with anything after that, a few drinks at 
most’ 
(Male, student, Scotland, aged 18 – 21) 
‘Took 40 mg Diazepam after a night out. Remember taking them at my flat alone. Wake up 
to find myself at some girls house I had never seen before and was told I had had sex that 
night and slept over. Was very confused as no memory of the event’ 





A lot of users who took excessive amounts claimed they did not realise at the time of consumption. 
‘Had some hilarious moments out with mates, it got even funnier when the fake Xans and 6 
mg Xans were going around and everyone had no recollection of what happened during the 
Xan binge’ 
(Male, student, North West, aged 22 – 25) 
‘Took 12 Valium. We [used] a marker on our hand to keep track of how many [we’d] had, 
both my mates passed out. One of their girlfriends wanted to take them home so I drove him 
at 5am (his car). I can’t drive, binned the car: lost a wheel and a wing mirror’  
(Male, employed, North West, aged 22 – 25) 
‘Took them when I was going to Los Angeles from Dublin in July 2017. I had written (forged) 
a prescription which was originally given to me. The GP gave me 50 [Valium] tablets that 
were 2 mg and refilled the prescription 5 times. I took 10 tablets when I arrived at the airport 
after having drank some vodka and beer. I took 5 more when at the departure lounge. When 
I went on the plane I drank some alcohol and took all the piriton tablets along with Nurofen 
Plus (codeine) and wine on the plane. I ''passed out'' until we landed and don't remember 
clearing immigration in L.A. I just remember arriving in my relatives house. When I arrived, I 
found that of the 400 tablets I had (8 bottles of 50 Diazepam tablets), I had completely 
finished 2 bottles leaving me with 300 tablets’ 
(Male, unemployed, Ireland, aged 18 – 21) 
‘Taken too many … whilst drinking because I didn't feel the effects straight away, my sanity 
and control slowly deteriorated throughout this period and I woke up in a state and had no 
idea what had happened, got in trouble with friends, lost money etc. On both Xanax and 
Diazepam’ 





4.8.3 Paradoxical stimulation: feeling invincible and ‘causing havoc’ 
‘You don't really have that many memorable ones on benzos! But I guess you go into full 'I 
don't give a fuck mode' if you get what I mean’ 
(Male, student, London, aged 18 – 21) 
‘I feel like I can do anything on them’ 
(Unknown gender, unemployed, Scotland, aged 18 – 21) 
It was noted that benzodiazepines often made users feel ‘invincible’ and that usage lead to irrational 
and erratic behaviour: Some reported shop-lifting, breaking into places, purposefully breaking 
things, driving and crashing their car whilst intoxicated, getting into fights, and/or physically 
attacking people. Many were kicked out of bars and clubs due to ‘causing havoc’. It was noted that 
these behaviours were only amongst poly-drug users and those who consumed excessive amounts 
of benzodiazepines. 
‘After Parklife, my friend took 8 [Valium] and ran through my friends door, to try and stay awake. 
Took it clean off its hinges’ 
(Male, employed, North West, aged 22 – 25) 
‘Took 2 Valiums, had 4 cans of lager, acted like a c**t and kicked my best mate in the neck’ 
(Male, student, North West, aged 18 – 21) 
‘I got drunk then took a Xanax to sleep and because I felt incredibly upset and anxious and woke 
up the night day having completely blacked out and beat up my housemate, breaking doors with 
a fire extinguisher and fell down the stairs causing me to get kicked out of my uni house’ 
(Female, student, North West, aged 22 – 25) 
4.8.4 Accidents and injuries 
Another negative side effect which was closely linked to the feeling of invincibility was that users 
often injured themselves whilst intoxicated. Over the years, studies have shown that even small 
doses of Valium, Xanax or other benzodiazepines can significantly diminish motor skills and thus lead 
to more accidents and injuries (see Bond et al., 1983; Block and Berchou, 1984; Thomas, 1988; 
Kozená et al., 1995; Verster et al., 2002; Friedman, 2006; Smink et al., 2010; Dassanayake et al., 
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2011; Ravera et al., 2011). Users in the current study often had no recollection of or control over 
certain events whilst intoxicated. 
‘I took [Xanax] after a night out when I took MDMA and I fell down the stairs, dislocated my 
elbow and don't remember any of it happening’ 
(Female, employed, South West, aged 18 – 21) 
‘I fell off a roof on Xanax and didn't remember. Luckily I was unhurt but this goes to show the 
inherent danger. This was whilst drinking, with less than 1 bar of Xanax’ 
(Male, employed, South East, aged 22 – 25) 
4.8.5 Emotional blunting and depression 
A small number of participants said that benzodiazepine drugs in fact sparked feelings of anxiety 
and/or depression. Again, these negative emotions were heightened with the addition of alcohol. 
‘Took 1 Valium to calm down, but it had the opposite effect, made me increasingly anxious and 
my head was too foggy to function and distract myself’ 
(Female, employed, North East, aged 22 – 25) 
‘Valium makes me feel depressed and [I am] normally likely to have break down if mixing with 
booze’ 
(Female, student, South West, aged 18 – 21) 
4.8.6 Tolerance, dependency and withdrawal 
Many users tried benzodiazepines ‘out of curiosity’, however were soon put off by their addictive 
properties.  
‘Tried out of curiosity, found to be by far the most addictive drug I've tried so I haven't 
touched it since and don’t plan on doing any benzo again’ 




‘I lost about 2 weeks to Xanax in the period between exams finishing and getting results. 
They are [madly] addictive’  
(Male, student, East of England, aged 18 – 21) 
Similar to participants’ in Rigg and Ibanez’s study (2010), some individuals in the current study said 
they began to use them as a coping mechanism for stress, anxiety or insomnia, but then usage lead 
to addiction, and benzodiazepines become the problem.  
‘Had a really bad experience with Xanax over a period of 2 weeks at most. My mate was 
addicted, and she recommended I take them to help me sleep. Soon I was addicted, taking 4 
a day at least. I was unrecognisable ... I was a zombie. I was aggressive. I ruined friendships. I 
have no memory of it which is the scariest part of it. When I came off it I was suicidal’ 
(Female, student, Scotland, aged 18 – 21) 
‘Have gotten caught by Alprazolam and had to attend an Emergency Department due to 
sudden stopping. Spent 7 days in a locked Hospital DETOX unit. Very scary but am free from 
that drug now’ 
(Male, employed, North West, aged 41+) 
In a face-to-face interview, a female aged 31 – 40 also spoke of initially taking non-prescribed 
Etizolam for sleep issues and chronic anxiety, which then developed into a two year Xanax addiction.  
P: Oh gosh, so it’s hard to say with Etizolam because they’re like little blue pills… I didn’t 
actually even know they were benzos!  
I: What did you think they were? 
P: Sleeping tablets, which in my head just didn’t connect… Yeah it’s really weird, this is how 
naïve I think I was… Well or stupid would be another word [laughs]. But yeah so, I was having 
one or two [a day]… at night ‘cos it was to get to sleep basically. I’d gone from kind of in a 
relationship to being on my own… Being really into partying and stuff but not ever using 
them really for after parties. It was more for like if I was not able to sleep ‘cos I’ve had 
problems with insomnia as well for a long time’ 
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After becoming physically dependent on them, she spoke of Etizolam becoming unavailable and thus 
using Xanax instead. Using them every evening just to assist with sleep, she continued to work long 
hours and socialise. She spoke of debilitating withdrawal symptoms like physical pain.  
 P: … I was still working like 60 hours a week- 
I: What! How!? 
P: I know. And I was going out pretty much every weekend as well. God knows how I didn’t 
kill myself.  
I: Was it the same reason when you were taking Xanax…. To get to sleep? 
P: Yeah- 
I: So it wasn’t in the daytime at all? 
P: No, no. You know what though – I remember one trip down to London with my boyfriend, 
we went out clubbing… Obviously you’re staying up all night. Normally my body would be 
used to having a Xanax but obviously I’m not gonna have one before I go out clubbing. So I 
didn’t have anything, I didn’t have anything on me. Anyway, on the way down on the train 
down to London, my back was in absolute agony. But I didn’t want my boyfriend to know so I 
kinda just pretended it wasn’t happening. But I really remember that night because I 
remember thinking “What am I doing?! Going out… Having a nice time but not having a nice 
time because I’m in so much pain?!” So I kept on going. 2016 – I don’t really remember much 
of 2016… 
I: So what made you stop? 
P: It’s a bit of a grim story. So, I nearly died… I ended up in hospital. I don’t really remember 
what happened. I think I had a breakdown or something… All I really remember is, me and 
my boyfriend split up and there was about 2 weeks where I was trying to work but I was in 
the house, and I don’t think I even left the house. I didn’t eat anything for about 10 days, and 
a couple of my friends were dead worried about me. They basically came round and marched 
me to the hospital, and when I walked in I don’t remember anything from A and E. They said 
it was sleep deprivation – Ironically. So I think it was chronic sleep deprivation- 
I: Oh so your body just kind of shut down.  
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P: Yeah it just shut down. When you’re not sleeping properly for that long… Ironically I don’t 
think they help you sleep. They send you to sleep, but the sleep that you get is just weird… It’s 
not refreshing, it’s tiring. It’s like tiring sleep… And by that point I was obviously having them, 
but they weren’t really sending me to sleep.  
Similar to previous studies which have highlighted the dangers of abrupt discontinuation (see 
Hollister et al., 1961; Péterssun, 1994; Ashton, 2002), this particular interviewee believed halting her 
usage was the issue which resulted in her being hospitalised:  
‘One of the things that kind of made it all unravel was that I decided I was going to stop, and 
I just stopped. I threw everything away’ 
Withdrawal effects were noted by some participants, including physical and crippling pain, loss of 
appetite, psychotic tendencies and rebound anxiety: 
‘… One thing I remember happening really vividly is that I thought there were loads of flies in 
my house … You know like that horrible buzz-y sound, I was hearing that. My mind was just 
obviously going mad’ 
(Female, employed, Yorkshire and the Humber, aged 31 – 40) 
‘Xanax makes you do stupid things and more importantly I would go on a bender i.e. taking it 
[for] over a week and then have the worst anxiety when I stopped. Like would freak 
out/couldn't sleep/thought I was going to die and this was a reoccurring problem’ 
(Female, student, North West, aged 18 – 21) 
4.8.7 Mortality 
A handful of participants said they had lost friends to benzodiazepines. All were used in conjunction 
with other drugs, in particular alcohol.   
‘…One of my close friends died from [Xanax]. He was a clubber, and he was using them 
anyway and no one knew, so he had a problem with them. But basically he got really pissed 
and was just a mess, went home and had too many and just passed away in his sleep’ 
(Female, employed, Yorkshire and the Humber, aged 31 – 40) 
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‘Mostly I know that a majority of people in the bar/entertainment/events world use Valium 
or Xanax heavily to sleep after work and after parties. Having now lost 3 friends to Valium 
sleep death after events or heavy weekends of work/party, in just 2 years, I'm glad of my 
own move away from reliance on them and am keen to see if there is any way to make 
people more aware of the dangers of long term abuse and the risks of literally disappearing 
in your sleep and leaving your loved ones wondering what the fuck happened’ 
(Male, employed, North West, aged 31 – 40) 
Poly-drug use dangers were also highlighted as serious concerns in previous chapters (see Chapter 
Two: section 2.7.5). These will be re-addressed in Chapter Seven.   
4.9 Summary of chapter and conclusion 
To summarise, this chapter highlighted the predominant use of Xanax and Valium amongst students 
aged 18 – 25 in the UK, alongside examining the context in which they are being taken, rates of 
usage and dosages. It is clear that other, problematic poly-drug users remain a key benzodiazepine 
user population, however this sample was not represented in this research due to the methodology 
outlined in the previous chapter. The young user group (18 – 21 year olds) preferred Xanax more and 
those aged 22+ preferred Valium.  
The various motivations included: self-medicating everyday sleep and/or anxiety issues; to sleep on 
long journeys; to feel more confident in social situations; to feel more confident in presentations 
and/or exams; to relax; to get high and heighten the effects of other drugs such as alcohol and/or 
cannabis; to counteract the effects of other drugs such as stimulants (MDMA, cocaine), psychedelics 
(acid, LSD) and/or study drugs (Modafinil/Ritalin); to avoid or dilute the negative emotional and 
physical side effects of hangovers and/or comedowns; to ease physical pain and; to correct irregular 
sleeping patterns. Ease of access, availability and low cost was acknowledged as a significant motive 
for some, especially when other substances were unavailable and the majority of participants 
reported to obtain their benzodiazepines’ from a dealer, closely followed by through a friend. Many 
highlighted the weak efficacy of NHS treatment services as a reason for self-medicating. 
Survey participants also reported a wide range of negative effects, such as temporary sedation 
impairing psychomotor tasks and feeling ‘groggy’ after use, which impaired concentration levels. A 
dominant negative effect was undoubtedly black-outs and total memory loss. Many reported 
paradoxical stimulation and feeling ‘invincible’, but this often lead to accidents and injuries. Some 
reported experiencing emotional blunting and depression or heightened anxiety. A handful were 
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aware of the addictive properties of benzodiazepines which hated their usage, and some spoke of 
losing friends to benzodiazepine-related deaths.   
The implications of these findings will be discussed further in Chapter Seven, where future 
recommendations will be made to users in an attempt to reduce avoidable dangers and harms and 
to ensure safety. Data from this research paper will also seek to advise health care practitioners, 
academics, substance use charities and future policy makers in order to reduce the non-prescribed 
use of benzodiazepines amongst young people in the UK.      
The following chapter will outline the research methodology for the chemical analysis of seized 

















Chapter Five: Chemical analysis methodology  
5.1 Introduction and chapter overview 
Content tests have previously revealed that street-bought drugs can contain either: a higher 
percentage of active ingredient than what it is sold as or; a lower amount of, or zero active 
ingredient and thus bulked out with other, perhaps more harmful substances or, harmless bulking 
agents like sugar (Coomber, 1997; Liang, 2006; Cole et al., 2010; Wood et al., 2011; Lucio do Lago et 
al, 2016). Both pose significant risks for the consumer as they may overdose or suffer from adverse 
drug interactions that are unknown and thus, untreatable (Blackstone et al., 2014).  
The following chapter will begin by reviewing existing studies and media coverage in order to 
highlight the need for content analysis. It will begin by attempting to examine the scale of the illicit 
benzodiazepine market (section 5.1.2). It will then outline the issues with counterfeits, specifically: 
drugs laced with other, more harmful adulterants (section 5.1.3.1); those with a higher 
concentration of the active ingredient and thus, increased purity (section 5.1.3.2) and; those with 
less active ingredient (section 5.1.3.3). Section 5.1.4 will examine the evolution of substance testing 
in the UK and its significance. This chapter will then outline the methodology created to perform 
chemical analysis to determine the content and purity of 29 seized ‘Valium’ samples and 29 seized 
‘Xanax’ samples from Greater Manchester. It will begin by stating the chemicals and reagents used 
(section 5.2). Section 5.3 will outline the presumptive test used and the results, followed by methods 
of NMR and the results (section 5.4). Section 5.5 will outline the GC-MS testing element. Specifically: 
the GC-MS settings used (section 5.5.1); the preparation of the eicosane stock solution (section 
5.5.2); the preparation of the reference and calibration standards (section 5.5.3 and 5.5.4 
respectively) and; the unknown sample preparations (section 5.5.5).  
5.1.2 Scale of the illicit benzodiazepine market  
As any illicit market, the scale of the sale and supply of non-prescribed benzodiazepine is difficult to 
measure. However, in the early months of 2018, The Guardian reported that a colossal 130 million 
benzodiazepines had penetrated the UK illicit drugs market since 2014 (see The Guardian, 2018a). 
Collected over four years which began in the same year of Kapil et al.’s study as mentioned in 
previous chapters, this data has attempted to shed light on the size of the illicit benzodiazepine 
market. However, this figure only represents the drugs which were seized and it can be assumed 
that the overall number is much higher.  
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Further evidence comes from an MHRA investigation which discovered that from the years 2013 – 
2016, approximately £115 – 200 million worth of medicines including Diazepam had been diverted 
from the legal supply chain and entered the illicit trade (see MHRA, 2018a). In addition, a BBC 
investigation exploring the supply of Xanax and in January 2017 reported three separate seizures of 
Alprazolam equating to over 50 kg, which would have been able to produce approximately 25 million 
Xanax bars containing 2 mg of active Alprazolam (see BBC News, 2018c).  
As stated at the beginning of this chapter, obtaining benzodiazepines via means other than 
legitimate sources raises the possibility of encountering counterfeits. The following section will 
highlight the variety of counterfeited drugs, and the implications of each.  
5.1.3 Counterfeits 
Although benzodiazepines are one of the most prevalent diverted drugs within the UK (see ACMD, 
2016), illicit drug traders tend to custom press their narcotics and add other adulterants in order to 
increase the bulk of substances and/or to enhance or copy the effects (Coomber, 1997; Cole et al., 
2011), with the intent to increase their profit margin and their clientele base (Tzvetkova et al., 2016).  
It is not simple to detect and quantify the scale of counterfeits, but it can be assumed that UK street 
Xanax is illegitimate as they are unobtainable via NHS prescription. The following section will 
highlight the danger of counterfeited drugs, which can be either: laced with other, more harmful 
adulterants (section 5.1.3.1); contain an increased amount of the active ingredient (section 5.1.3.2) 
or; contain smaller amounts of the active ingredient (section 5.1.3.3).  
5.1.3.1 Laced with other harmful adulterants 
Recently, the UK media reported that Xanax bought via social media had been cut with Etizolam 
(BBC News, 2018f), boric acid, rat poison, floor polish, and pesticides (Daily Mail, 2018). In Scotland, 
reports showed counterfeited street ‘Diazepam’ to contain benzodiazepine analogues Diclazepam, 
Etizolam and Flubromazepam, and synthetic opioid U-47700 (Police Scotland, 2016). Another major 
cause for concern is the presence of fentanyl-laced Xanax in the US (see CBS News, 2016; Fox News, 
2018), and the possibility of it penetrating the UK scene. Consuming adulterated benzodiazepines 
can cause death by adverse drug interactions (Jackson et al., 2011) and health care professionals are 
unequipped in dealing with the unknown side effects. In particular, opioid-laced Xanax bars are a 
huge cause for concern, as their central nervous system depressant properties are much more 
potent than benzodiazepines, and users may overdose.  
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5.1.3.2 Increase in purity 
The second danger associated with counterfeit drugs is an increase in the concentration of active 
ingredient and thus, the potential of overdosing. The increase in purity can be seen in other drugs: 
an EMCDDA report revealed that just under two decades ago, the average ecstasy found in MDMA 
pills ranged from around 50 – 80 mg (Wood et al., 2011). However, more recent data reveals that 
pills nowadays contain twice the amount: approximately 125 mg, and some ‘super pills’ have 
reportedly contained 270 – 340 mg (EMCDDA, 2016b). In addition, the most recent EMCDDA 
European Drug Report (2018) reported the highest levels of cocaine purity in the last decade.  
With regards to benzodiazepines, the UK media have reported extremely potent custom pressed 
benzodiazepines. A detailed BBC investigation reported the emergence of red Xanax bars mid-2016. 
The ‘red devils’ were thought to contain over 5 mg of active Alprazolam and could be bought from 
online vendors for as little as 35p per pill (see BBC, 2018c). As an already potent benzodiazepine at 2 
mg, 5 mg Xanax bars are extremely dangerous and can cause even greater adverse negative effects 
(as discussed in Chapter Two: section 2.7). 
5.1.3.3 Decrease in purity  
On the other hand, much media coverage is thought to be exaggerated and does not accord with 
personal accounts from dealers and/or forensic evidence (Coomber, 1997). Instead, it is thought that 
substances are frequently cut with benign substances like sugars (ibid.). Variation in the quantities of 
active ingredients as well as bulking agents within substances poses further risks. Users may become 
accustomed to certain dosages based on personal tolerances and/or drug habits. However, these 
may be inappropriate for another batch which may contain a vastly greater quantity of the active 
ingredient or a different bulking agent for example. 
5.1.4 Substance testing in the UK 
The knowledge and perceived importance of unknown substance use has seemed to grow in recent 
years. UK drug charity The Loop introduced forensic drug testing at nightclubs in 2013 and at music 
festivals in the summer of 2014, and Multi Agency Safety Testing (MAST) from summer 2016 
whereby party-goers are able to anonymously submit their unknown, illicit substances for 
quantitative and qualitative analysis. The Loop’s Twitter reports showed that samples sold as MDMA 
crystal powder in London were actually found to contain N-ethylpentylone which causes paranoia, 




However, with a dominant focus on club drugs like MDMA and cocaine, The Loop misses out the user 
population who use drugs in other contexts: i.e. those taking Xanax at 5am after a rave to come 
down from stimulants (see Chapter Four: section 4.5.5). The content analysis of benzodiazepines 
remains relatively undiscovered and thus, the forensic testing element of this research project 
wishes to shed light on the true contents of street Valium and Xanax in the UK. Moreover, it is 
difficult to generalise chemical analysis results from The Loop as the substances tested are 
dominantly those handed in which may lead skew the results. 
In the current study, a presumptive colour test namely ‘M.M.C. International B.V – General 
Screening/ Multi Party Drugs Test’ was initially used to reveal the adequacy of home testing kits and 
to note any false positives. The methods and results will be displayed in sections 5.3.1 and 5.3.2 
respectively. Then, the methods and results of the nuclear magnetic resonance (NMR) tests will be 
displayed in sections 5.4.1 and 5.4.2 respectively, which were used to assist in the confirmation of 
the structural characterisation of the unknown compounds. Section 5.5 of this chapter will describe 
the methodology used for GC-MS analysis. GC-MS was used for the identification of the chemical 
profile of the unknown samples. Over the years, there have been multiple published studies which 
have used GC-MS to identify the contents and purity of illicit, street bought substances (see Yegles et 
al., 1997; Yilmaz and Akba, 2010; Jalali et al, 2016; Lucio do Lago and Angnes, 2016).  
5.2 Chemicals and reagents 
All reagents including methanol, eicosane and the reference standards were of commercial quality 
(Sigma-Aldrich, Gillingham, UK) and used without further purification.  
Reference materials and standards were obtained, under UK Home Office licence, by authorised 
personnel and in compliance with both the UK Misuse of Drugs Act (1971) and UK Misuse of Drugs 
Regulations (2001). The test samples used within this study were received during the period of 
September 2017 – May 2018. Test samples (street samples) were provided by Greater Manchester 
Police (GMP) personnel, in accordance with the legislation and under the approved Memorandum of 
Understanding operating between the Manchester Drug Analysis and Knowledge Exchange 
(MANDRAKE) and GMP. All controlled and restricted materials were stored, transferred, used and 
destroyed in compliance with the UK Misuse of Drugs Act (1971) and UK Misuse of Drugs Regulations 
(2001). The researcher was unable to access information regarding the precise location and event of 
each seized sample.   
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A total of 29 assumed ‘Valium’ samples and 29 assumed ‘Xanax’ samples were tested. All of the 
‘Valium’ samples were in pill form. V1 was the anomaly (see appendix 44 for pictures) and weighed 
118.2 mg. V2 – V29 were from the same batch (see appendix 45 for pictures) and weighed from 53.3 
mg (V7) to 67.4 mg (V27). See appendix 46 for all the unknown ‘Valium’ samples’ weight and 
description. The majority of the ‘Xanax’ samples were in tablet form (see appendix 47 for pictures) 
and weighed around 250 mg. However, some samples were in powder form and the weight of each 
sample ranged from 44 mg (sample X6) to 914.6 mg (sample X4). X26 was an anomaly, and was in 
the form of a blue pill labelled ‘UPJOHN 90’16 (see appendix 48 for pictures). See appendix 49 for all 
the unknown ‘Xanax’ samples’ weight and description. 
5.3 Presumptive tests 
Presumptive tests are a fast way of enabling immediate action when dealing with unknown 
substances (United Nations, 1994). Specifically, colour tests are commonly used by the Police force 
to determine the presence of various drugs (Philp and Fu, 2017). As an easy, one-step procedure, the 
‘M.M.C. International B.V – General Screening/ Multi Party Drugs Test’ is a cheap and fast way of 
testing unknown substances. It is able to identify the following (as displayed on the packaging): 
methadone; barbiturates/ketamine; cocaine/crack; ephedrine; heroin/mescaline; 
(meth)amphetamines/PMA; methaqualone/methylphenidate; oxycodone and; XTA (MDMA). See 
appendix 50 for a photograph of the packaging. Although benzodiazepines are not listed, it was 
important to run this test to identify any other potential adulterants and present any false positives 
of controlled substances (United Nations, 1994). Thus, informing users of the reliability and validity 
of such tests.  
The following section will display the method of the presumptive testing element (section 5.3.1) 
followed by the results (section 5.3.2). 
5.3.1 Method 
Where necessary, tablets were ground and homogenized before running the presumptive test. Of 
the unknown samples, seven were chosen at random to perform the presumptive tests (X1, X2, X3, 
X8, X11, X16, and X17) alongside one test including the reference standard. A heaped spatula of the 
sample was added to an ampoule and vigorously shaken before being left to sit for five minutes.  
                                                          




5.3.2 Results  
Any colour change was noted immediately after adding the sample to the ampoule, and after five 
minutes. Initially there was no change in all eight tests (X1, X2, X3, X8, X11, X16, and X17), inclusive 
of the Alprazolam reference standard (see appendix 52 for images). After five minutes, the only 
noticeable change was a slight murky off-white tinge that X16 had developed (see appendix 53 for 
images). The closest substance related to the produced colour (as stated on the box – see appendix 
50) was methadone. As methadone is a controlled drug and the match was perceived as very 
unlikely, this result was disregarded. The presumptive tests in this study have shown the possibility 
of false positives and that they are not reliable when testing benzodiazepines.   
The presumptive test revealed little change therefore GC-MS analysis was appropriate to determine 
the true contents in each sample. 
5.4 Nuclear magnetic resonance (NMR) 
Every compound has its own unique spectra and thus, NMR is frequently used for structural 
characterisation to help confirm what the specific compound is (see Huidobro et al, 2007). The 
following section will begin by outlining the sample preparation of 18 samples used for the NMR 
tests (section 5.4.1). Section 5.4.2 will then display the NMR results, which were necessary to 
confirm the structure of the unknown samples before GC-MS analysis.    
5.4.1 Sample preparations 
For the current study, including both reference standards, a handful of unknown samples (X1, X3, X4, 
X6, X9, X16, X17, X28 – X32, V1 – V6) were chosen to run Dimethyl Sulfoxide-d6 (DMSO) and 
acetonitrile-d3 in order to give extra confirmation of the chemical structure of each substance. For 
each reference sample, two NMR tests were performed. In each test, 10 mg of the reference powder 
was added to 600 µL either deuterated DMSO or acetonitrile. The amount of unknown substance 
powder added to the DMSO and/or acetonitrile ampoule was dependent on how much powder was 
left over. Measurements ranged from 10 mg – 20 mg. 
Solubility was an issue at the required concentration. Thus, all samples were ultra-sonicated and 
filtered using 0.45 mm filters. Used ampoules and pipettes were discarded in the relevant glass 
deposit bin. The individual DMSO tests ran for approximately 3 minutes and the acetonitrile tests ran 




DMSO only extracted what the tablet is made up of, not the active ingredient. Thus, the results listed 
in appendix 53 displayed cutting agents like lactose. Acetonitrile tests extracted the active 
ingredient. The spectra displayed on each test matched the active ingredient spectra however the 
low match scores are due to there being no current database. Thus, researchers are urged to create 
a database for these substances to enable quick testing in future research.  
See below for a few examples and comparisons of the NMR spectra’s.  
 




Figure 3: Alprazolam reference acetonitrile NMR spectra 
 
Figure 4: Alprazolam reference acetonitrile NMR spectra compared to the Alprazolam reference 




Figure 5: Sample X3 DMSO NMR spectra (Alprazolam) 
 












Figure 7: Diazepam reference acetonitrile NMR spectra 
 
Figure 8: The Diazepam reference DMSO NMR spectra compared to the Diazepam reference 




Figure 9: Sample V26 DMSO NMR spectra (Diazepam) 
 




Figure 11: Sample V26 acetonitrile NMR spectra compared to the Diazepam reference acetonitrile 
NMR spectra 
As displayed in figure 11 above, the NMR Spectra of sample V26 showed a match with the NMR 
Spectra of the Diazepam reference which confirms that sample V26 contains Diazepam. However, 
the quantity of active ingredient in the street samples remained unknown, thus the need to 










5.5 Gas Chromatography-Mass Spectrometry (GC-MS)  
The following sub-section will outline the methodology used for GC-MS analysis. Specifically: the GC-
MS settings (section 5.5.1); the preparation of the eicosane stock solution (section 5.5.2); the 
preparation of the reference standards (section 5.5.3); the preparation of the calibration standards 
(section 5.5.4) and; the preparation of the ‘Valium’ (section 5.5.5.1) and ‘Xanax’ (section 5.5.5.2) 
samples.  
5.5.1 GCMS settings 
GC-MS analysis was performed using an Agilent 7890B GC and a 5977B mass selective detector 
(Agilent Technologies, Wokingham, UK). An Agilent Technologies 7693 auto-sampler was used in 
order to perform automated injections. The mass spectrometer was operated in the electron 
ionisation mode at 70 Ev and separation was achieved with a HP5 MS column with 0.25 µm film 
thickness (30 mm x 0.25 mm i.d., 0.25 µm). Helium acted as the carrier gas at a constant flow rate of 
1.2 mL min-1 and a 0.5 µL aliquot of each sample was injected with a split ratio of 50:1. Mass spectra 
were obtained in full scan mode (50-550 amu). All samples were injected three times and the total 
run time was 30 minutes. The temperatures of the injector and the GC interface were maintained at 
280 °C. The MS source and quadrupole temperatures were set at 230 °C and 150 °C respectively.  
A method was developed in order to identify Alprazolam and Diazepam in the unknown samples. 
The following oven temperature was developed that provided a different retention time for both 
active components. This can be seen in the following table. 
 Rate (deg C / min) Value (degrees c) Hold time (min) 
Initial  60 2 
Ramp 1 30 290 20 
 
Table 10: GC-MS oven temperature and hold time  
5.5.2 Eicosane stock solution preparation 
Eicosane was used as the internal standard. For the first method, 0.02 g of eicosane was weighed 
and transferred into a 100 mL volumetric flask before being filled with methanol in order to create a 
concentration of 200 µg mL-1. This was diluted by a factor of two in order to create a 100 µg mL-1 




For the second method, a new eicosane stock solution was created. 0.1 g (actually 0.1003 g) of 
eicosane was vigorously sonicated in a 100 mL volumetric glass with methanol, before 2000 µL was 
taken and added to 8000 µL of methanol to create a concentration of 200 µg mL-1. 
5.5.3 Reference standards 
In order to determine the active ingredients in the unknown samples, it was necessary to perform 
GC-MS analysis using reference standard Alprazolam and Diazepam in order to compare mass 
spectral data. 
0.005 g the Diazepam reference powder was added to 5 mL of methanol to create a 1 mg mL-1 
solution. 200 µL of this was added to 800 µL of blank methanol to create D200 µg mL-1. 500 µL of 
D200 µg mL-1 was added to 500 µL of the eicosane stock solution (method two), ready for GC-MS 
analysis. The Alprazolam reference standard was made up following the same method of the 
Diazepam reference standard.  
5.5.4 Calibration standards 
In order to determine the concentration levels of the unknown samples, five calibration standards of 
each Alprazolam and Diazepam were needed to create two calibration curves. These were later 
compared to the unknown samples and will be displayed in Chapter Six: section 6.2. 
To make the calibration stock solution, 0.01 g (actually 0.0107 g) of the Alprazolam reference powder 
was weighed accurately and transferred into a 10.0 mL volumetric flask before being diluted to volume 
with methanol in order to create a 1 mg mL-1 stock solution.  
Five intermediate solutions were made with different concentrations of Alprazolam ranging between 
100 µg mL-1 – 300 µg mL-1. To make the final concentration of the calibration samples, each sample 
had 500 µL taken and was transferred into a GC-MS vial alongside 500 µL of the eicosane stock solution 
used in the first method (see section 5.5.2). The final calibration standards contained 50 µg mL-1, 75 
µg mL-1, 100 µg mL-1, 125 µg mL-1 and 150 µg mL-1 of Alprazolam and the same for Diazepam17. See 
Chapter Six: section 6.2.1: figures 17 and 18: for Diazepam (detection limit: 8.1 µg mL-1, quantification 
limit: 24.5 µg mL-1) and Alprazolam (detection limit: 10.7 µg mL-1, quantification limit: 32.5 µg mL-1) 
respectively. Each calibration solution was repeated six times.  
                                                          
17 0.01 g (actually 0.0102 g) of the Diazepam reference powder was used in the same process.  
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5.5.5 Unknown sample preparation 
5.5.5.1 Unknown ‘Valium’ sample preparation  
All unknown ‘Valium’ samples were presumed to contain 10 mg of Diazepam due to their colour and 
correspondence to usual prescription dosage and online information (see ‘MSJ/Diazepam guide’ on 
www.substance.org.uk18).  
Each sample was finely ground using a pestle and mortar and homogenized. After the samples were 
weighed, 2/10ths of each sample was taken and placed into a new 7 mL vial (see appendix 46 for 
‘Valium’ sample weight and description). 2 mL of methanol was added to each vial in order to create 
a 2 mg mL-1 solution. All samples were filtered once using 0.2 µm filters. 200 µL of the filtered 
sample solution was taken and added to 800 µL of methanol to create a 400 µg mL-1 solution. The 
final solution for GC-MS analysis consisted of 500 µL of the sample solution and 500 µL of the 
eicosane stock solution (see 5.5.2 – method two) in order to create a final concentration of 200 µg 
mL-1. Each sample was run three times.  
5.5.5.2 Unknown ‘Xanax’ sample preparation 
All unknown ‘Xanax’ samples were presumed to contain 2 mg of Alprazolam based on usual 
prescription dosages and online information (see ‘Xanax’ on www.drugs.com19). 
Similar to the previous samples, each sample was finely ground using a pestle and mortar and 
homogenized before half of each sample was weighed and transferred to a new 7 mL vial (see 
appendix 49 for ‘Xanax’ sample weight and description). Each sample was handled with care and 
precision, and all instruments used were washed with acetone between uses to eliminate possible 
cross contamination. 5 mL of methanol was added to each vial using an Eppendorf manual pipette in 
order to create a 1 µg mL-1 solution. Samples were ultra-sonicated before the precipitated solutions 
were filtered twice using 0.2 µm filters. The final concentration for GC-MS analysis consisted of 500 
µL of the eicosane stock solution (see section 5.5.2 – method one) along with 500 µL of the filtered 
sample solution. 
The method was adapted for results which showed little or no peaks. For the second wave of the 
repeat tests, 250 µL of the second eicosane stock solution was added to 750 µL of each unknown 
sample to create the vials ready for GC-MS analysis. The overall weight of X27 was below the 
                                                          
18 http://www.substance.org.uk/resources/msj-diaepam-guide 
19 https://www.drugs.com/xanax.html  
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standard weight taken for sample prep and therefore the weight taken from this sample was altered 
in order to create the correct concentration. Each sample was run three times. 
5.6 Summary of chapter 
To summarise, Chapter Five displayed a successful and a relatively quick (run time of 30 minutes) 
GC-MS experimental method to determine the contents and concentration levels of 29 suspected 
‘Valium’ pills and 29 suspected ‘Xanax’ tablets which were seized in Manchester. The new, 
developed GC-MS method qualified, quantified and determined compounds that should not have 
been present. The reference standards were also run using the same method. 
This GC-MS method may be used for further research when detecting Valium, Xanax and other 
benzodiazepines. Although DMSO and acetonitrile NMR testing assists in the determination of the 
structural characterisation of unknown samples, the lack of a database meant the results showed 
low match scores. Researchers are urged to create a NMR database for benzodiazepines.  
The presumptive testing namely ‘M.M.C. International B.V – General Screening/ Multi Party Drugs 
Test’ displayed no colour match with benzodiazepines on the packaging. Therefore, the slight colour 
change displayed by sample X16 can be concluded as a showing a false positive. This shows that this 
specific colour testing kit is inadequate when trying to detect benzodiazepines in unknown samples.    










Chapter Six: GC-MS analysis results 
6.1 Introduction and chapter overview 
This chapter presents the findings from the quantitative and qualitative analysis of the 29 assumed 
‘Xanax’ bars and the 29 assumed ‘Valium’ tablets seized in Manchester. It will begin with laying out 
the reference standard and calibration results (section 6.2), which were used to match the unknown 
samples. Section 6.3 will present the results from of all 29 ‘Valium’ samples including content and 
purity, and section 6.4 will outline the outline the same for all 29 ‘Xanax’ samples.  
6.2 Reference standards and calibration  
GC-MS allowed for the visualization of the mass spectral data which can be found below. The mass 
spectrometry figures for Alprazolam and Diazepam are reliable as the match with previous studies 
(see Yilmaz and Akba, 2010; Zhang et al., 2014). 
 
Figure 12: Mass spectra of eicosane 
 




Figure 14: Structural formula and mass spectra of Diazepam reference standard 
 
Figure 15: Gas chromatogram of Alprazolam reference standard 
 
Figure 16: Structural formula and mass spectra of Alprazolam reference standard 
The following table displays the retention time and mass spectrometry of eicosane, the Alprazolam 
reference and the Diazepam reference.  
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 Retention time Mass spectrometry  
Eicosane 8.976 min 57.1, 71.1, 43.1, 85.1, 99.1 
Alprazolam 12.609 min 279.1, 204.1, 308.1, 273.1, 
77.0, 252.1, 136.9, 177.0, 
245.1, 163.0 
Diazepam 10.729 min 256.0, 283.1, 221.1, 165.0, 
109.9, 77.1, 193.0, 241.0, 
51.0 
Table 11: Retention time and mass spectra of eicosane, Alprazolam and Diazepam 
The calibration graphs displayed below were used to compare data from the unknown samples in 
order to decipher the concentration levels of the unknown samples. Both R2’d values are above the 









Figure 17: Diazepam calibration graph 

















Figure 18: Alprazolam calibration graph 
6.3 ‘Valium’  
The integrated area ratio was calculated for each unknown ‘Valium’ sample before using the 
calibration formula (see appendix 54 for a screenshot of the excel document). The figures were then 
compared to the calibration graph (see figure 17above) in order to quantify the amount of active 
Diazepam (if any) in samples V1 – V29.  
The amount of active Diazepam found in each sample ranged from 12.97 mg (V21) – 26.79 mg (V3). 





















Name of sample 































Table 12: ‘Valium’ results table V1 – V29 
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Generally speaking, the tested Valium pills contained either double the amount of active Diazepam 
(around 20 mg) or around 15 mg. This is significantly higher than what they were sold as (10 mg). 
These can have pose significant dangers as explored in Chapter Five: section 5.1.3.2, which will be 
discussed further in Chapter Seven. 
Displayed below are the gas chromatograms and mass spectra of: sample V1 (no Diazepam); sample 
V3 (highest amount of Diazepam) and; sample V21 (smallest amount of Diazepam). 
Figure 19: Gas chromatogram of sample V1 (no Diazepam20) 
 
Figure 20: Gas chromatogram of sample V3 (highest amount of Diazepam) 
                                                          




Figure 21: Mass spectra of sample V3 (highest amount of Diazepam) 
 
Figure 22: Gas chromatogram of sample V21 (smallest amount of Diazepam) 
 





The integrated area ratio was also calculated for each unknown ‘Xanax’ sample (see appendix 55 for 
a screenshot of the excel document) and compared to the calibration graphs in order to quantify X1 
– X29. The figures were then compared to the calibration graph (see figure 18 in section 6.2) in order 
to quantify the amount of active Alprazolam (if any) in samples X1 – X29.  
The amount of active Alprazolam found in each sample ranged from 0.70 mg (X15) – 2.21 mg (X1). 
X4, X6, X7, X9, X16 and X17 contained no Alprazolam. Sample X4 had a 559 match and a 25.9% 
probability score with Triazolam at 13.33 minutes. Sample X16 had a 902 match and a 91.9% 
probability score with Zolpidem at 11.863 minutes. A full table of the results is on the next page. 
Generally speaking, excluding X1, X4, X6, X7, X9, X16 and X17, the results showed that the remaining 
22 Xanax tablets contained half (around 1 mg) or less than half of their presumed amount of active 
Alprazolam. This is significantly less than what they were sold as (2 mg). The wide variance of mg 
dosage could show detrimental effects for users as highlighted in Chapter Five: section 5.1.3 and will 
be elaborated in Chapter 7. In addition, four samples contained no active ingredient and were cut 
with harmless cutting agents like glucose, and two samples contained no active ingredient and were 
cut with other substances: Triazolam (X4) and Zolpidem (X16). These are both benzodiazepine-like 
substances and it is believed they were used as cutting agents to limit costs. This will be discussed 

















N/A – 25.9% match with 
Triazolam 
X5 0.98 
X6 N/A – no active ingredient  
X7 N/A – no active ingredient 
X8 1.19 








N/A – 91.9% match with 
Zolpidem 













Table 13: ‘Xanax’ results table X1 – X29 
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The figures displayed below are the gas chromatograms and mass spectra of: sample X1 (highest 
amount of Alprazolam); sample X4 (Triazolam); sample X15 (smallest amount of Alprazolam); sample 
X16 (Zolpidem). GC-MS analysis was also performed on a Zolpidem reference standard (see figures 
31 and 32) for extra confirmation and comparison of sample X16.  
 
 Figure 24: Gas chromatogram of sample X1 (highest amount of Alprazolam) 
 




Figure 26: Gas chromatogram of sample X4 (Triazolam) 
 
Figure 27: Mass spectra of sample X4 (Triazolam) 
 
Figure 28: Gas chromatogram of sample X15 (smallest amount of Alprazolam) 
 




Figure 30: Gas chromatogram of sample X16 (Zolpidem) 
 
Figure 31: Mass spectra of sample X16 (Zolpidem) 
 




Figure 33: Structural formula and mass spectra of Zolpidem reference standard 
6.5 Summary of chapter and conclusion 
To summarise, Chapter Six displayed the results of 29 unknown ‘Valium’ samples and 29 unknown 
‘Xanax samples using a new, quick method of GC-MS analysis. 
The ‘Xanax’ samples (thought to contain 2 mg of Alprazolam) ranged from 0.70 – 2.21 mg and the 
‘Valium’ samples (thought to contain 10 mg of Diazepam) ranged from 12.97 – 26.79 mg. Six of the 
29 ‘Xanax’ samples did not contain any active Alprazolam and of those, two were cut with other 
research chemicals. One ‘Valium’ tablet did not contain any active Diazepam. The results suggest 
users consuming street bought Xanax, formerly believed to be adulterated in the UK as explored in 
Chapter Five: section 5.1.3, are in fact consuming less of the active ingredient than thought. As 
explored in Chapter Four: section 4.7.1, many Valium users believe they are less likely to come 
across counterfeits, as opposed to Xanax users, however, this has been proven to be the opposite 
way around. The results show that Valium users are in fact consuming much more than they believe, 
and Xanax users are consuming less. These results will be discussed further throughout Chapter 





Chapter Seven: Discussion, limitations and future recommendations 
7.1 Introduction and chapter overview 
This final chapter will consider the implications of the research findings. Key findings from the social 
science data presented in Chapter Four and the chemical analysis element of the research presented 
in Chapter Six will be revisited with the intention to reflect on what the research has contributed to 
answering the initial research questions outlined in Chapter One:  
 Which benzodiazepines are popular? 
 Who is taking benzodiazepines? 
 What are the motivations for use? 
 What are the effects (both desired and undesired) of benzodiazepine usage? 
 Where do users source their non-prescribed benzodiazepines? 
 What factors influence benzodiazepine users’ decisions on what benzodiazepines they 
use and where they obtain them?  
 What are the true contents of illicitly sourced benzodiazepines? 
 Are street-bought ‘Valium’ tablets safer than ‘Xanax’ bars? 
However, before discussing the key findings and implications of this study, this chapter begins with 
some reflections on the benefits and limitations of the research methodology (section 7.2). The 
following sections will go on to outline the key results from the research project, specifically: user 
demographics (section 7.3); prevalence and preference (section 7.4); access, availability and cost 
(section 7.5); user motivations (section 7.6); substance use replacement (section 7.7) and; adverse 
negative effects (section 7.8). Section 7.9 will highlight the key findings from the forensic testing 
element. Section 7.10 will conclude the thesis and specifically address: future researcher (section 
7.10.1); policy makers (7.10.2); mental health services (section 7.10.3); substance misuse services 





7.2 A reflection on the social science methodology – benefits for future researchers 
The following section will begin by outlining the benefits of the methodology used in this research 
project and how it can be adopted and developed in further research. It will then highlight the 
limitations of each approach and their implications for future use. 
7.2.1 Contribution to using social media as a research tool  
The social science research methodology used a diverse range of online and offline distribution 
methods which led to the efficient collection of data from 771 respondents (595 after data cleaning). 
Using social media to access a geographically dispersed sample population has been noted in 
previous research (Holmes, 2009; Suri and Patel, 2012; O’Connor et al., 2014; Wolfe et al., 2014; 
Whitaker et al., 2017). However, the social science methodology used in the current study 
developed this further by specifically joining Facebook groups and pages to target specific 
populations. As highlighted in Chapter Three: section 3.3.4.1 and 3.3.4.2, the research process 
uncovered some noteworthy nuances around targeting student and academic population. It was 
discovered that the day and time of postings was an important factor to consider when reaching out 
to potential participants. When targeting the student population via specific University Facebook 
groups, the best time to post was between 6 and 10pm on a Sunday or Monday or in the holidays, 
when the pages were not inundated by ticket selling posts. In contrast, when targeting academics on 
Twitter, it was deemed best to tweet during the day as they were actively involved in discovering 
new papers and sharing them online. The online interaction between the researcher and potential 
participants via Facebook and Twitter users was considered to be extremely important with regards 
to gaining as many participants as possible and social science researchers are urged to use this 
methodology for future research. 
Although there were many benefits from using social media as a research tool, there was also an 
overarching downside of using Facebook and Twitter to promote the survey link. The dominant 
ethical issue which arose from the research methods was maintaining participant confidentiality, 
which has been previously highlighted by other online researchers and academics (Suri and Patel, 
2012; British Psychological Society, 2017; Hunter et al., 2018). For each respondent in the current 
study, the survey software Qualtrics displayed a GeoIP address, which limited the researcher’s ability 




7.3 User demographics  
As explored in Chapter One and Two of this thesis, UK media headlines and data from the CSEW 
suggest benzodiazepine usage amongst children and young people has been prevalent in the last 
year or two (BBC News, 2018a; BBC News, 2018d; Birmingham Mail, 2018; Home Office, 2018; VICE, 
2018a). The current study consisted of predominantly 18 – 21 year olds (n=422, 70.9%) and 22 – 25 
year olds (n=127, 21.3%) which confirms Valium and Xanax are commonly used amongst the 
younger population. Some respondents made it evident that other user populations do exist, 
however the current research project did not represent this sample. Both males and females equally 
used benzodiazepines for a range of functions, however, motivations often overlapped and 
intertwined with one another. The research findings suggest that the use of benzodiazepines is 
becoming normalised amongst university students and that harm reduction reports must be issued 
(elaborated in section 7.10.5). Moreover, the current study revealed that although small, 
participants aged 26+ claimed to use benzodiazepines also (n=46, 7.7%). However, due to university 
ethical regulations that govern the collection of data from minors and concerns around accessing 
school-aged users, the decision to limit the research to 18 years and over has meant that the 
research cannot confirm the media reported spike in users under 18 and therefore, further research 
that targets this younger cohort is needed. In addition, the focus on university students has resulted 
in a skewed sample that does not examine the user habits and motivations amongst other non-
student populations: non-university, working class young adults and; the middle-aged and older user 
population.  
Nevertheless, despite not accessing under 18s in the current study, it is plausible that similar 
motivations around use and ease of access would make benzodiazepines equally appealing to this 
age group. Specifically, the expression of using benzodiazepines in conjunction with alcohol as a 
means of getting drunk quicker and for less money may be a significant motivation for children and 
adolescents under 18, as benzodiazepine drugs are sometimes more readily available than alcohol. 
7.4 Valium versus Xanax: prevalence and preference 
In Chapter’s One and Two, the need for more research into the use of benzodiazepines among 
young adults in the UK was called for to ensure a better understanding of which benzodiazepines 
were used and why. Reflecting on the findings, it appears that a significant change has occurred 
since the Kapil and colleagues study (Kapil et al., 2014). There, it was discovered that Valium was the 
most frequently used and misused benzodiazepine (n=62, 53.4%) followed by Lorazepam (n=26, 
22.4%) and Xanax (n=20, 17.2%). UK media reports also reported Valium more than any other 
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benzodiazepine (see Chapter Two: section 2.4: table 3). However, data from the current study 
showed that although more respondents had tried Valium (n=499, 83.9%) as opposed to Xanax 
(n=481: 80.8%) at some point in their lifetime, for recent usage (in the past 2 months21), respondents 
had used more Xanax (n=313, 52.6%) than Valium (n=273, 45.9%). This data reveals that the 
reported use of Xanax has increased significantly since 2014, from 1 in 6 individuals (17.2%) to over 1 
in 2 individuals (52.6%).   
When justifying their preferences, many users contradicted one another. Many disliked Xanax due to 
its potency, however many preferred this as it was better value for money. A positive conclusion to 
draw from this is that users are aware of the difference in potency. However, more information 
must be given to users to spread awareness. Benzodiazepine preference was split fairly equally 
(Valium: n=276, 46.4%; Xanax: n=265, 44.5%). However, it was noted that more males preferred 
Xanax (m=47.2%, f=41.4%) and more females preferred Valium (f=50.6%, m=42.6%). It was also 
discovered that Xanax was more popular amongst those aged under 21. This gender and age 
difference is something that warrants further research and exploration.  
7.5 Access, availability and cost 
7.5.1 Price 
Prices varied greatly dependent on the source, and some have once paid as little as 15p per Valium 
and 30p for a Xanax; a significant finding was that benzodiazepines are generally only available to 
buy in bulk. However, respondents stated they usually pay £1 per Valium pill and £2 for Xanax, which 
suggests users usually spend around £2 per occasion based on that fact that the majority of Valium 
users take 2 tablets and Xanax uses take 1 to get to sleep (V=108, 32.7%; X=125, 37.9%), to self-
medicate (V=69, 35.4%; X=125, 37.9%), to get high (V=107, 29.1%; X=146, 39.7%) or to counteract 
stimulants (V=124, 33.6%; X=157; 42.5%). The low cost of these drugs can be seen as a significant 
motive for benzodiazepine users when compared to other drug pricings which produce similar 
effects such as ketamine (£20 - £30 for 1 g) or cannabis (£10 per gram22).  
7.5.2 Source 
On the contrary to Kapil et al.’s 2014 study who discovered the main source of benzodiazepines to 
be via prescription from a health care professional (n=64, 55.2%) followed by friends and/or family 
                                                          
21 The survey ran from the 1st March 2018 – 8th June 2018 therefore ‘recent usage’ accounts for 1st January 
2018 – 8th April 2018 
22 Prices based on anecdotal evidence, in Greater Manchester 
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(n=46, 39.7%), the internet (n=31, 26.7%), street dealers (n=23, 19.8%) and abroad (n=13, 11.2%), 
the main sources for benzodiazepine users from the current study were via a dealer (n=350, 57.1%) 
and/or friend (n=316, 53.1%). Over a quarter of individuals sourced their benzodiazepines via the 
dark-web (n=172, 28.9%) and only a small fraction of individuals sourced them on the clear-web 
(n=27, 4.5%). A handful of respondents also stated they obtain their benzodiazepines abroad in 
countries like Thailand. This information suggests there has been a significant shift away from 
sourcing benzodiazepine drugs via legitimate means and instead, through buying them online, 
current users are more likely to purchase non-pharmaceutical quality benzodiazepines of variable 
content.  
The link between street dealers and selling specific groups of drugs was noted: benzodiazepine 
dealers also supplied ketamine (n=113, 19%) and/or cannabis (n=90, 15.1%). This may be because 
depressant-like substances attract a specific pool of substance users and dealers prefer to be 
consistent. Alternatively, dealers may only be comfortable dealing substances which produce similar 
effects. Future researchers are urged to explore this link further.   
Chapter Four: section 4.4.3 showed that Xanax users have been deterred due to their usual source 
being unreliable. This appears to offer support for policy makers and law enforcement initiatives 
that targeting supply routes does have an impact on users’ decisions to purchase drugs. 
7.6 User motivations 
The following section will highlight the key motivations for the non-prescribed use of 
benzodiazepines as stated by the 595 participants in the current study. The data will be compared to 
existing knowledge highlighted in Chapters One and Two. 
7.6.1 Multifunctional use 
Even though the majority of non-prescribed users sourced their benzodiazepines from non-
prescribed sources, many still took them for their licensed purposes. Over half of respondents in the 
current study took benzodiazepine’s to help sleep (n=330, 55.5%), compared to two-thirds in of 
respondents in Kapil et al.’s study (n=77, 66.4%). A third of those in the current study used them for 
anxiety related issues (n=195, 32.8%), similar to the 2014 study (n=43, 37.1%). However, although 
the UK media dominantly focuses on self-medicating individuals, respondents from the current study 
also revealed a number of other motivations for non-prescribed use. The majority did so to: 
counteract the effects of stimulants (n=369, 62%), almost a 6-fold increase from Kapil et al.’s study 
(n=12, 10.3%); closely followed by using them to get high (n=368, 61.8%), which is double the 
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amount using them ‘for social reasons’ and ‘to get high’ in the 2014 study (n=36, 31% and n=28, 
24.1% respectively). The UK media have ignored this population of users; however, they must be 
acknowledged and aware of poly-drug use dangers (elaborated further in section 7.8.4). Qualitative 
answers also revealed that benzodiazepines are used: to boost confidence prior to meeting peers or 
for high-pressure situations like presentations or exams; to sleep on long journeys; to ease or 
eradicate the negative effects associated with a hangover or comedown; to correct irregular sleep 
patterns and/or to ease physical pain. Therefore, the multi-functionality of benzodiazepine use 
found in this study goes beyond the self-medicating narrative that is dominant in the existing media 
discourse highlighted in Chapters One and Two. 
7.6.2 Counteract other drug effects 
A possible causation for the 6-fold increase in using benzodiazepines to counteract stimulants as 
described in the previous sub-section may be due to the recent increase in stimulant and 
amphetamine purity and potency, and the need for more effective drugs to wind down (see Chapter 
Five: section 5.1.3.2: EMCDDA, 2016b; EMCDDA, 2018). Researchers are urged to explore this link 
further.  
However, users from the current study also reported using benzodiazepines to come down from 
study drugs such as Modafinil or Ritalin, and to counteract the unwanted side effects from 
hallucinogenic drugs. This is new information regarding the non-prescribed use of UK users and must 
be explored more in-depth.  
7.6.3 Self-medicating leading to problematic usage 
Although many users praised Xanax and Valium for their anxiolytic properties, a few respondents 
stated they initially took the drugs to ease or eradicate anxious thoughts that then developed into 
psychological and physical dependency and debilitating withdrawal symptoms such as rebound 
anxiety and psychotic episodes. This evidence is especially useful when informing health care 
providers and policy makers to prevent problematic usage. Many respondents, particularly males, 
also spoke of the inefficient support from mental health treatment services (see Chapter Four: 
section 4.5.2). Although the Government is aware of the inadequate help and is actively attempting 
the improve access to treatment services as in their 2014 report launch (see Department of Health, 
2014), participants from the current study still complained about the weak efficacy of traditional 
treatment methods and the slow access to services even over four years after the report was 
published. Thus, it is advised that more measures are put in place for those suffering from anxiety, 
depression and other mental health issues: in schools, colleges, university as well as in the 
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community in order to prevent adverse negative effects, dependency and rates of benzodiazepine-
related mortality. Those who are vulnerable to using and misusing benzodiazepines must be helped 
before they fall into bad user habits. This will be elaborated in section 7.10.2 and 7.10.3.  
7.7 Substance use replacement 
Although it was a controversial topic and despite the recent medicalisation of cannabis in the UK, 
many survey participants claimed to prefer benzodiazepines as opposed to cannabis for relaxation 
and/or recreation as the latter caused anxiety, paranoia and unwanted hangovers. Cannabis use as a 
whole has dropped over 8% from 1996 (39.1%) to the most recent year (30.7%) (Home Office, 2018). 
A potential explanation for this shift may be due to the growth in adverse cannabis strains 
containing higher levels of THC in recent years. Researchers are urged to explore the shift in 
cannabis use from a user’s perspective and explore the variation of cannabis strains.  
Moreover, in the most recent Crime Survey for England and Wales, figures show that although illicit 
drug use in the year 2017/18 has increased from the previous year, those aged 16-24 reported a 
significant drop in overall drug use compared to the year of 1996. Twenty years ago, nearly half 
(48.5%) of young people had reported use of an illicit substance, whereas in the most recent report 
of 2017/18, it was merely just over a third (34.8%). Furthermore, 19.4% of young people admitted 
use of a class A at least once in their lifetime 1996, compared to 15.3% of 16-24 year olds in 
2017/18. Ecstasy and hallucinogen use have dropped from 11.7% and 16.1% in 1996 to 11.3% and a 
mere 6.6% in 2017/18 respectively. Whilst these government statistics suggest that traditional drug 
use is on the decline, results from the current study suggest they are being replaced with 
prescription drugs in a self-medicating context to treat the problems that accompany modern life for 
young people in the UK such as social media, body image, soaring house prices and crippling 
university debt, pressure in higher education and increased expectations on young people to 
achieve. However, this research project did not focus on the underlying motivations for self-
medicating users and thus, social researchers are urged to examine the root causes of anxiety in 
teens and young people in order to tackle the root of the issue. 
Furthermore, the move towards depressant drugs may play an important factor in determining new 
substance use trends. The first figures regarding ketamine in England and Wales use was collected in 
2006/07 (2.3%) which have now doubled (4.7%) (CSEW, 2017/18). Ketamine is frequently used in 
club-drug scenes, commonly for after parties when individuals wish to come down from stimulant 
drugs like ecstasy (Moore and Measham, 2009), and the rise in depressant substance usage may be 
due to drug users wanting to chase a different type of high.  
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7.8 Adverse negative effects and dangers  
Chapter Two: section 2.7 examined the adverse negative effects of benzodiazepines as discovered in 
previous studies and reports (see Gardner and Cowdry, 1985; Bond et al, 1991; Bond and Silveira, 
1993; O’Sullivan et al, 1994; Longo and Johnson, 2000; Ashton, 2002; Payton, 2002; Friedman, 2006; 
Lader, 2011; Griffin et al, 2013; Ford and Law, 2014; Andersson and Kjellgren, 2017). However, what 
we did not know is the side effects from non-pharmaceutical grade benzodiazepines. Participants in 
the current study confirmed that benzodiazepines caused: black-outs; total memory loss; the feeling 
of invincibility which often led to bad decisions and/or accidents and injuries; heightened levels of 
anxiety; hangover effects such as grogginess, feeling sluggish and spaced out the few days after 
usage; headaches; drowsiness and instability; cognitive decline and; poor concentration ability.  
The following section will elaborate these points further and highlight the deleterious effects, 
specifically: black-outs and memory loss (section 7.8.1); invincibility and erratic behaviour (section 
7.8.2); driving (section 7.8.3); poly-drug use, consuming excessive amounts and mortality (section 
7.8.4); dependency, tolerance and withdrawal (section 7.8.5). 
7.8.1 Black-outs and memory loss: vulnerability  
Previous studies have highlighted the effects of benzodiazepines on consciousness and memory (see 
Block and Berchou, 1984; Barker et al., 2004; Michael et al., 2007) which was also stated by 
participants in the current study. Personal stories highlighted the true seriousness of benzodiazepine 
misuse, especially from a user who spoke of once being spiked with benzodiazepines (Chapter Four: 
section 4.8.1) and another who could not recall having sexual relations whilst he was intoxicated 
(see Chapter 4: section 4.8.2). Users and service providers must be made aware of the inherent 
dangers of misuse, as users become exceptionally vulnerable to sexual exploitation and risk taking 
behaviour.  
7.8.2 Invincibility and erratic behaviour 
Previous academics have mentioned benzodiazepine use resulting to erratic behaviour and 
sometimes indulging in criminal behaviour (Gardner and Cowdry, 1985; O’Sullivan et al., 1994; 
Paton, 2002; Griffin et al., 2013; Ford and Law, 2014; Andersson and Kjellgren, 2017). The current 
study revealed that benzodiazepine users reported abnormal and sometimes criminal acts, such as: 
stealing; destructive behaviour and; violence. This suggests that the implications of benzodiazepine 




Similar to the study by Verster et al. (2002), drowsiness was felt whilst driving a day after usage, with 
users saying that they fell asleep at the wheel (see Chapter Four: section 4.8.1). As Baldwin et al. 
(2013), Griffin et al. (2013) and Ford and Law (2014) explained, due to long elimination half-lives of 
active metabolites, sedative effects can be felt even up to 4 days after use (see Chapter Two: section 
2.2.3). Benzodiazepine users must be aware of the long-lasting side effects and should not drive or 
partake in other complex psychomotor tasks after usage. 
In addition, a handful of participants said they drug-drove and some even crashed. The lack of 
concentration ability, psychomotor skills and feeling ‘invincible’ is a side effect particularly when 
benzodiazepine usage is excessive or combined with alcohol consumption. Awareness of these 
issues must be raised amongst users and will be elaborated in section 7.10.5. 
7.8.4 Poly-drug use, consuming excessive amounts and mortality  
The majority of benzodiazepine users in the current study used benzodiazepines alongside other 
drugs, in particular, alcohol (n=395, 66.4%). As explored in Chapter Two: section 2.7.5, the 
concurrent use of multiple depressant substances is extremely concerning as vital bodily functions 
are significantly depressed and may lead to coma or death, and all adverse effects are amplified 
when benzodiazepines are used with alcohol, making this territory a cause for concern. Users must 
be made aware of substance interactions and consider this when they consume benzodiazepines. 
Without correct guidance and knowledge, adverse negative effects and fatalities can occur.  
As highlighted in Chapter Four: section 4.5.5, a dominant motivation for some benzodiazepine users 
is to counteract the effects of stimulants. This poly-substance use, often following a prolonged 
period of use of alcohol, stimulant and hallucinogenic drug use, has implications for harm reduction 
advice. From a public health perspective, the findings suggest that users must be made aware of the 
risks that arise from drug interactions stemming from poly-substance use in order to reduce harm. In 
particular, the effects of combining stimulants with central nervous depressants and the combining 
of multiple central nervous depressant drugs such as alcohol, ketamine and benzodiazepines. This 
warrants the need for future research, particular the use of benzodiazepines in post-clubbing 
setting. 
Moreover, service providers must be aware that some users consume excessive amounts which, of 
course, incur greater risks and dangers. In the current study, a small amount of users took 6- 10 
Valium to get high (n=14) or over 10 (n=12). Xanax users took 3 to get high (n=34), 4 (n=16), 5 (n=9) 
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or over 10 (n=1). This is especially alarming as it is significantly higher than the recommended 
amount. Subsequently, this could result in detrimental effects such as severe depressant of the 
central nervous system, especially when mixed substances like alcohol, ketamine or cannabis.  
A few participants said they had lost friends to benzodiazepine overdose, which highlights the 
significance of this phenomenon even more. In the one-to-one interview, the participant spoke of a 
friend dying from mixing other drugs with Xanax. One survey respondent also spoke of losing 
friends, though it was to Valium. This confirms that both Xanax and Valium are equally as dangerous 
when they are used in conjunction with other drugs and awareness must be spread to limit fatalities.  
7.8.5 Dependency, tolerance and withdrawal  
Evidence suggests benzodiazepine users are sometimes using the drugs for extended periods of time 
and at high dosages, thus increasing the likelihood of becoming dependent. This raises cause for 
concern as to whether GPs or treatment services in the UK are sufficiently equipped to provide 
adequate support and tapering methods for those increasingly in need. Specific action is needed 
before users become tolerant.  
7.9 Chemical analyses of Manchester street samples 
Chapter Five outlined a new, successful method for the quick determination of the content of 
benzodiazepines which is urged to be used in future research. As highlighted in Chapter Five: section 
5.1.4, substance testing charity The Loop is proactive in clubs and music festivals across the nation. 
However, with a strong focus on the clubbing scene and thus, testing mainly stimulant substances 
like MDMA and cocaine, sedative drugs like benzodiazepines are often forgotten about. The social 
science data from this study confirms that benzodiazepines, in particular Valium and Xanax, are 
widely used by individuals in the UK and after chemically analysing seized street samples, many are 
of varied purity or counterfeited. Substance testing facilities like The Loop are urged to also test 
substances used outside the clubbing scene in order to spread awareness and reduce harm.  
Firstly, the outcomes of the presumptive testing showed that although benzodiazepines are not 
listed in the multi-party drugs test, it can be used to identify other adulterants. The results of this 
study can be used as a recommendation that this specific colour test is inadequate to identify 
benzodiazepine compounds in an unknown substance.  
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7.9.1 Purity levels and perception of risk 
Generally, Kapil et al.’s study revealed that 10% (n=12) of benzodiazepine users did so as they 
believed the family of drugs were safer than illicit street drugs. However, it was assumed that users 
in the current day would be obtaining their benzodiazepines from non-legitimate sources and thus, 
the perceived risk would be much higher.  
In the current study, many participants believed that Valium had a better chance of being legitimate 
and thus, safer to use (see Chapter Four: section 4.7.1). Many also believed that Valium is much less 
potent than Xanax. However, the forensic testing element of this project revealed that almost all 
‘Valium’ tablets (assumed to be 10 mg) contained over 15 mg of active Diazepam, and half of the 
samples (n=14: V2 – V5, V7 – V9, V13 – V19) ranged from 20.32 mg – 26.79 mg, which is over double 
the presumed mg. As explored in Chapter Five: section 5.1.3.2, dealers may be making them super 
strength as they are cheap to produce and/or to increase their clientele base. One ‘Valium’ sample 
contained no active ingredient. On the other hand, the tested ‘Xanax’ bars ranged from 0.7 mg – 
2.21 mg. Six samples contained no active Alprazolam, of which, two were cut with other 
benzodiazepine-like substances (X4 contained Triazalom; X16 contained Zolpidem). Although no 
harmful substances were found to have adulterated all 58 samples, levels of purity varied 
significantly. These results confirm that any illicitly sourced substance has the potential to be 
illegitimate, and the perception that street-bought ‘Valium’ is safer and less potent than ‘Xanax’ is 
incorrect. 
However, this research focused solely on Greater Manchester samples. Little is known about street-
bought benzodiazepines in other regions in the UK. More testing is needed.  
7.10 Conclusion and future recommendations  
Drawing upon key findings as displayed throughout this chapter, harm reduction reports must be 
issued to GPs, service providers, policy makers and the wider community which illustrate the nature 
and context of non-prescribed benzodiazepine use: which benzodiazepines are popular and why; 
where they are accessed and for how much; the motivations behind use; the inherent dangers 
stemming from usage. Reports need to be drafted and issued to all benzodiazepine users to prevent 
adverse negative effects, tolerance and dependence. If individuals still wish to engage with 
benzodiazepines, they must be made aware of how to take them properly and they must be aware 
of the dangers they bring.  
155 
 
This thesis will conclude with a series of future recommendations to the following: future 
researchers, and explore more avenues of social or analytical science research (section 7.10.1); 
policy makers (section 7.10.2); mental health service providers (section 7.10.3); substance misuse 
organisations and charities (section 7.10.4) and; current users (section 7.10.5). It draws upon the key 
findings using existing and new knowledge in order to minimise harm and fatalities stemming from 
benzodiazepine use and misuse. The following section will summarise the key findings of this 
research project and the implications for each.  
7.10.1 Message for future researchers 
7.10.1.1 Social science 
The qualitative and quantitative survey design primarily focused on collecting: user demographics 
and motivations for usage; which benzodiazepines are most popular and why; the source of 
benzodiazepines and; the effects (desired and undesired) from usage. As outlined in section 7.7, 
some respondents also suggested they chose benzodiazepines as opposed to any other sedative 
drug due to a number of reasons. However, the underlying motivation for self-medicating users was 
not discovered. Future research is needed to unpick possible causations for anxiety in teens and 
young people.  
Scientific researchers are urged to adopt the survey methodology outlined in Chapter Three, and 
carry out research into the non-prescribed use of benzodiazepines in other regions of the UK. More 
research is also needed into other benzodiazepine user groups, specifically: those under the age of 
18; the young, non-student population; working-class individuals and; the older user population.   
Additionally, researchers are urged to further explore the recreational use of benzodiazepines in a 
post-clubbing context, and to discover the effects of poly-drug use. Specifically: benzodiazepines and 
study drugs such as Modafinil; benzodiazepines and stimulants like MDMA and cocaine and; 
benzodiazepines and depressant substances like ketamine.  
Substance use replacement was touched upon throughout this research project, however it still 
remains relatively undiscovered. Researchers are urged to explore the shift away from traditional 
harder drugs to prescription drugs and CNS depressant drugs. Researchers are also urged to explore 
the link between street dealers supplying specific groups of drugs.  
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In addition, there is a dearth of knowledge in the field of the sales of specific drug groups. 
Researchers are encouraged to explore the link between street dealers supplying specific groups of 
drugs.  
7.10.1.2 Forensic testing  
This research project has highlighted the importance of substance testing and thus, more testing 
needs to be done in other areas. Currently, drug testing services such as The Loop focus on people in 
a clubbing context. This research suggests that benzodiazepines are frequently taken prior to a night 
out or after a stimulant session and therefore the drugs are not on their person while they are near 
these testing facilities. It is advised that more accessible testing centres are put in place for those 
wanting to examine the contents of their benzodiazepines. For example, home testing kits which 
account for benzodiazepines, or installing accessible testing facilities on university campuses. 
In addition, researchers are urged to create a benzodiazepine database for NMR to ensure quick 
analysis. 
7.10.2 Message for policy makers 
It’s been over four years since the 2014 NHS report stating the plan to improve access to treatment 
services but this has clearly failed for some. The current study has proven that current mental health 
services in the UK are not fully adequate in treating mental health issues amongst young people: 
individuals choose to illicitly source benzodiazepine drugs for personal use in order to self-medicate 
as opposed to seeking other treatment. As explored in Chapter Five and Six, street-bought 
benzodiazepines are often counterfeited and thus, may lead to adverse negative effects or fatal 
overdose.  
With teenage suicides having risen by 67% since 2010, mental health is clearly an overarching 
priority and more measures must be put in place to avoid deaths, and to avoid young people feeling 
the need to illicitly source possible counterfeit medications. This research also revealed that some 
benzodiazepine users take excessive amounts to intentionally overdose when they were feeling low. 
With the growth of online drug markets and street dealers, and costing around £2 per occasion, this 
makes benzodiazepines an accessible option. 
However, Xanax users have been deterred due to their usual source being unreliable. This appears to 
offer support for policy makers and law enforcement initiatives that targeting supply routes does 
have an impact on users’ decisions to purchase drugs. 
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This is a national health issue. It is absolutely vital that more money is invested into this sector and 
additional methods of treatment exist in order to prevent problems of drug dependency, adverse 
negative effects and mortality. Governmental bodies are advised to invest more money into mental 
health services and charities, to appoint more bodies who are equipped to deal with the diverse 
range of individuals’ issues. 
7.10.3 Message for mental health service providers 
Firstly, more research needs to be done to examine the causations of mental health problems. The 
current study did not stretch so far as to examine the underlying causes of anxiety in young people. 
Researchers are urged to carry out this research. Then, root causes of anxiety must be targeted and 
overcome before the individual chooses to use benzodiazepines to self-medicate. As explained in the 
previous sub-section, more adequate mental health treatment services must be put in place in order 
to tackle anxiety and depression efficiently, such as: less stigmatisation, better access to treatment, 
awareness in schools, colleges, university, at home and in the community. Most importantly, mental 
health service providers must be made aware of the context, content and motivations for 
benzodiazepine usage. Thus, key data from this research project must be condensed and issued to 
those relevant.  
7.10.4 Message for substance misuse organisations and charities  
Similar to the sub-sections above, substance misuse organisations and charities who deal with the 
problematic aspects of use must be made aware of the context, content and motivations for 
benzodiazepine usage. Thus, key data from this research project must be condensed and issued to 
those relevant. Adverse negative effects, in particular black-outs and memory loss, are overarching 
problems which may place intoxicated users in vulnerable situations.  
Although a lot of users praised Xanax and Valium for their anxiolytic properties, a few respondents 
stated they initially took the drugs to ease or eradicate anxious thoughts which then developed into 
psychological and physical dependency and debilitating withdrawal symptoms such as rebound 
anxiety and psychotic episodes. Substance misuse charities must be made aware of these effects in 
order to give the correct advice to users to attend the services.  
7.10.5 Message for current users 
Users need to be aware of all the adverse negative effects of benzodiazepines, mainly, black-outs 
and memory loss. Users are advised to stay safe and with friends at all times. Users must be also be 
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aware that mixing benzodiazepines with other downers like alcohol and ketamine is dangerous and 
may suppress vital bodily functions like the heartrate and breathing significantly, to such an extent 
the user stops breathing. Mixing stimulants like MDMA and cocaine with benzodiazepine drugs may 
cause shock on these vital bodily functions and must also be acknowledged. Other drug interactions 
are fairly unknown so users are advised to stay cautious. Benzodiazepine users must be aware of the 
long-lasting side effects and should not drive or partake in other complex psychomotor tasks up at 
least two days after usage. 
Users must be made aware that chemical analysis revealed that Valium drugs were double the 
strength (sold as 10 mg but some tested were almost 27 mg). Tested Xanax samples revealed they 
were half the strength (sold as 2 mg but found to be around 1 mg); cut with other substances or 
none at all. Even though they are classed as prescribed medications, users must be wary that the 
content of street-bought drugs varies significantly and that dosages should therefore start small. 
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Appendix 13: Full copy of the online survey 
Start of Block: Demographics  
  
Q1 Age  
 
o 18-21  (1)   
o 22-25  (2)   
o 26-30  (3)   
o 31-40  (4)   
o 41+  (5)   
  
Q2 Sex  
 
o Male  (1)   
o Female  (2)   
o Other (please state)  (3) _________________ 
  
Q3 Sexuality  
 
o Heterosexual/ straight  (1)   
o Homosexual/ gay/ lesbian  (2)   
o Bisexual  (3)   
o A sexual  (4)   
o I'd rather not say  (5)   
o Other  (6)   
   
Q4 Ethnicity  
 
o White  (1)   
o Black  (2)   
o Asian  (3)   
o Mixed  (4)   
o Chinese  (5)   
o Click to write Choice 7  (6)   
o Other (please state)  (7) _________________ 
  
Q5 Current home  
 
o South East (Brighton, Canterbury)  (1)   
o London  (2)   
o North West (Manchester, Preston, Liverpool, Burnley, Bolton)  (3)   
o East of England (Cambridge, Norwich, Peterborough)  (4)   
o West Midlands (Birmingham, Wolverhampton, Coventry)  (5)   
o South West (Exeter, Falmouth, Newquay)  (6)   
o Yorkshire and the Humber (Leeds, Sheffield, York, Hull)  (7)   
o East Midlands (Nottingham, Loughborough, Leicester)  (8)   
o North East (Newcastle, Durham)  (9)   
o I'd rather not say  (10)   
o Outside of England (please state)  (11) _________________ 
  
Q6 What is your occupation?  
 
o Full/ part-time student  (1)   
o Employed (paid work)  (2)   
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o Employed (voluntary work)  (3)   
o Self-employed  (4)   
o A homemaker  (5)   
o Unable to work  (6)   
o Other (please state)  (7) _________________ 
End of Block: Demographics 
 
Start of Block: Which BZDs  
  
Q7 Which benzo(s) have you taken? (You may chose multiple answers)  
 
 Valium (Diazepam)  (1)   
 Xanax (Alprazolam)  (2)   
 Ativan (Lorazepam)  (3)   
 Klonopin (Clonazepam)  (4)   
 Tranxene (Clorazepate)  (5)   
 Librium (Chlordiazepoxide)  (6)   
 Estazolam  (7)   
 Other (please state)  (8) _________________ 
  
Q8 Which BZDs have you used in the last 2 months? (You may chose multiple answers) 
  
 Valium (Diazepam)  (1)   
 Xanax (Alprazolam)  (2)   
 Ativan (Lorazepam)  (3)   
 Klonopin (Clonazepam)  (4)   
 Tranxene (Clorazepate)  (5)   
 Librium (Chlordiazepoxide)  (6)   
 Estazolam  (7)   
 Other (please state)  (8) _________________ 
 I haven't used them recently  (9)   
  
Q9 What is your preferred benzo?  
 
o Valium (Diazepam)  (1)   
o Xanax (Alprazolam)  (2)   
o Ativan (Lorazepam)  (3)   
o Klonopin (Clonazepam)  (4)   
o Tranxene (Clorazepate)  (5)   
o Librium (Chlordiazepoxide)  (6)   
o Estazolam  (7)   
o Other (please state)  (8) _________________  
  














Start of Block: Why, how, when, where  
  
Q11 What is your reason for taking them? (You may chose multiple answers)  
 
 For anxiety or similar issues - prescribed  (1)   
 For anxiety or similar issues - non-prescribed  (2)   
 To get to sleep  (3)   
 To get high  (4)   
 To counteract the effect of stimulants (i.e. MDMA or Cocaine)  (5)   
 Other (please state)  (6) _________________ 
  
 
Q12 On average, how often do you take them?  
 
o More than once a day  (1)   
o Every day  (2)   
o Every other day  (3)   
o 1-2 times a week  (4)   
o Once a fornight  (5)   
o Once a month  (6)   
o Every few months  (7)   
o Other (please state)  (8) _________________ 
 
Q13 How many do you generally take on each occasion?  
 
  1 (1)  2 (2)  3 (3)  4 (4)  5 (5)  6-10 (6)  Over 10 
(7)  
Valium 
(1)   
                     
Xanax (2)                        
Ativan (3)                        
Klonopin (4
)   
                     
Tranxene (
5)   
                     
Librium 
(6)   
                     
Estazolam 
(7)   
                     
Other 
(please 
state) (8)   
                     
  
 
Q14 Please comment with the type of benzo you'd take, which milligram/ microgram dosage 
you would normally take and why(i.e. 1x5mg Valium to calm my nerves before public 












Q15 How do you take your benzos? (You may choose multiple answers)  
 
 Swallow it  (1)   
 Snort it  (2)   
 Inject it  (3)   




Q16 Please briefly describe a memorable encounter involving benzos. In what context did 
you take them? What effects did you feel? 
(Which, when, where, why, how many & at what dosage)  







End of Block: Why, how, when, where  
  
Start of Block: Other substance usage  
  
Q17 Which other substances have you tried? (You may choose multiple answers)  
 
 Alcohol  (1)   
 Tobacco  (2)   
 Cannabis  (3)   
 MDMA - crystal/ powder form  (4)   
 MDMA - pill form  (5)   
 Cocaine  (6)   
 Ketamine  (7)   
 LSD/ Acid  (8)   
 Magic Mushrooms  (9)   
 Amphetamines (speed)  (10)   
 Modafinil/ Ritalin  (11)   
 Heroin  (12)   
 Crack Cocaine  (13)   
 Other (please state)  (14) _________________ 
 None of the above  (15)   
 
Q18 What do you consume before/ alongside/ after taking benzos (within the hour)? (You 
may choose multiple answers)   
 
 Nothing  (1)   
 Alcohol  (2)   
 Tobacco  (3)   
 Cannabis  (4)   
 MDMA - crystal/ powder form  (5)   
 MDMA - pill form  (6)   
 Cocaine  (7)   
 Ketamine  (8)   
 LSD/ Acid  (9)   
 Magic Mushrooms  (10)   
 Amphetamines (speed)  (11)   
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 Modafinil/ Ritalin  (12)   
 Heroin  (13)   
 Crack Cocaine  (14)   
 Other (please state)  (15) _________________ 




End of Block: Other substance usage  
 
Start of Block: Supply  
  
Q19 Where do you get your benzodiazepines?  
 
 Through the NHS - prescribed  (1)   
 Through the NHS - non-prescribed  (2)   
 Through a friend  (3)   
 Through a family member  (4)   
 From a work or study colleague  (5)   
 Online - clearweb  (6)   
 Online - darkweb  (7)   
 Dealer  (8)   
 Other (please state)  (9) _________________  
 
 
Q20 If you chose dealer, is it the same person who deals you... (You may choose multiple 
answers)  
 
 N/A  (1)   
 Only benzos  (2)   
 Cannabis  (3)   
 MDMA - crystal/ powder form  (4)   
 MDMA - pill form  (5)   
 Cocaine  (6)   
 Ketamine  (7)   
 LSD/ Acid  (8)   
 Magic Mushrooms  (9)   
 Amphetamines (speed)  (10)   
 Modafinil/ Ritalin  (11)   
 Heroin  (12)   
 Crack Cocaine  (13)   
 Other (please state)  (14) _________________ 
  
 Q21a If you pay for your benzos, how much (on average) do you pay PER tablet or bar?  
 
  I do not 
pay for 
them (1)  
50p (2)  £1 (3)  £1.50 (4)  £2 (5)  £3 (6)  £4 (7)  Other (8)  
Valium 
(1)   
                        
Xanax 
(2)   
                        
Ativan 
(3)   
                        
Klonopin 
(4)   




 (5)   
                        
Librium 
(6)   
                        
Estazola
m (7)   




(8)   
                        
  
 








Q22 How many do you generally purchase at a time?  
 
o N/A  (1)   
o 1-5  (2)   
o 6-10  (3)   
o 11-20  (4)   
o 21-30  (5)   
o 31-50  (6)   
o 51-100  (7)   
o Over 100  (8)   
  
End of Block: Supply  
  
Start of Block: Substance replacement  
  
Q23 Why do you chose benzodiazepine(s) as opposed to any other similar substance (a 
sedative/ something which will calm the mind and body i.e. weed)? (You 
may choose multiple answers)  
 
 It is a prescribed drug  (1)   
 They are the only drug I have tried which will calm me down  (2)   
 It has the best desired effect  (3)   
 They are cheap  (4)   
 They are easily accessible  (5)   
 They are easy to hide  (6)   
 They are easy to consume  (7)   







End of Block: Substance replacement  
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Appendix 15: Participant information sheet for survey participants  
I am carrying out research regarding the medical and non-medical use of benzodiazepines such as 
Diazepam (trade name Valium) and Alprazolam (trade name Xanax). Participants are required to 
have personal experience of benzodiazepine usage. 
  
Background  
Benzodiazepines are classed as hypnotic and anxiolytic drugs which are traditionally prescribed to 
treat insomnia and assist in the management of mental health issues such as anxiety and panic 
disorder. Alongside medicinal usage, benzodiazepines are also used for recreational purposes and to 
self-medicate.  
There is little knowledge regarding the supply of the diverted and illicitly supplied medicines, 
however concerns of casualties and at worst death are a result of misuse, poly-drug use and the 
consumption of counterfeit tablets, which is spreading rapidly in countries such as Scotland and the 
US.   
 
What is the purpose of this research?  
There is little information surrounding the prevalence and nature of benzodiazepine usage within 
the UK. This research wishes to explore:  
 Which types of benzos people are taking  
 Why people are taking them  
 How many they are taking and at what dosage  
 The context in which they are being taken  
 The market of illicitly supplied pharmaceuticals   
This quantitative survey will be complimented with in-depth one-to-one interviews and chemical 
analyses of seized street samples.  
 
What will happen with the results of this study?  
The findings will be used: to gain a clearer understanding of the prevalence and nature of 
benzodiazepine usage; to build an understanding of the supply of benzodiazepines; to inform users 
about the harms of recreational benzodiazepine usage; to make individuals aware of counterfeit 
samples and; inform individuals about the dangers surrounding poly drug use.  
Why do you want me to take part?  
 
As an individual with direct experience of benzodiazepine usage, it is hoped that you will provide 
insight into: the extent of benzodiazepine usage (medicinal and non-medicinal) and the reasons 
behind consumption.  
 
What will it involve?  
You will be asked to complete a web-based survey which is estimated to take around 10-
15 minutes. You may also wish to agree to a follow-up face-to-face interview which will allow the 






Confidentiality   
All the responses you provide during the full course of this research will maintain strictly 
confidential. You will not be identifiable in any publications. Should you wish to participate in the 
follow-up study, your anonymity will be preserved and full consent forms will be issued. Throughout 
this research, ethical guidelines are adopted from the Social Research Association (2003).   
 
Contact details  
Head researcher: Harriet Bloomfield, Masters by Research student at Manchester Metropolitan 
University, M15 6LL. Email: harriet.bloomfield@stu.mmu.ac.uk   
 
Research supervisor: Dr Rob Ralphs, supervisor and reader in Criminology at Manchester 
Metropolitan University, M15 6LL. Email: R.Ralphs@mmu.ac.uk. Tel: 0161 247 3014  
 



















Appendix 16: Screenshot of Reddit post 
 









Appendix 18: Facebook pages and their geographical location  
Personal Facebook page – https://www.facebook.com/harrietbloomfield  
Facebook Marketplace - https://www.facebook.com/marketplace/110336295660526/   
 
East Midlands (Nottingham, Loughborough, Leicester, Lincoln)  
Closed Facebook group – Buy/Sell Tickets (Notts uni) – UniSalad –   
https://www.facebook.com/groups/352110954925626/   
Closed Facebook group – Overheard at Trent. 
– https://www.facebook.com/groups/1589775194583920/   
Closed Facebook group – Overheard at Leicester 
– https://www.facebook.com/groups/1395453730700118/   
Closed Facebook group – Overheard at Lincoln 
– https://www.facebook.com/groups/1571879906359544/   
  
East of England (Cambridge, Norwich, Peterborough, Essex)  
Closed Facebook group – Overheard at Colchester Sixth Form 
– https://www.facebook.com/groups/187934794639632/?ref=br_rs   
  
London  
Public Facebook group – Official UAL Freshers’ 2017-18 
– https://www.facebook.com/groups/1438388166180000/about/    
Closed Facebook group – Overheard at Imperial 
– https://www.facebook.com/groups/646648388729305/   
Closed Facebook group – Overheard at Kings. 
– https://www.facebook.com/groups/1453411631548774/   
Closed Facebook group – Overheard at Queen Mary 
– https://www.facebook.com/groups/705067822861454/   
Closed Facebook group – Overheard at Central St Martins 
– https://www.facebook.com/groups/1456038254617516/  
 
North East (Newcastle, Durham)  
Closed Facebook group – Overheard at 
Durham Uni – https://www.facebook.com/groups/99499879280/   
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Closed Facebook group – Overheard at Newcastle 
– https://www.facebook.com/groups/584319688315165/   
Closed Facebook group – Overheard at Northumbria 
– https://www.facebook.com/groups/577299895688491/   
  
North West (Manchester, Salford, Liverpool)  
Closed Facebook group – Fallowfield Students Group (FSG) 
– https://www.facebook.com/groups/Fallowfieldbuynselltickets/  
Public Facebook group – Manchester Uni & Manchester Met Freshers 2017-2018 
– https://www.facebook.com/groups/938866779473395/   
Closed Facebook group – Overheard at Manchester Metropolitan 
– https://www.facebook.com/groups/342914559180413/   
Closed Facebook group – Fallowfield Buy / Sell tickets 2017/18 
– https://www.facebook.com/groups/1244490875607605/   
Closed Facebook group – WHP/Parklife Tickets 
– https://www.facebook.com/groups/1482100905181541/?ref=br_rs  
Closed Facebook group – Overheard at Manchester 
– https://www.facebook.com/groups/528931703885381/  
Closed Facebook group – Overheard at Salford 
– https://www.facebook.com/groups/467400876768896/   
Closed Facebook group – Overheard at Liverpool 
– https://www.facebook.com/groups/589856854403117/   
Closed Facebook group – Overheard at Liverpool hope. 
– https://www.facebook.com/groups/579754708776047/about/   
Closed Facebook group – Overheard 
at John Moores – https://www.facebook.com/groups/574035859331989/   
Public Facebook group – Overheard at Lancaster 
– https://www.facebook.com/groups/overheard.at.lancaster/?fref=nf   
 
South East (Brighton, Canterbury, Portsmouth, Southampton)  
Closed Facebook group – Overheard at Portsmouth 





South West (Bristol, Bath, Exeter, Falmouth, Newquay, Bournemouth)  
Closed Facebook group – Overheard at Bournemouth! 
– https://www.facebook.com/groups/1434396380123502/   
Closed Facebook group – Overheard at Bristol. 
– https://www.facebook.com/groups/745593605504743/   
Closed Facebook group – Overheard at UWE 
– https://www.facebook.com/groups/976667319028790/   
Closed Facebook group – Official UWE Freshers 2017 – University of the West of England Bristol. 
– https://www.facebook.com/groups/UWEBristolFreshers2017/   
Public Facebook group – Clifton and Stoke Bishop Tickets. 
– https://www.facebook.com/groups/632857390090581/about/    
Closed Facebook group – Overheard at Bath 
– https://www.facebook.com/groups/475984969255191/   
  
West Midlands (Birmingham, Coventry)  
Closed Facebook group – Overheard at Birmingham 
– https://www.facebook.com/groups/430446117114537/   
Closed Facebook group – Overheard at Coventry 
– https://www.facebook.com/groups/1507028259568885/  
  
Yorkshire and the Humber (Leeds, Sheffield, York, Hull)  
Closed Facebook group – Overheard at Leeds. 
– https://www.facebook.com/groups/721002447924770/   
Public Facebook group – Leeds Uni Tickets 
– https://www.facebook.com/groups/117100318646642/  
Closed Facebook group – Overheard at Beckett 
– https://www.facebook.com/groups/1432905533608253/   
Closed Facebook group – Overheard at Sheffield. 
– https://www.facebook.com/groups/743908699022155/   
Closed Facebook group – Overheard at Hallam 
– https://www.facebook.com/groups/564632107000144/about/   
Closed Facebook group – Overheard at Hull 





Rejected access   
 
Scotland   
Public Facebook group – Edinburgh Ticket Exchange 
- https://www.facebook.com/groups/166610787148289/about/   


















Appendix 19: Facebook post no.1: Thursday 01/03/2018 
 
Personal Facebook page – https://www.facebook.com/harrietbloomfield 
Closed Facebook group – Fallowfield Students Group (FSG) – 
https://www.facebook.com/groups/Fallowfieldbuynselltickets/ 
Facebook Marketplace - https://www.facebook.com/marketplace/110336295660526/  
Closed Facebook group – Fallowfield Buy / Sell tickets 2017/18 – 
https://www.facebook.com/groups/1244490875607605/  
Public Facebook group – Manchester Uni & Manchester Met Freshers 2017-2018 – 
https://www.facebook.com/groups/938866779473395/  
Closed Facebook group – WHP/Parklife Tickets – 
https://www.facebook.com/groups/1482100905181541/?ref=br_rs 
 
Total posts = 6  
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Appendix 20: Facebook post no.2: Wednesday 14/03/2018 at 18.30 – 19.00 
 
Closed Facebook group – Buy/Sell Tickets (Notts uni) – 
https://www.facebook.com/groups/352110954925626/  
Closed Facebook group – Fallowfield Buy / Sell tickets 2017/18 – 
https://www.facebook.com/groups/1244490875607605/  
Public Facebook group – Manchester Uni & Manchester Met Freshers 2017-2018 – 
https://www.facebook.com/groups/938866779473395/  
Closed Facebook group – Fallowfield Students Group (FSG) – 
https://www.facebook.com/groups/Fallowfieldbuynselltickets/ 
Public Facebook group – Official UAL Freshers’ 2017-18 – 
https://www.facebook.com/groups/1438388166180000/about/   
 
Total posts = 5 
217 
 
Appendix 21: Facebook post no.3: Monday 26/03/2018 at 19.00 – 21.00 hours  
 
Personal Facebook page – https://www.facebook.com/harrietbloomfield 
Public Facebook group – Leeds Uni Tickets – https://www.facebook.com/groups/117100318646642/ 
Facebook Marketplace - https://www.facebook.com/marketplace/110336295660526/  
Closed Facebook group – Fallowfield Students Group (FSG) – 
https://www.facebook.com/groups/Fallowfieldbuynselltickets/ 
Public Facebook group – Manchester Uni & Manchester Met Freshers 2017-2018 – 
https://www.facebook.com/groups/938866779473395/  
Closed Facebook group – WHP/Parklife Tickets – 
https://www.facebook.com/groups/1482100905181541/?ref=br_rs 




Public Facebook group – Edinburgh Ticket Exchange – 
https://www.facebook.com/groups/166610787148289/about/  
Closed Facebook group – Overheard at Durham Uni – 
https://www.facebook.com/groups/99499879280/  
Closed Facebook group – Overheard at Newcastle – 
https://www.facebook.com/groups/584319688315165/  
Closed Facebook group – Overheard at Leicester – 
https://www.facebook.com/groups/1395453730700118/  
Closed Facebook group – Overheard at Bournemouth! – 
https://www.facebook.com/groups/1434396380123502/  
Closed Facebook group – Official UWE Freshers 2017 – University of the West of England Bristol. – 
https://www.facebook.com/groups/UWEBristolFreshers2017/  
Closed Facebook group – Overheard at Manchester – 
https://www.facebook.com/groups/528931703885381/ 
Closed Facebook group – Overheard at Salford – 
https://www.facebook.com/groups/467400876768896/  
Public Facebook group – Official UAL Freshers’ 2017-18 – 
https://www.facebook.com/groups/1438388166180000/about/   
 
















Appendix 22: Facebook post no.4: Tuesday 02/04/2018 at 19.30 – 20.30 hours 
 
 
Closed Facebook group – Overheard at Liverpool Hope. – 
https://www.facebook.com/groups/579754708776047/  
Closed Facebook group – Overheard at Manchester Metropolitan – 
https://www.facebook.com/groups/342914559180413/  
Public Facebook group – Overheard at Lancaster – 
https://www.facebook.com/groups/overheard.at.lancaster/?fref=nf  
Closed Facebook group – Overheard at Durham Uni – 
https://www.facebook.com/groups/99499879280/  
Closed Facebook group – Overheard at Newcastle – 
https://www.facebook.com/groups/584319688315165/  
Closed Facebook group – Overheard at Leicester – 
https://www.facebook.com/groups/1395453730700118/  




Closed Facebook group – Official UWE Freshers 2017 – University of the West of England Bristol. – 
https://www.facebook.com/groups/UWEBristolFreshers2017/  
Public Facebook group – Official UAL Freshers’ 2017-18 – 
https://www.facebook.com/groups/1438388166180000/about/   
 











Appendix 23: Facebook post no.5: Tuesday 03/04/2018 at 19.30 – 20.00 hours  
 
Closed Facebook group – Overheard at Hallam – 
https://www.facebook.com/groups/564632107000144/about/  
Closed Facebook group – Overheard at Plymouth – 
https://www.facebook.com/groups/600563860014085/  
Closed Facebook group – Overheard at Brookes. – 
https://www.facebook.com/groups/1502526173339410/  
Closed Facebook group – Overheard at UWE – 
https://www.facebook.com/groups/976667319028790/  
Closed Facebook group – Overheard at Birmingham – 
https://www.facebook.com/groups/430446117114537/  
Closed Facebook group – Overheard at Bristol. – 
https://www.facebook.com/groups/745593605504743/  




Closed Facebook group – Overheard at Bath – 
https://www.facebook.com/groups/475984969255191/  
Closed Facebook group – Overheard at Portsmouth – 
https://www.facebook.com/groups/188927307973292/  
Closed Facebook group – Overheard at Coventry – 
https://www.facebook.com/groups/1507028259568885/  
Closed Facebook group – Overheard at Kings. – 
https://www.facebook.com/groups/1453411631548774/  
Closed Facebook group – Overheard at Northumbria – 
https://www.facebook.com/groups/577299895688491/  
Closed Facebook group – Overheard at Liverpool – 
https://www.facebook.com/groups/589856854403117/  
Closed Facebook group – Overheard at John Moores – 
https://www.facebook.com/groups/574035859331989/  
Closed Facebook group – Overheard at Heriot-Watt. – 
https://www.facebook.com/groups/1541428172799204/  
Closed Facebook group – Overheard at Leeds. – 
https://www.facebook.com/groups/721002447924770/  
 




Appendix 24: Facebook post no.6: Monday 23/04/2018 at 18.30 – 19.30 hours  
 
Personal Facebook page – https://www.facebook.com/harrietbloomfield 
Public Facebook group – Leeds Uni Tickets – https://www.facebook.com/groups/117100318646642/ 
Closed Facebook group – Fallowfield Students Group (FSG) – 
https://www.facebook.com/groups/Fallowfieldbuynselltickets/ 
Public Facebook group – Manchester Uni & Manchester Met Freshers 2017-2018 – 
https://www.facebook.com/groups/938866779473395/  




Public Facebook group – Edinburgh Ticket Exchange – 
https://www.facebook.com/groups/166610787148289/about/  
Closed Facebook group – Overheard at Durham Uni – 
https://www.facebook.com/groups/99499879280/  
Closed Facebook group – Overheard at Newcastle – 
https://www.facebook.com/groups/584319688315165/  
Closed Facebook group – Overheard at Bournemouth! – 
https://www.facebook.com/groups/1434396380123502/  
Closed Facebook group – Official UWE Freshers 2017 – University of the West of England Bristol. – 
https://www.facebook.com/groups/UWEBristolFreshers2017/  
Closed Facebook group – Overheard at Manchester – 
https://www.facebook.com/groups/528931703885381/ 
Closed Facebook group – Overheard at Salford – 
https://www.facebook.com/groups/467400876768896/  
Public Facebook group – Official UAL Freshers’ 2017-18 – 
https://www.facebook.com/groups/1438388166180000/about/   
Closed Facebook group – Overheard at Hallam – 
https://www.facebook.com/groups/564632107000144/about/  
Closed Facebook group – Overheard at UWE – 
https://www.facebook.com/groups/976667319028790/  
Closed Facebook group – Overheard at Birmingham – 
https://www.facebook.com/groups/430446117114537/  
Closed Facebook group – Overheard at Bristol. – 
https://www.facebook.com/groups/745593605504743/  
Closed Facebook group – Overheard at Bath – 
https://www.facebook.com/groups/475984969255191/  
Closed Facebook group – Overheard at Portsmouth – 
https://www.facebook.com/groups/188927307973292/  
Closed Facebook group – Overheard at Coventry – 
https://www.facebook.com/groups/1507028259568885/  
Closed Facebook group – Overheard at Kings. – 
https://www.facebook.com/groups/1453411631548774/  
Closed Facebook group – Overheard at Northumbria – 
https://www.facebook.com/groups/577299895688491/  




Closed Facebook group – Overheard at John Moores – 
https://www.facebook.com/groups/574035859331989/  
Closed Facebook group – Overheard at Heriot-Watt. – 
https://www.facebook.com/groups/1541428172799204/  
Closed Facebook group – Overheard at Leeds. – 
https://www.facebook.com/groups/721002447924770/  
Closed Facebook group – Buy/Sell Tickets (Notts uni) – UniSalad – 
https://www.facebook.com/groups/352110954925626/  
Closed Facebook group – Overheard at Queen Mary – 
https://www.facebook.com/groups/705067822861454/  
Closed Facebook group – Overheard at Beckett – 
https://www.facebook.com/groups/1432905533608253/  
Closed Facebook group – Overheard at Liverpool hope. – 
https://www.facebook.com/groups/579754708776047/  
Closed Facebook group – Overheard at Sheffield. – 
https://www.facebook.com/groups/743908699022155/  
Closed Facebook group – Overheard at Central St Martins – 
https://www.facebook.com/groups/1456038254617516/  
Closed Facebook group – Overheard at Lincoln – 
https://www.facebook.com/groups/1571879906359544/  
Closed Facebook group – Overheard at Trent. – 
https://www.facebook.com/groups/1589775194583920/  
Closed Facebook group – Overheard at Imperial – 
https://www.facebook.com/groups/646648388729305/  
Closed Facebook group – Overheard at Colchester Sixth Form – 
https://www.facebook.com/groups/187934794639632/?ref=br_rs  
Closed Facebook group – Clifton and Stoke Bishop Tickets – 
https://www.facebook.com/groups/632857390090581/  
 




Appendix 25: Tweet no.1: Thursday 1/03/2018 at 11:49am 
 





Appendix 27: Tweet no.3: Henry Fisher on Thursday 08/03/2018 at 08:03am 
 








Appendix 29: Tweet no.5: Max Daly on Tuesday 27/03/2018 at 14.43pm 
 






Appendix 30a: Full table of postings and response rates 
DATE Number of responses Where the link was posted 
March   
01/03/2018 20 Facebook, Twitter (Harriet Bloomfield) 
02/03/2018 31   
03/03/2018 3   
04/03/2018 3   
05/03/2018 9   
06/03/2018 2   
07/03/2018 3 Twitter (reply to Harry Shapiro) 
08/03/2018 6 Twitter (Henry Fisher),  
09/03/2018 8   
10/03/2018 9   
11/03/2018 4   
12/03/2018 2   
13/03/2018 10 
Twitter (Harriet Bloomfield reply to 
Hannah Ewens and others)  
14/03/2018 8 Facebook 
15/03/2018 4   
16/03/2018 1   
17/03/2018 2   
18/03/2018 0   
19/03/2018 0   
20/03/2018 0   
21/03/2018 1   
22/03/2018 1   
23/03/2018 6   
24/03/2018 1   
25/03/2018 0   
26/03/2018 86 Facebook  
27/03/2018 108 Twitter (Max Daly) 
28/03/2018 32   
29/03/2018 17   
30/03/2018 13   
31/03/2018 8   
April     
01/04/2018 19   
02/04/2018 24 Facebook 
03/04/2018 21 Facebook 
04/04/2018 6   
05/04/2018 9   
06/04/2018 5   
07/04/2018 2   
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08/04/2018 0   
09/04/2018 2   
10/04/2018 2   
11/04/2018 0   
12/04/2018 0   
13/04/2018 0   
14/04/2018 0   
15/04/2018 1   
16/04/2018 2   
17/04/2018 3   
18/04/2018 2   
19/04/2018 1   
20/04/2018 0   
21/04/2018 0   
22/04/2018 0   
23/04/2018 100 Facebook 
24/04/2018 55 Twitter 
25/04/2018 7   
26/04/2018 3   
27/04/2018 2   
28/04/2018 1   
29/04/2018 2   
30/04/2018 4   
May     
01/05/2018 4   
02/05/2018 2   
03/05/2018 1   
04/05/2018 0   
05/05/2018 0   
06/05/2018 2   
07/05/2018 0   
08/05/2018 6   
09/05/2018 1   
10/05/2018 3   
11/05/2018 3 The TAB article 
12/05/2018 6   
13/05/2018 3   
14/05/2018 3   
15/05/2018 1   
16/05/2018 0   
17/05/2018 2   
18/05/2018 0   
19/05/2018 1   
20/05/2018 0   
21/05/2018 1   
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22/05/2018 2   
23/05/2018 0   
24/05/2018 0   
25/05/2018 2   
26/05/2018 0   
27/05/2018 0   
28/05/2018 0   
29/05/2018 1   
30/05/2018 0   
31/05/2018 0   
June     
01/06/2018 1   
02/06/2018 0   
03/06/2018 0   
04/06/2018 1   
05/06/2018 0   
06/06/2018 0   
07/06/2018 0   
08/06/2018 1   
      
TOTAL 718 (minus 2x pilot tests) 
  
Appendix 31: Snippets of interviews for TAB article 
P: Male, 19  
I: Which benzos have you taken, and which is your favourite?  
P: I’ve only taken Valium, don’t know the others  
I: What is your reason for taking them?  
P: I only really take Vals occasionally after a night out to get to sleep. If I've been dropping at a 
festival and carry on ‘til about 6am, I'm not going to be able to get to sleep without them  
  
P1: Female, 19  
P2: Female, 20  
I: Which benzos have you taken, and which is your favourite?  
P2: I’ve tried both, but Valium is the best I think because it’s not as strong as Xanax  
P1: Xanax is way too strong, but Valium doesn’t do it for me anymore… I end up taking a few after a 
night out to get a solid sleep but then the few days after that I feel so spaced out and can’t do 
anything productive  
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P2: Hmm yeah, I kinda start being productive on them but once I started taking Vallies in the 
morning to get me through my art deadline. I got it done and did well but I can hardly remember 
that week which is freaky  
  
P: Female, 19  
I: Have you had any bad experiences with benzos?  
P: I once took a Xanax just before Antwerp and didn’t make it outside the house, I was totally 
zombie-fied and slept for 2 days. My friend said I was so weird at pres… apparently I was undressing 
and dancing on top of her boyfriend but I can’t remember a thing. It’s so weird and embarrassing I 
definitely won’t take it again.  
  
P: Male, 22  
I: Which benzos have you tried?  
P: Just Valium. I've never taken Xanax because I see what's happened to my mates when they're on 
them. They literally just flop, can't speak properly and dribble everywhere. It is funny but then just 



















Appendix 32: Full copy of The TAB article 
We asked Manchester students about their experiences with Xanax and Valium 
Benzo consumption is a rising trend in our student community - Harriet Bloomgret MANCHESTER 
 
Valium, Xanax, Klonopin and other benzos are powerful hypnotic and anxiolytic drugs which are 
traditionally prescribed to treat severe cases of insomnia, anxiety and panic disorder. There has been 
a rise in trends of recreational consumption amongst students, but we found that people had mixed 
reviews about them. We reached out to students about "the trendy" drugs. How much were people 
taking? Why? And since when did it become so fashionable? 
 
Benzos can be very strong, especially when mixed with other depressant substances like alcohol. We 
spoke to a few students who describe taking several benzos, either in one go or throughout the night, 
and often mix the drugs with other substances. 
One of the most popular uses of Valium is as a sleeping pill. Students use it after a night of partying to 




"I only really take Vals occasionally after a night out to get to sleep. If I've been dropping at a 
festival and carry on til about 6am, I'm not going to be able to get to sleep without them" 
 
Although Valium might be good if you’re having trouble sleeping… Its active metabolite elimination 
half-life is 4 days, meaning you could feel tired and lethargic for a while after. 
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Sarah, 19, from UoM and Cat, 20, from MSoA 
"Valium doesn’t do it for me anymore… I end up taking a few after a night out to get a solid 
sleep but then the few days after that I feel so spaced out and can’t do anything productive" 
"I started taking Vallies in the morning to get me through my art deadline. I got it done and 
did well but I can hardly remember that week which is freaky" 
 
Xanax however, is much more potent. When putting things into perspective, the equivalent dosage 
(compared to 5mg of Valium) of Xanax would be 0.25mg… That’s merely a quarter of an average 
Xanax bar. With a half-life of 6-27 (based on 0.25mg), the drug is shorter acting than Valium if it’s 
taken in the right dose. 
Caroline, 19 
 
"I once took a Xanax just before Antwerp and didn’t make it outside the house, I was totally 
zombie-fied and slept for 2 days. My friend said I was so weird at pres… apparently I was 
undressing and dancing on top of her boyfriend but I can’t remember a thing. It’s so weird and 






Alex (22) said: 
 
"I've never taken Xanax because I see what's happened to my mates when they're on them. 
They literally just flop, can't speak properly and dribble everywhere. It is funny but then just 
goes weird very quickly…" 
 
But why now? Where have they come from? David Sunter, a former researcher at Manchester 
Metropolitan University claims: 
"There's definitely been a shift away from smoking Weed… It's just not the same anymore 
with all these new strengths like skunk. It sends people loopy… But with benzos you can just 
take one or two and pass out" 
Whether you love them or hate them, please fill in this survey. 




Appendix 33: Screenshot of The TAB article 1 
 





Appendix 35: Interview guide 
*Must make them read the participant information sheet first   
*Must sign form of consent prior to the interview  
  
1. Gather participants demographics – gender, age, occupation, uni town and home town  
 
2. Which benzo’s do you use/ have you used, and WHY?   
  
3. How often do you use them and at what dosage?   
  
4. What substances do you take them before/ alongside/ after?  
 
5. How do you take them? (Orally/ sniff/ inject) 
 
6. Where do you get your BZDs from? How/ why? & in what quantity   
 
7. Do you think benzo usage is a result of being in a big city like Manchester?  
 
8. Do you think BZDs are a replacement of more traditional drug like cannabis? Or even 
heroin? (Speak about Scotland’s Valium crisis) 
 
9. Do you think there is a correlation between benzo use and the use of other substances? In 
















Appendix 36: Participant information sheet for interviewees 
I am carrying out research regarding the medical and non-medical use of benzodiazepines such as 
Diazepam (trade name Valium) and Alprazolam (trade name Xanax). Participants are required to 
have personal experience of benzodiazepine usage.  
 
Background  
Benzodiazepines are classed as hypnotic and anxiolytic drugs which are traditionally prescribed to 
treat insomnia and assist in the management of mental health issues such as anxiety and panic 
disorder. Alongside medicinal usage, benzodiazepines are also used for recreational purposes and to 
self-medicate.  
There is little knowledge regarding the supply of the diverted and illicitly supplied medicines, 
however concerns of casualties and at worst death are a result of misuse, poly-drug use and the 
consumption of counterfeit tablets, which is spreading rapidly in countries such as Scotland and the 
US.   
 
What is the purpose of this research?  
There is little information surrounding the prevalence and nature of benzodiazepine usage within 
the UK. This research wishes to explore:  
 Which types of benzos people are taking  
 Why people are taking them  
 How many they are taking and at what dosage  
 The context in which they are being taken  
 The market of illicitly supplied pharmaceuticals   
 
A quantitative survey will be complimented with in-depth one-to-one interviews and chemical 
analyses of seized street samples.  
 
What will happen with the results of this study?  
With your consent, the interview will be audio recorded before being transcribed and stored in a 
secure place. All responses are completely anonymous; in the interviews your real name will not be 
used. The data will be used in the final report which will be published.   
The findings will be used: to gain a clearer understanding of the prevalence and nature of 
benzodiazepine usage; to build an understanding of the supply of benzodiazepines; to inform users 
about the harms of recreational benzodiazepine usage; to make individuals aware of counterfeit 
samples and; inform individuals about the dangers surrounding poly drug use.  
 
Why do you want me to take part?  
As an individual with direct experience of benzodiazepine usage, it is hoped that you will provide 
insight into: the extent of benzodiazepine usage (medicinal and non-medicinal) and the reasons 






What will it involve?  
You will be asked to take part in a one-to-one interview which will last around 30-60 minutes. The 
interviews will be audio recorded and then destroyed once it has been typed up. The transcript will 
be secured in a secure place.   
 
Confidentiality   
All the responses you provide during the full course of this research will maintain strictly 
confidential. You will not be identifiable in any publications. Your anonymity will be preserved and 
full consent forms will be issued. Throughout this research, ethical guidelines are adopted from the 
Social Research Association (2003).   
 
Contact details  
Head researcher: Harriet Bloomfield, Masters by Research student at Manchester Metropolitan 
University, M15 6LL. Email: harriet.bloomfield@stu.mmu.ac.uk   
 
Research supervisor: Dr Rob Ralphs, supervisor and reader in Criminology at Manchester 
Metropolitan University, M15 6LL. Email: R.Ralphs@mmu.ac.uk. Tel: 0161 247 3014  
 






















Appendix 37: Consent form for interviewees 
Please insert your initials along the left hand side to confirm you are happy to continue. 
 
1. I can confirm that I have read and understood the information sheet dated and 
have had the opportunity to ask questions about the interview procedure. 
 








4. I understand that at my request, a copy of my data can be made available to me.  
 
________________________ ________________         ____________________ 
Name of Participant Date Signature 
 
 
_________________________ ________________         ____________________ 
Researcher Date Signature 















Appendix 38: Survey key code 
Each question included 
98 – Missing 
99 – Not applicable  
1. Age 
- 18-21 - 1 
- 22-25 - 2 
- 26-30 - 3 
- 31-40 - 4 
- 41+ - 5  
2. Sex 
- Male – 1 
- Female – 2 
- Transgender – 3 
3. Sexuality 
- Heterosexual/ straight - 1 
- Homosexual/ gay/ lesbian - 2  
- Bisexual - 3 
- A-sexual - 4 
- I’d rather not say - 5  
- Other – 6 
4. Ethnicity 
- White - 1 
- Black - 2 
- Asian - 3 
- Mixed- 4 
- Chinese – 5 
- Arab – 6  
- Hispanic – 7 
5. Where are you based? 
- South East – 1  
- London – 2  
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- North West – 3  
- East of England – 4  
- West Midlands – 5  
- South West – 6  
- Yorkshire and the Humber – 7  
- East Midlands – 8  
- North East – 9  
- Scotland – 10  
- Ireland – 11  
- Wales – 12 
- Outside of England – 13  
- I’d rather not say – 14 
6. What is your occupation? 
- Full-time/ part-time student - 1 
- Employed (paid work) – 2  
- Unemployed – 3  
- Other – 4  
7. Which benzo(s) have you taken? 
Split into 9 separate headings on SPSS (Valium (Diazepam), Xanax (Alprazolam), Ativan (Lorazepam), 
Klonopin (Clonazepam), Tranxene (Clorazepate), Librium (Chlordiazepoxide), Estazolam, Estizolam, 
Other) 
Then coded each:  
1 = yes  
2 = no  
98 = missing  
99 = not applicable  
8. Which do you currently use/ have used in the past 2 months? 
Split into 10 separate headings on SPSS (Same as above + ‘not recently’) 
Then coded each:  
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1 = yes  
2 = no  
98 = missing  
99 = not applicable  
9. Preferred benzo 
- Valium (Diazepam) – 1  
- Xanax (Alprazolam) – 2  
- Ativan (Lorazepam) – 3  
- Klonopin (Clonazepam) – 4  
- Tranxene (Clorazepate) – 5  
- Librium (Chlordiazepoxide) – 6  
- Estazolam – 7  
- Eitzolam – 8  
- Other – 9  
- No preference – 10 
- None, dislike them all – 11 
10. Why is this your preferred benzo? 
Text answer. Exported back into Excel and split further:  
1. Valium 
2. Xanax 
Useful quotes used throughout the results section.  
11. User motivations? 
Split into 6 separate headings on SPSS (For anxiety or similar issues – prescribed, for anxiety or 
similar issues – non-prescribed, to get to sleep, to get high, to counteract the effects of stimulants 
and other). ‘Other’ heading was elaborated (to relax, for a confidence boost, for long journeys, for 
physical pain relief and they are good with alcohol).  
Then coded each:  
1 = yes  
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2 = no  
98 = missing  
99 = not applicable  
12. How often 
- Daily - 1 
- Weekly - 2 
- Fortnightly - 3 
- Monthly - 4  
- Every few months - 5 
- Rarely (yearly/ only tried once) – 6 
- Not for a long time – 7 
- Binge – 8 
- Whenever I need to – 9  
- Other – 10 
13. How many on each occasion 
Split into 7 different headings on SPSS (Valium, Xanax, Ativan, Klonopin, Tranxene, Librium, 
Estazolam) 
Then coded each:  
1 = yes  
2 = no  
98 = missing  
99 = not applicable  
Valium and Xanax were the only two with a significant amount of respondents therefore the others 
were not mentioned in the results. 
14. MG and dosage context 
Answers were exported back to Excel and split as follows: 





15. How do you consume your benzos? 
Split into 6 headings on SPSS (swallow, snort, inject, sublingually, chew it and dissolve in drink) 
Then coded each:  
1 = yes  
2 = no  
98 = missing  
99 = not applicable  
16. Memorable encounter 
Free text. Answers were split into: 
1. Positive 
2. Negative 
Most positive answers were related to the recreational use of benzodiazepines and used to 
elaborate statistics for user motivations.  
Most negative encounters were used to elaborate points previously made regarding the adverse 
negative effects of benzodiazepines.  
17. Other substance use  
Split into 11 headings (alcohol, tobacco, cannabis, MDMA, cocaine, ketamine, hallucinogens, 
amphetamines (speed), Modafinil/Ritalin, opiates/crack cocaine, other).  
Then coded each:  
1 = yes  
2 = no  
98 = missing  
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99 = not applicable  
18. Substance use alongside benzos 
Split into 12 headings (alcohol, tobacco, cannabis, MDMA, cocaine, ketamine, hallucinogens, 
amphetamines (speed), Modafinil/Ritalin, opiates/crack cocaine, nothing, other).  
Then coded each:  
1 = yes  
2 = no  
98 = missing  
99 = not applicable  
19. Source  
Split into 9 headings on SPSS (prescribed, non-prescribed (diverted), through a friend, through a 
family member, from a work or study colleague, online – clearweb, online – darkweb, dealer, other) 
Then coded each:  
1 = yes  
2 = no  
98 = missing  
99 = not applicable  
20. If you chose dealer, is it the same person who deals… 
Split into 13 headings on SPSS (Only benzos, cannabis, MDMA (crystal/ powder form), MDMA (pills), 
cocaine, ketamine, LSD/ acid, magic mushrooms, amphetamines, Modafinil/Ritalin, opiates, crack 
cocaine, other). 
Then coded each:  
1 = yes  
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2 = no  
98 = missing  
99 = not applicable  
21. Price 
There were a lot of varied answers for Q21, therefore bar Valium and Xanax, others were deleted. 
Valium had 8 headings (don’t pay, 50p, £1, £1.50, £2, £3, £4, other) and Xanax also had 8 headings 
(don’t pay, 50p, £1, £1.50, £2, £3, £4, other).  
Then coded each:  
1 = yes  
2 = no  
98 = missing  
99 = not applicable  
Additional comments to Q21 
Text answers were transferred back to Excel and relevant, descriptive answers were taken and 
placed throughout the survey to enhance statistical findings.  
22. How many purchase  
- 1-5 - 1 
- 6-10 - 2 
- 11-20 - 3 
- 21-50 - 4  
- 51+ - 5 
23. Why chose benzos  
8 subheadings were created on SPSS (it is a prescribed drug, it is the only drug I have tried to get this 
effect, it has the best desired effect, they are cheap, they are easily accessible, they are easy to hide, 
they are easy to consume, other (text)) 
Then coded each:  
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1 = yes  
2 = no  
98 = missing  
99 = not applicable  
‘Other’ answers were exported back to Excel and relevant and important quotes were extracted and 
put throughout the results section.  
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Appendix 39: Coding question 10: Valium  




Appendix 41: Coding question 14: splitting Valium and Xanax 
 




Appendix 43: Other accounts of memorable encounters (question 16) 
‘3 mg of Xanax, however mixed it with Cannabis. I went to the Manchester Christmas Markets with 
my friends. One of the weirdest experiences of my life. I was calm and in control throughout the 
situation. Food tasted amazing. I was with a group of friends all experiencing the same feelings as 
myself. Went back to a friends and binge watched It's Always Sunny in Philadelphia’ 
‘With my mates. One of them was proper battered on Xanax: he had taken like 12 tablets and 
couldn't perform basic activities such as leaving the room to go to the shop. It took him 3 hours to 
walk across the road. And I basically chilled out watching South Park’ 
‘Took 2 Xanax when I was having relationship troubles and was overthinking situations when trying 
to sleep so I took the Xanax and fell asleep quickly and had a peaceful, anxiety free sleep’ 
‘Took 5 Xanax and felt like I was floating, couldn't walk properly but I felt fuzzy and warm’ 
‘Took a Valium to calm my thoughts and just felt soothed, more relaxed than I had in a long time’ 
‘Took Valium to sleep well after a late boozy night. It was often very easy to [lose] track of time and 
this would enable me to ensure I would still keep up with enough sleep. Took Valium to relax me 
through a large and painful tattoo on my shinbone’ 
‘Fucked my sleeping pattern up after a festival (on account on hammering 1.5 g of MDMA in the 
space of 3 days), my mate gave me a [Valium] to take before bed to fall asleep at a reasonable hour. 
Ate it. Fell Asleep. Woke up. Felt FUCKING AMAZING and proper refreshed, best night sleep I ever did 
have’ 
‘Getting back to campsite at a festival at 7am, sitting on an inflatable chair whilst feeling the effects 
of taking one Xanax and feeling very waved, light, floaty. Feeling more comfortable than I was before 
the effects’ 
‘[I] had been at a day festival in London all day, had taken MDMA this evening a terrorist attack 
happened and all the tubes were closed, I started panicking so my boyfriend gave me 2. I stopped 
caring/worrying and then just seemed to wake up in bed’ 
‘I had a heavy Saturday night with no sleep and had work Sunday afternoon, I felt really paranoid due 
to no sleep so I took 2 mg of Xanax and in the space of an hour I felt relaxed and my anxiety had gone 
which meant I could function properly at work and felt normal (except for being tired)’ 
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‘I took 3 x 5 mg Valium for a coach journey from London to Nottingham after a weekend partying in 
London. I couldn't be asked with the long coach and remember time just flying by where I was so 
high. I also remember a bender last summer where two friends and I went through 100 Valium 
(pretty sure they were fake) in three days when I had a free house. We initially started taking them 
after a night out and before you know it [we’ve] been smoking weed and taking Valium for three 
days straight, only moving to get supplies. As you could probably imagine my memories of this three 
day period are pretty unclear’ 
‘Took 2 Xanax and forgot the convo every now and then, everything seemed to be going by so fast 
and slow at the same time’ 
‘I took 7 x 1 mg [Xanax] at a gathering I felt happy and warm (like someone had put a blanket over 
me)’ 
‘I took a Xanax after tripping at a festival when I couldn't sleep. I was seeing flashing images behind 
my eyelids; when the [Xanax] kicked in I felt tremendously relaxed. Possibly the best physical 
experience [I] have had in my life so far’ 
‘Took 2 Xanax bars, and had a few drinks at a student bar, remember very little, everyone thought I 
was very drunk, felt relaxed, dazed, and happy, smoked some weed then went bed, didn't wake up 
until 5pm the next day’ 
‘I took 2 Valium and chipped my tooth in a club’ 
‘Took 2 Vallies and a load of K and couldn't feel my legs on a night out, ended up sitting in a puddle. 
Was pretty cool’ 
‘Took 3 Xanax, tried to bump a taxi... almost got arrested’ 
‘Took 4 – 6 [Valium] on my art coursework hand in and ended up delivering 20 pieces of paper one by 
one from opposing sides of the art department. Following this I snuck back to my halls with a traffic 
barrier by myself’ 
‘Took them in lectures and fell asleep dribbling on my laptop’ 
‘Took Valium in a friends room after a night out and [I] kept thinking all the square photos on her 
wall were windows with snow behind’ 
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‘Took 2 Xanax, drank some rum.. Took 2 more, then took some E, ket, coke, and MDMA. I went on a 3 
day bender of sesh and generally fucked my life in multiple ways... ended up eating 8 Xans. Moral of 
the story: stay the fuck away from Xanax but Vallies are sound’ 
‘Took 20 Valium and 2 Xanax without even realising how much I'd taken. Same dosages as before, I 
was talking to some friends in my room and I thought 20 minutes had gone by but they were there 
for 2 hours. I don't remember what I was talking about for 2 hours’ 
‘After a night cramming and exam at uni with no sleep, I took a Xanax when I got home and within 
an hour I had fallen asleep in the kitchen with a full cup of tea in one hand whilst in the middle of 
watching a video on my phone’ 
‘Had a night staying at a mates then got kicked out. Mixed a lot of alcohol with a lot of clomazepam. 
Woke up with a nosebleed at Ingatestone instead of my stop. Another time I took a couple of Valium 
whilst drinking and was told the next day we visited a strip club. I was then told by my friend [I] got 
two lap dances for 50 pounds each or something. I don't even remember any of it. Feel really silly 
about that one’ 
‘I have a rule of only taking 1 Xanax but the one time I broke it I took a couple and was texting my 
girlfriend the next day, apparently the only thing [I] was replying to her with was 'my showers 
flooded' cos it had done that day but evidently it seems in my state that was the only bit of relevant 
information’ 
‘I remember taking Xanax after a big bender at my friends house party.  I had taking a combination 
of pills alcohol Ket Coke Codeine and I remember taking a Xan before bed and literally feeling so calm 
and like floaty if I think about it I can still remember the feeling of feeling so chilled out and warm I 
fell asleep for about 15 hours and missed my bus home. Despite this experience being nice I haven't 
taken a [Xanax] since as I've seen the effects they have had on people and it's really put me off’ 
‘Job interview, doubled dosed just before as I still felt nervous, kicked in during the interview and 
don't remember it very my at all. I didn't get the job’ 
‘Took 3 mg of Xanax with alcohol and had a complete black out where I made toast in the sink and 




‘Took 7 x 2 mg Xanax, fell into a pond with a friend, then took off all my wet clothes and returned 
home wearing just a coat. I don't have much memory after falling in the pond. Memory loss of when 
you take them is the main reason I dislike them’ 
‘Took a couple of 2 mg Xanax on a night out, black out, fell off a bicycle (still have a scar), shoplifted 
a massive amount of food (Xanax gives me massive munchies) and had a great time clubbing’ 
‘Had 0.5 x 2 mg Xanax on a night out and felt very calm and confident and slightly slowed down at 
the time, but have little to no memory of the night’ 
‘Had a Valium on an overnight train, sent me puddled. Kept having a dream, waking up, falling 
asleep and having the same dream, over and over’ 
‘[I took] 1 Xanax after a night out and the combination with alcohol made me black out and not 
remember the last 6 hours, I woke all my housemates up and left the front door wide open’ 
‘First took them at 14/15 blacked out and felt very comfortable for the following days. My other 
friends caused havoc and one was found passed out in a park and the one had to go live in Blackpool 
with his dad. Crazy times’ 
‘Had a really bad experience with Xanax over a period of 2 weeks at most. My mate was addicted, 
and she recommended [I] take them to help me sleep. Soon I was addicted, taking 4 a day at least. I 
was unrecognisable ... I was a zombie. I was aggressive. I ruined friendships. I have no memory of it 
which is the scariest part of it. When [I] came off it [I] was suicidal’ 
‘Nothing is memorable on high dose benzos, I've travelled half way down the country blacked out, 
broken into Portuguese squats and fallen asleep in a nightclub’ 
‘Taken too many, handful whilst drinking because I didn't feel the effects straight away, my sanity 
and control slowly deteriorated throughout this period and I woke up in a state and had no idea what 
had happened, got in trouble with friends, lost money etc. On both Xanax and Diazepam’ 
‘Took 1 Xanax mixed with alcohol the night before and woke up in Germany ([don’t] remember 
getting in the car or anything)’ 





‘Took 7 Xanax on a night out and got in a fight which I can only remember because I called someone 
that night who then told me the next day’ 
‘Took loads of Xanax at carnival. My friend got in a fight with people from a different part of London. 
Thought I could help. Got punched in the face straight away. But was just out of it doing stupid things 
annoying my friends being stupid’ 
‘Took some Xanax can’t remember how many and severely injured my ankle climbing over a high 
wall and dropping into a night club, sprain or possible fracture. Was also on alcohol and ketamine’ 
‘Took them at Parklife to counteract the negative effects of acid, stopped me tripping which was shit 
but me and my mate were just wandering round without a care in the world, don't remember much 
lol probs wouldn't do it again’ 
Appendix 44: Image of presumed Valium tablet (V1 – anomaly)  
 









Appendix 46: Unknown ‘Valium’ weight and description  
Name of sample Previous name Features Weight in grams 2/10 weight in grams 
V1 361 Blue pill - 'ROCHE 10' 0.1182 0.0235 
V2 710 Blue pill - 'MSJ' 0.0542 0.0109 
V3 710 Blue pill - 'MSJ' 0.0541 0.0107 
V4 710 Blue pill - 'MSJ' 0.0661 0.0134 
V5 710 Blue pill - 'MSJ' 0.0577 0.0112 
V6 710 Blue pill - 'MSJ' 0.0596 0.0119 
V7 710 Blue pill - 'MSJ' 0.0533 0.0106 
V8 710 Blue pill - 'MSJ' 0.0592 0.0116 
V9 710 Blue pill - 'MSJ' 0.056 0.0111 
V10 710 Blue pill - 'MSJ' 0.055 0.011 
V11 710 Blue pill - 'MSJ' 0.0593 0.0117 
V12 710 Blue pill - 'MSJ' 0.0598 0.012 
V13 710 Blue pill - 'MSJ' 0.0545 0.0109 
V14 710 Blue pill - 'MSJ' 0.0575 0.0111 
V15 710 Blue pill - 'MSJ' 0.0556 0.011 
V16 710 Blue pill - 'MSJ' 0.0528 0.0105 
V17 710 Blue pill - 'MSJ' 0.0537 0.0107 
V18 710 Blue pill - 'MSJ' 0.0562 0.0111 
V19 710 Blue pill - 'MSJ' 0.0563 0.0111 
V20 710 Blue pill - 'MSJ' 0.0625 0.0123 
V21 710 Blue pill - 'MSJ' 0.0663 0.0134 
V22 710 Blue pill - 'MSJ' 0.0626 0.0126 
V23 710 Blue pill - 'MSJ' 0.062 0.0124 
V24 710 Blue pill - 'MSJ' 0.066 0.0135 
V25 710 Blue pill - 'MSJ' 0.0668 0.0136 
V26 710 Blue pill - 'MSJ' 0.0638 0.0128 
V27 710 Blue pill - 'MSJ' 0.0674 0.0136 
V28 710 Blue pill - 'MSJ' 0.0624 0.0126 




Appendix 47: Image of presumed Xanax bar 
 











Appendix 49: Unknown ‘Xanax’ weight and description 
Name of sample Previous name Features Weight in grams 1/2 weight in grams 
X1 53 Powder 0.5135 0.2575 
X2 B109 Full Xanax bar 0.2966 0.1341 
X3 73 Powder 0.3365 0.1582 
X4 550 Powder 0.9146 0.4421 
X5 559D Full Xanax bar 0.2382 0.1173 
X6 555A Powder 0.044 0.0221 
X7 559E Powder 0.1685 0.0845 
X8 559B Full Xanax bar 0.2382 0.1195 
X9 555B Powder 0.0451 0.0228 
X10 558A Full Xanax bar 0.2301 0.1158 
X11 559C Full Xanax bar 0.2231 0.1115 
X12 B104 Full Xanax bar 0.2533 0.1261 
X13 B102 Full Xanax bar 0.2478 0.1238 
X14 B112 Full Xanax bar 0.2448 0.1226 
X15 559A Powder 0.122 0.0612 
X16 B115 Half a Xanax bar 0.1 0.0501 
X17 B103 Full Xanax bar 0.2719 0.135 
X18 B114 Full Xanax bar 0.2533 0.1266 
X19 B110 Full Xanax bar 0.2535 0.1269 
X20 B105 Full Xanax bar 0.251 0.1258 
X21 B101 Full Xanax bar 0.2467 0.1142 
X22 B107 Full Xanax bar 0.2582 0.1291 
X23 B106 Full Xanax bar 0.2607 0.1308 
X24 B108 Full Xanax bar 0.2521 0.126 
X25 B113 Full Xanax bar 0.2605 0.1301 
X26 B151 
 Blue tablet - 'UPJOHN 
90' 0.1145 0.057 
X27 B111 Full Xanax bar 0.237 0.1188 
X28 226 Full Xanax bar - small 0.2087 0.1026 




















Appendix 52: Image of X16 colour change after 5 minutes 
















Class: NPS – Benzodiazepines 
Compound: Alprazolam 
Match score: 0.997 
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 10mg  DMSO: 
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Class: Cutting Agent 
Compound: Alpha-D-
Lactose.H2O    
Match score: 0.994 
 
Acetonitrile: Possible unknowns 
Class: NPS – Synthetic 
Cannabinoids 
Compound: 5F-AKB-48 
Match score: 0.835 
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Class: Cutting Agent 
Compound: Alpha-D-
Lactose.H2O 
Match score: 0.980 
 









Class: Cutting Agent 
Compound: alpha-D-Lactose.H20    
Match score: 0.986  
 
Acetonitrile: Possible unknowns 
Class: NPS – Synthetic 
Cannabinoids 
Compound: 5F-AKB-48 




Match score: 0.820 
 










Class: Cutting Agent 
Compound: alpha-D-Lactose.H20    
Match score: 0.991 
 
Acetonitrile: Possible unknowns 
Class: NPS – Synthetic 
Cannabinoids 
Compound: 5F-AKB-48 




Match score: 0.835 
 









Class: Cutting Agent 
Compound: alpha-D-Lactose.H20    
Match score: 0.991 
 
Acetonitrile: 
Class: NPS – Synthetic 
Cannabinoids 
Compound: 5F-AKB-48 














Class: NPS Steroids  
Compound: Nadrolone Decante   
Match score: 0.903 
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Compound: 5F-AKB-48 





















Compound: phencyclidine HCI 
Match score: 0.788 
DMSO: tried 
to filter but it 
exploded. 
Not much 
liquid for the 
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Class: Cutting Agent 
Compound: alpha-D-Lactose.H20    
Match score: 0.981 
 
Acetonitrile: Possible unknowns 
Class: NPS – Synthetic 
Cannabinoids 
Compound: 5F-AKB-48 




Match score: 0.818 
Only 9mg 











Class: Cutting Agent 
Compound: alpha-D-Lactose.H20    
Match score: 0.995 
 
Acetonitrile: Possible unknowns 
Class: NPS – Synthetic 
Cannabinoids 
Compound: 5F-AKB-48 
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Compound: Meperidine HCI 
(pethidine)   











Class: NPS – Synthetic 
Cannabinoids  
Compound: 5F-AKB-48 
Match score: 0.865 








DMSO: Possible unknowns 
Class: Pharmaceutical 
Compound: Quetiapine 
Class: Cutting Agent 
Compound: alpha-D-
Lactose.H2O 
Match score: 0.812 
 
Acetonitrile: Possible unknowns 
Class: Narcotic 
Compound: Bupropion 
Class: NPS – Piperazines 
Compound: 1-(2-
trifluoromethylphenyl)piperazine 





Worst of all 
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Match score: 0.855 
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Compound: Phencyclidine HCI 












DMSO: Nothing detected 
 
Acetonitrile: Possible unknowns 
Class: NPS – Synthetic 
Cannabinoids  
Compound: 5F-AKB-48 




Match score: 0.832 
 












Compound: Phencyclidine HCI 
















Compound: Phencyclidine HCI 
Match score: 0.911 
 
V4  15mg  
 
DMSO: 




Compound: Phencyclidine HCI 
Match score: 0.909 
 
V5  15mg 
 
DMSO: 




Compound: Phencyclidine HCI 
Match score: 0.915 
 
V6  15mg 
 
DMSO: 




Compound: Phencyclidine HCI 





Appendix 54: Integrated area ratios of ‘Valium’ samples  








Appendix 56a: Raw SPSS data: Frequency tables 
Q1 Age 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 18-21 422 70.9 70.9 70.9 
22-25 127 21.3 21.3 92.3 
26-30 19 3.2 3.2 95.5 
31-40 11 1.8 1.8 97.3 
41+ 16 2.7 2.7 100.0 







 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Male 326 54.8 55.3 55.3 
Female 263 44.2 44.6 99.8 
Transgender 1 .2 .2 100.0 
Total 590 99.2 100.0  
Missing Missing 5 .8   








 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Heterosexual/ straight 498 83.7 83.7 83.7 
Homosexual/ gay/ lesbian 18 3.0 3.0 86.7 
Bisexual 68 11.4 11.4 98.2 
A sexual 2 .3 .3 98.5 
I'd rather not say 7 1.2 1.2 99.7 
Other 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q4 Ethnicity 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid White 529 88.9 88.9 88.9 
Black 5 .8 .8 89.7 
Asian 14 2.4 2.4 92.1 
Mixed 40 6.7 6.7 98.8 
Chinese 2 .3 .3 99.2 
Arab 2 .3 .3 99.5 
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Hispanic 1 .2 .2 99.7 
Missing 2 .3 .3 100.0 




 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid South East 33 5.5 5.5 5.5 
London 100 16.8 16.8 22.4 
North West 170 28.6 28.6 50.9 
East of England 26 4.4 4.4 55.3 
West Midlands 26 4.4 4.4 59.7 
South West 85 14.3 14.3 73.9 
Yorkshire and the Humber 64 10.8 10.8 84.7 
East Midlands 35 5.9 5.9 90.6 
North East 18 3.0 3.0 93.6 
Scotland 25 4.2 4.2 97.8 
Ireland 5 .8 .8 98.7 
Wales 4 .7 .7 99.3 
I'd rather not say 4 .7 .7 100.0 
Total 595 100.0 100.0  
 
Q6 Occupation 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Full/ part-time student 492 82.7 82.7 82.7 
Employed 89 15.0 15.0 97.6 
Unemployed 7 1.2 1.2 98.8 
Other 3 .5 .5 99.3 
Missing 4 .7 .7 100.0 






Q7 - Valium 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 499 83.9 83.9 83.9 
No 96 16.1 16.1 100.0 
Total 595 100.0 100.0  
 
Q7 - Xanax 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 481 80.8 80.8 80.8 
No 114 19.2 19.2 100.0 
Total 595 100.0 100.0  
 
Q7 - Klonopin 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 61 10.3 10.3 10.3 
No 534 89.7 89.7 100.0 







Q7 - Ativan 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 47 7.9 7.9 7.9 
No 548 92.1 92.1 100.0 
Total 595 100.0 100.0  
 
Q7 - Estazolam 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 36 6.1 6.1 6.1 
No 559 93.9 93.9 100.0 
Total 595 100.0 100.0  
 
Q7 - Etizolam 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 30 5.0 5.0 5.0 
No 565 95.0 95.0 100.0 







Q7 - Other 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 31 5.2 5.2 5.2 
No 564 94.8 94.8 100.0 
Total 595 100.0 100.0  
 
Q8 - Xanax 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 313 52.6 52.6 52.6 
No 282 47.4 47.4 100.0 
Total 595 100.0 100.0  
 
Q8 - Valium 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 273 45.9 45.9 45.9 
No 322 54.1 54.1 100.0 







Q8 - Not recently 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 181 30.4 30.4 30.4 
No 414 69.6 69.6 100.0 
Total 595 100.0 100.0  
 
Q8 – Other 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 40 6.7 6.7 6.7 
No 555 93.3 93.3 100.0 









Q9 - Preferred benzo 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Valium 276 46.4 46.4 46.4 
Xanax 265 44.5 44.5 90.9 
Other 31 5.2 5.2 96.1 
None - dislike them all AND 
no preference 
15 2.5 2.5 98.7 
Missing 8 1.3 1.3 100.0 
Total 595 100.0 100.0  
 
Q11 - Sleep 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 330 55.5 55.6 55.6 
No 264 44.4 44.4 100.0 
Total 594 99.8 100.0  
Missing System 1 .2   
Total 595 100.0   
 
Q11anxietycombined 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 195 32.8 32.8 32.8 
No 400 67.2 67.2 100.0 




Q11 - High 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 368 61.8 62.0 62.0 
No 226 38.0 38.0 100.0 
Total 594 99.8 100.0  
Missing System 1 .2   
Total 595 100.0   
 
Q11 - Counteract stim 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 369 62.0 62.1 62.1 
No 225 37.8 37.9 100.0 
Total 594 99.8 100.0  
Missing System 1 .2   









Q12 - Frequency of use 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Daily 26 4.4 4.4 4.4 
Weekly 91 15.3 15.3 19.7 
Fortnightly 84 14.1 14.1 33.8 
Monthly 88 14.8 14.8 48.6 
Every few months 191 32.1 32.1 80.7 
Rarely 49 8.2 8.2 88.9 
Not for a while 26 4.4 4.4 93.3 
Binge 11 1.8 1.8 95.1 
Whenever I need to 17 2.9 2.9 98.0 
Other 7 1.2 1.2 99.2 
Missing 5 .8 .8 100.0 
Total 595 100.0 100.0  
 
 
Q13 - Valium 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 125 21.0 21.0 21.0 
2 180 30.3 30.3 51.3 
3 69 11.6 11.6 62.9 
4 31 5.2 5.2 68.1 
5 28 4.7 4.7 72.8 
6-10 16 2.7 2.7 75.5 
Over 10 15 2.5 2.5 78.0 
Missing 35 5.9 5.9 83.9 
Not applicable 96 16.1 16.1 100.0 












Q13 - Xanax 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1 220 37.0 37.0 37.0 
2 147 24.7 24.7 61.7 
3 42 7.1 7.1 68.7 
4 21 3.5 3.5 72.3 
5 11 1.8 1.8 74.1 
Over 10 1 .2 .2 74.3 
1/2 a Xanax bar 14 2.4 2.4 76.6 
Missing 25 4.2 4.2 80.8 
Not applicable 114 19.2 19.2 100.0 
Total 595 100.0 100.0  
 
Q15 - Swallow 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 590 99.2 99.2 99.2 
No 4 .7 .7 99.8 
Missing 1 .2 .2 100.0 
Total 595 100.0 100.0  
 
Q15 - Snort 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 96 16.1 16.1 16.1 
No 498 83.7 83.7 99.8 
Missing 1 .2 .2 100.0 




Q15 - Inject 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 1 .2 .2 .2 
No 593 99.7 99.7 99.8 
Missing 1 .2 .2 100.0 
Total 595 100.0 100.0  
 
 
Q15 - Sublingually 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 10 1.7 1.7 1.7 
No 584 98.2 98.2 99.8 
Missing 1 .2 .2 100.0 









Q15 - Chew it 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 1 .2 .2 .2 
No 593 99.7 99.7 99.8 
Missing 1 .2 .2 100.0 
Total 595 100.0 100.0  
 
Q15 - DissolveInDrink 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 4 .7 .7 .7 
No 591 99.3 99.3 100.0 
Total 595 100.0 100.0  
 
 
Q17 - Alcohol 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 590 99.2 99.2 99.2 
No 3 .5 .5 99.7 
Missing 2 .3 .3 100.0 










Q17 - Tobacco 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 560 94.1 94.1 94.1 
No 33 5.5 5.5 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q17 - Cannabis 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 571 96.0 96.0 96.0 
No 22 3.7 3.7 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q17MDMAcombi 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 545 91.6 91.6 91.6 
No 48 8.1 8.1 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q17 - Cocaine 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 524 88.1 88.1 88.1 
No 69 11.6 11.6 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q17 - Ketamine 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 520 87.4 87.4 87.4 
No 73 12.3 12.3 99.7 
Missing 2 .3 .3 100.0 





 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 436 73.3 73.3 73.3 
No 157 26.4 26.4 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q17 - Amphetamines 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 365 61.3 61.3 61.3 
No 228 38.3 38.3 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q17 - Modafinil/ Ritalin 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 317 53.3 53.3 53.3 
No 276 46.4 46.4 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q17opiatescrack 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 155 26.1 26.1 26.1 
No 438 73.6 73.6 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q17 - Other 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 72 12.1 12.1 12.1 
No 521 87.6 87.6 99.7 
Missing 2 .3 .3 100.0 




Q18 - Alcohol 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 395 66.4 66.4 66.4 
No 200 33.6 33.6 100.0 
Total 595 100.0 100.0  
 
Q18 - Tobacco 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 268 45.0 45.0 45.0 
No 327 55.0 55.0 100.0 
Total 595 100.0 100.0  
 
Q18 - Cannabis 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 80 13.4 13.4 13.4 
No 515 86.6 86.6 100.0 
Total 595 100.0 100.0  
 
Q18MDMAcombi 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 208 35.0 35.0 35.0 
No 387 65.0 65.0 100.0 
Total 595 100.0 100.0  
 
Q18 - Cocaine 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 189 31.8 31.8 31.8 
No 406 68.2 68.2 100.0 









Q18 - Ketamine 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 198 33.3 33.3 33.3 
No 397 66.7 66.7 100.0 
Total 595 100.0 100.0  
 
Q18Hallucinogens 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 83 13.9 13.9 13.9 
No 512 86.1 86.1 100.0 
Total 595 100.0 100.0  
 
Q18 - Amphetamines 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 59 9.9 9.9 9.9 
No 536 90.1 90.1 100.0 
Total 595 100.0 100.0  
 
Q18 - Modafinil/ Ritalin 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 27 4.5 4.5 4.5 
No 568 95.5 95.5 100.0 
Total 595 100.0 100.0  
 
Q18Opiatescrack 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 7 1.2 1.2 1.2 
No 588 98.8 98.8 100.0 








Q18 - Nothing 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 144 24.2 24.2 24.2 
No 451 75.8 75.8 100.0 
Total 595 100.0 100.0  
 
Q19 - prescribed by NHS or psychiatrist 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 75 12.6 12.6 12.6 
No 518 87.1 87.1 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q19 – Non-prescribed but diverted 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 71 11.9 11.9 11.9 
No 522 87.7 87.7 99.7 
Missing 2 .3 .3 100.0 







Q19 - Friend 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 316 53.1 53.1 53.1 
No 277 46.6 46.6 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q19 - Family 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 22 3.7 3.7 3.7 
No 571 96.0 96.0 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q19 - Work/ study colleague 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 22 3.7 3.7 3.7 
No 571 96.0 96.0 99.7 
Missing 2 .3 .3 100.0 




Q19 - Clearweb 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 27 4.5 4.5 4.5 
No 566 95.1 95.1 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q19 - Darkweb 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 172 28.9 28.9 28.9 
No 421 70.8 70.8 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q19 - Dealer 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 340 57.1 57.1 57.1 
No 253 42.5 42.5 99.7 
Missing 2 .3 .3 100.0 




Q19 - Other 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 22 3.7 3.7 3.7 
No 571 96.0 96.0 99.7 
Missing 2 .3 .3 100.0 
Total 595 100.0 100.0  
 
Q20 - Only benzos 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 108 18.2 18.2 18.2 
No 159 26.7 26.7 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 










Q20 - Cannabis 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 90 15.1 15.1 15.1 
No 177 29.7 29.7 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 
Total 595 100.0 100.0  
 
Q20 - MDMA (crystal/powder) 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 86 14.5 14.5 14.5 
No 181 30.4 30.4 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 









Q20 - MDMA (pills) 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 98 16.5 16.5 16.5 
No 169 28.4 28.4 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 
Total 595 100.0 100.0  
 
Q20 - Cocaine 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 94 15.8 15.8 15.8 
No 173 29.1 29.1 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 









Q20 - Ketamine 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 113 19.0 19.0 19.0 
No 154 25.9 25.9 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 
Total 595 100.0 100.0  
 
Q20 - LSD/ Acid 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 27 4.5 4.5 4.5 
No 240 40.3 40.3 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 









Q20 - Magic Mushrooms 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 17 2.9 2.9 2.9 
No 250 42.0 42.0 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 
Total 595 100.0 100.0  
 
Q20 - Amphetamines 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 15 2.5 2.5 2.5 
No 252 42.4 42.4 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 









Q20 - Modafinil/ Ritalin 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 17 2.9 2.9 2.9 
No 250 42.0 42.0 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 
Total 595 100.0 100.0  
 
Q20 - Heroin and other opiates 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 4 .7 .7 .7 
No 263 44.2 44.2 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 









Q20 - Crack Cocaine 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 2 .3 .3 .3 
No 265 44.5 44.5 44.9 
Missing 75 12.6 12.6 57.5 
Not applicable 253 42.5 42.5 100.0 
Total 595 100.0 100.0  
 
Q21Valdonotpay 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 135 22.7 22.7 22.7 
No 330 55.5 55.5 78.2 
missing 130 21.8 21.8 100.0 
Total 595 100.0 100.0  
 
Q21Val50p 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 87 14.6 14.6 14.6 
No 378 63.5 63.5 78.2 
missing 130 21.8 21.8 100.0 
Total 595 100.0 100.0  
 
Q21Val£1 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 142 23.9 23.9 23.9 
No 323 54.3 54.3 78.2 
missing 130 21.8 21.8 100.0 







 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 35 5.9 5.9 5.9 
No 430 72.3 72.3 78.2 
missing 130 21.8 21.8 100.0 
Total 595 100.0 100.0  
 
Q21Val£2 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 48 8.1 8.1 8.1 
No 417 70.1 70.1 78.2 
missing 130 21.8 21.8 100.0 
Total 595 100.0 100.0  
 
Q21Val£3 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 14 2.4 2.4 2.4 
No 451 75.8 75.8 78.2 
missing 130 21.8 21.8 100.0 
Total 595 100.0 100.0  
 
Q21Val£4 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 4 .7 .7 .7 
No 461 77.5 77.5 78.2 
missing 130 21.8 21.8 100.0 
Total 595 100.0 100.0  
 
Q21ValOther 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 18 3.0 3.0 3.0 
No 577 97.0 97.0 100.0 






 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 60 10.1 10.1 10.1 
No 364 61.2 61.2 71.3 
missing 171 28.7 28.7 100.0 
Total 595 100.0 100.0  
 
Q21Xan50p 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 48 8.1 8.1 8.1 
No 376 63.2 63.2 71.3 
missing 171 28.7 28.7 100.0 




 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 91 15.3 15.3 15.3 
No 333 56.0 56.0 71.3 
missing 171 28.7 28.7 100.0 
Total 595 100.0 100.0  
 
Q21Xan£1.50 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 56 9.4 9.4 9.4 
No 368 61.8 61.8 71.3 
missing 171 28.7 28.7 100.0 











 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 141 23.7 23.7 23.7 
No 283 47.6 47.6 71.3 
missing 171 28.7 28.7 100.0 
Total 595 100.0 100.0  
 
Q21Xan£3 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 49 8.2 8.2 8.2 
No 375 63.0 63.0 71.3 
missing 171 28.7 28.7 100.0 
Total 595 100.0 100.0  
 
Q21Xan£4 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 13 2.2 2.2 2.2 
No 411 69.1 69.1 71.3 
missing 171 28.7 28.7 100.0 
Total 595 100.0 100.0  
 
Q21XanOther 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 14 2.4 2.4 2.4 
No 410 68.9 68.9 71.3 
missing 171 28.7 28.7 100.0 









Q22 - How many purchase 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1-5 182 30.6 30.6 30.6 
6-10 118 19.8 19.8 50.4 
11-20 77 12.9 12.9 63.4 
21-50 76 12.8 12.8 76.1 
51+ 55 9.2 9.2 85.4 
missing 11 1.8 1.8 87.2 
not applicable 76 12.8 12.8 100.0 
Total 595 100.0 100.0  
 
 
Q23 - Prescribed 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 101 17.0 17.0 17.0 
No 494 83.0 83.0 100.0 
Total 595 100.0 100.0  
 
 
Q23 - Only drug tried 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 97 16.3 16.3 16.3 
No 497 83.5 83.5 99.8 
Missing 1 .2 .2 100.0 
Total 595 100.0 100.0  
 
 
Q23 - Best desired effect 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 350 58.8 58.8 58.8 
No 244 41.0 41.0 99.8 
Missing 1 .2 .2 100.0 






Q23 - Cheap 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 317 53.3 53.3 53.3 
No 277 46.6 46.6 99.8 
Missing 1 .2 .2 100.0 
Total 595 100.0 100.0  
 
 
Q23 - E/Accessible 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 228 38.3 38.3 38.3 
No 366 61.5 61.5 99.8 
Missing 1 .2 .2 100.0 
Total 595 100.0 100.0  
 
 
Q23 - E/Hide 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 90 15.1 15.1 15.1 
No 504 84.7 84.7 99.8 
Missing 1 .2 .2 100.0 
Total 595 100.0 100.0  
 
Q23 - E/Consume 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 261 43.9 43.9 43.9 
No 333 56.0 56.0 99.8 
Missing 1 .2 .2 100.0 








Appendix 56b: Raw SPSS data: Cross tabulations 
 
Q19 - Darkweb * Q7 - Valium Crosstabulation 
 
Q7 - Valium 
Total Yes No 
Q19 - Darkweb Yes Count 153 19 172 
% within Q7 - Valium 30.7% 19.8% 28.9% 
No Count 344 77 421 
% within Q7 - Valium 68.9% 80.2% 70.8% 
Missing Count 2 0 2 
% within Q7 - Valium 0.4% 0.0% 0.3% 
Total Count 499 96 595 
% within Q7 - Valium 100.0% 100.0% 100.0% 
 
 
Q19 - Darkweb * Q7 - Xanax Crosstabulation 
 
Q7 - Xanax 
Total Yes No 
Q19 - Darkweb Yes Count 163 9 172 
% within Q7 - Xanax 33.9% 7.9% 28.9% 
No Count 317 104 421 
% within Q7 - Xanax 65.9% 91.2% 70.8% 
Missing Count 1 1 2 
% within Q7 - Xanax 0.2% 0.9% 0.3% 
Total Count 481 114 595 





















Q11anxietycombined * Q1 Age Crosstabulation 
 
Q1 Age 
Total 18-21 22-25 26-30 31-40 41+ 
Q11anxietycombined Yes Count 128 47 8 5 7 195 
% within Q1 Age 30.3% 37.0% 42.1% 45.5% 43.8% 32.8% 
No Count 294 80 11 6 9 400 
% within Q1 Age 69.7% 63.0% 57.9% 54.5% 56.3% 67.2% 
Total Count 422 127 19 11 16 595 
% within Q1 Age 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
 
Q11anxietycombined * Q2 Gender Crosstabulation 
 
Q2 Gender 
Total Male Female Transgender 
Q11anxietycombined Yes Count 106 89 0 195 
% within Q2 Gender 32.5% 33.8% 0.0% 33.1% 
No Count 220 174 1 395 
% within Q2 Gender 67.5% 66.2% 100.0% 66.9% 
Total Count 326 263 1 590 






Q11 - High * Q2 Gender Crosstabulation 
 
Q2 Gender 
Total Male Female Transgender 
Q11 - High Yes Count 224 140 1 365 
% within Q2 Gender 68.7% 53.2% 100.0% 61.9% 
No Count 102 123 0 225 
% within Q2 Gender 31.3% 46.8% 0.0% 38.1% 
Total Count 326 263 1 590 











Q2 Gender * Q11 - Counteract stim Crosstabulation 
 
Q11 - Counteract stim 
Total Yes No 
Q2 Gender Male Count 222 104 326 
% within Q2 Gender 68.1% 31.9% 100.0% 
Female Count 144 119 263 
% within Q2 Gender 54.8% 45.2% 100.0% 
Transgender Count 0 1 1 
% within Q2 Gender 0.0% 100.0% 100.0% 
Total Count 366 224 590 
% within Q2 Gender 62.0% 38.0% 100.0% 
 
 
Q13 - Valium * Q11 - Sleep Crosstabulation 
 
Q11 - Sleep 
Total Yes No 
Q13 - Valium 1 Count 83 42 125 
% within Q11 - Sleep 25.2% 15.8% 21.0% 
2 Count 108 72 180 
% within Q11 - Sleep 32.7% 27.2% 30.3% 
3 Count 39 30 69 
% within Q11 - Sleep 11.8% 11.3% 11.6% 
4 Count 18 13 31 
% within Q11 - Sleep 5.5% 4.9% 5.2% 
5 Count 16 12 28 
% within Q11 - Sleep 4.8% 4.5% 4.7% 
6-10 Count 10 6 16 
% within Q11 - Sleep 3.0% 2.3% 2.7% 
Over 10 Count 9 6 15 
% within Q11 - Sleep 2.7% 2.3% 2.5% 
Missing Count 20 15 35 
% within Q11 - Sleep 6.1% 5.7% 5.9% 
Not applicable Count 27 69 96 
% within Q11 - Sleep 8.2% 26.0% 16.1% 
Total Count 330 265 595 







Q13 - Valium * Q11 - High Crosstabulation 
 
Q11 - High 
Total Yes No 
Q13 - Valium 1 Count 47 78 125 
% within Q11 - High 12.8% 34.4% 21.0% 
2 Count 107 73 180 
% within Q11 - High 29.1% 32.2% 30.3% 
3 Count 48 21 69 
% within Q11 - High 13.0% 9.3% 11.6% 
4 Count 23 8 31 
% within Q11 - High 6.3% 3.5% 5.2% 
5 Count 22 6 28 
% within Q11 - High 6.0% 2.6% 4.7% 
6-10 Count 14 2 16 
% within Q11 - High 3.8% 0.9% 2.7% 
Over 10 Count 12 3 15 
% within Q11 - High 3.3% 1.3% 2.5% 
Missing Count 24 11 35 
% within Q11 - High 6.5% 4.8% 5.9% 
Not applicable Count 71 25 96 
% within Q11 - High 19.3% 11.0% 16.1% 
Total Count 368 227 595 


















Q13 - Valium * Q11anxietycombined Crosstabulation 
 
Q11anxietycombined 
Total Yes No 
Q13 - Valium 1 Count 37 88 125 
% within 
Q11anxietycombined 
19.0% 22.0% 21.0% 
2 Count 69 111 180 
% within 
Q11anxietycombined 
35.4% 27.8% 30.3% 
3 Count 24 45 69 
% within 
Q11anxietycombined 
12.3% 11.3% 11.6% 
4 Count 12 19 31 
% within 
Q11anxietycombined 
6.2% 4.8% 5.2% 
5 Count 10 18 28 
% within 
Q11anxietycombined 
5.1% 4.5% 4.7% 
6-10 Count 7 9 16 
% within 
Q11anxietycombined 
3.6% 2.3% 2.7% 
Over 10 Count 9 6 15 
% within 
Q11anxietycombined 
4.6% 1.5% 2.5% 
Missing Count 15 20 35 
% within 
Q11anxietycombined 
7.7% 5.0% 5.9% 
Not applicable Count 12 84 96 
% within 
Q11anxietycombined 
6.2% 21.0% 16.1% 
Total Count 195 400 595 
% within 
Q11anxietycombined 










Q13 - Valium * Q11 - Counteract stim Crosstabulation 
 
Q11 - Counteract stim 
Total Yes No 
Q13 - Valium 1 Count 78 47 125 
% within Q11 - Counteract 
stim 
21.1% 20.8% 21.0% 
2 Count 124 56 180 
% within Q11 - Counteract 
stim 
33.6% 24.8% 30.3% 
3 Count 44 25 69 
% within Q11 - Counteract 
stim 
11.9% 11.1% 11.6% 
4 Count 20 11 31 
% within Q11 - Counteract 
stim 
5.4% 4.9% 5.2% 
5 Count 19 9 28 
% within Q11 - Counteract 
stim 
5.1% 4.0% 4.7% 
6-10 Count 13 3 16 
% within Q11 - Counteract 
stim 
3.5% 1.3% 2.7% 
Over 10 Count 9 6 15 
% within Q11 - Counteract 
stim 
2.4% 2.7% 2.5% 
Missing Count 23 12 35 
% within Q11 - Counteract 
stim 
6.2% 5.3% 5.9% 
Not applicable Count 39 57 96 
% within Q11 - Counteract 
stim 
10.6% 25.2% 16.1% 
Total Count 369 226 595 
% within Q11 - Counteract 
stim 










Q13 - Xanax * Q11 - Sleep Crosstabulation 
 
Q11 - Sleep 
Total Yes No 
Q13 - Xanax 1 Count 125 95 220 
% within Q11 - Sleep 37.9% 35.8% 37.0% 
2 Count 78 69 147 
% within Q11 - Sleep 23.6% 26.0% 24.7% 
3 Count 26 16 42 
% within Q11 - Sleep 7.9% 6.0% 7.1% 
4 Count 9 12 21 
% within Q11 - Sleep 2.7% 4.5% 3.5% 
5 Count 5 6 11 
% within Q11 - Sleep 1.5% 2.3% 1.8% 
Over 10 Count 0 1 1 
% within Q11 - Sleep 0.0% 0.4% 0.2% 
1/2 a Xanax bar Count 8 6 14 
% within Q11 - Sleep 2.4% 2.3% 2.4% 
Missing Count 16 9 25 
% within Q11 - Sleep 4.8% 3.4% 4.2% 
Not applicable Count 63 51 114 
% within Q11 - Sleep 19.1% 19.2% 19.2% 
Total Count 330 265 595 


















Q13 - Xanax * Q11 - High Crosstabulation 
 
Q11 - High 
Total Yes No 
Q13 - Xanax 1 Count 146 74 220 
% within Q11 - High 39.7% 32.6% 37.0% 
2 Count 110 37 147 
% within Q11 - High 29.9% 16.3% 24.7% 
3 Count 34 8 42 
% within Q11 - High 9.2% 3.5% 7.1% 
4 Count 16 5 21 
% within Q11 - High 4.3% 2.2% 3.5% 
5 Count 9 2 11 
% within Q11 - High 2.4% 0.9% 1.8% 
Over 10 Count 1 0 1 
% within Q11 - High 0.3% 0.0% 0.2% 
1/2 a Xanax bar Count 10 4 14 
% within Q11 - High 2.7% 1.8% 2.4% 
Missing Count 15 10 25 
% within Q11 - High 4.1% 4.4% 4.2% 
Not applicable Count 27 87 114 
% within Q11 - High 7.3% 38.3% 19.2% 
Total Count 368 227 595 




Q13 - Xanax * Q11anxietycombined Crosstabulation 
 
Q11anxietycombined 
Total Yes No 
Q13 - Xanax 1 Count 68 152 220 
% within 
Q11anxietycombined 
34.9% 38.0% 37.0% 
2 Count 51 96 147 
% within 
Q11anxietycombined 
26.2% 24.0% 24.7% 
3 Count 16 26 42 
% within 
Q11anxietycombined 
8.2% 6.5% 7.1% 
4 Count 8 13 21 
% within 
Q11anxietycombined 
4.1% 3.3% 3.5% 
307 
 
5 Count 5 6 11 
% within 
Q11anxietycombined 
2.6% 1.5% 1.8% 
Over 10 Count 0 1 1 
% within 
Q11anxietycombined 
0.0% 0.3% 0.2% 
1/2 a Xanax bar Count 3 11 14 
% within 
Q11anxietycombined 
1.5% 2.8% 2.4% 
Missing Count 14 11 25 
% within 
Q11anxietycombined 
7.2% 2.8% 4.2% 
Not applicable Count 30 84 114 
% within 
Q11anxietycombined 
15.4% 21.0% 19.2% 
Total Count 195 400 595 
% within 
Q11anxietycombined 
100.0% 100.0% 100.0% 
 
 
Q13 - Xanax * Q11 - Counteract stim Crosstabulation 
 
Q11 - Counteract stim 
Total Yes No 
Q13 - Xanax 1 Count 157 63 220 
% within Q11 - Counteract 
stim 
42.5% 27.9% 37.0% 
2 Count 93 54 147 
% within Q11 - Counteract 
stim 
25.2% 23.9% 24.7% 
3 Count 28 14 42 
% within Q11 - Counteract 
stim 
7.6% 6.2% 7.1% 
4 Count 15 6 21 
% within Q11 - Counteract 
stim 
4.1% 2.7% 3.5% 
5 Count 5 6 11 
% within Q11 - Counteract 
stim 
1.4% 2.7% 1.8% 
Over 10 Count 1 0 1 
% within Q11 - Counteract 
stim 
0.3% 0.0% 0.2% 
308 
 
1/2 a Xanax bar Count 10 4 14 
% within Q11 - Counteract 
stim 
2.7% 1.8% 2.4% 
Missing Count 16 9 25 
% within Q11 - Counteract 
stim 
4.3% 4.0% 4.2% 
Not applicable Count 44 70 114 
% within Q11 - Counteract 
stim 
11.9% 31.0% 19.2% 
Total Count 369 226 595 
% within Q11 - Counteract 
stim 
100.0% 100.0% 100.0% 
 
 
Q2 Gender * Q9 - Prefered benzo? Crosstabulation 
  Valium Xanax 
Q2 Gender Male Count  139 154 
% within Q2 Gender  42.6% 47.2% 
Female Count  133 109 
% within Q2 Gender  50.6% 41.4% 
Transgender Count  1 0 
% within Q2 Gender  100.0% 0.0% 
Total Count  273 263 
% within Q2 Gender  46.3% 44.6% 
 
 
Q1 Age * Q9 - Prefered benzo? Crosstabulation 
 
 Valium Xanax 
Q1 Age 18-21 Count 187 202 
% within Q1 Age 44.3% 47.9% 
22-25 Count 67 47 
% within Q1 Age 52.8% 37.0% 
26-30 Count 10 5 
% within Q1 Age 52.6% 26.3% 
31-40 Count 5 4 
% within Q1 Age 45.5% 36.4% 
41+ Count 7 7 
% within Q1 Age 43.8% 43.8% 
Total Count 276 265 




Appendix 57: Benzodiazepines in a recreational context: night-out timeline 
 
 
 
 
